Allaart C, Lems W, Huizinga T. The BeSt way of withdrawing biologic agents. Clin Exp Rheumatol; 2014. p. S14–8. Exclusion Code: X1. [PubMed: 24129130]

Askling J, Smith M. Anti-TNFα therapy did not increase short- or medium-term risk for cancer in patients with rheumatoid arthritis. Ann Intern Med. 2010;152(10):JC5–13. Exclusion Code: X1. [PubMed: 20479018]

Brown G, Wang E, Leon A, et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis: Systematic review of clinical features, histopathological findings, and management experience. J Am Acad Dermatol. 2017 Feb;76(2):334–41. doi: 10.1016/j.jaad.2016.08.012. PMID: 27720274 Exclusion Code: X1. [PubMed: 27720274] [CrossRef]

Curtis JR, Perez-Gutthann S, Suissa S, et al. Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources. Semin Arthritis Rheum. 2015 Feb;44(4):381–8. doi: 10.1016/j.semarthrit.2014.07.006. PMID: 25300699 Exclusion Code: X1. [PubMed: 25300699] [CrossRef]

Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum. 2010 Apr;39(5):327–46. doi: 10.1016/j.semarthrit.2008.10.002. PMID: 19117595. Exclusion Code: X1. [PubMed: 19117595] [CrossRef]

Gualtierotti R, Casella F. Is it safe to withdraw etanercept in established rheumatoid arthritis after low disease activity achievement? Intern Emerg Med; 2014. p. 223–4. Exclusion Code: X1. [PubMed: 24307478]

Henness S, Yang LP. Modified-Release Prednisone: in Patients with Rheumatoid Arthritis. p. 2067. Exclusion Code: X1. [PubMed: 24249648]

Hetland ML. Modern treatment strategies in rheumatoid arthritis. Dan Med Bull. 2011 Nov;58(11):B4320. PMID: 22047935. Exclusion Code: X1. [PubMed: 22047935]

Jacobs J, Bijlsma J, Laar J. Glucocorticoids in early rheumatoid arthritis: are the benefits of joint-sparing effects offset by the adverse effect of osteoporosis? the effects on bone in the utrecht study and the CAMERA-II study. Neuroimmunomodulation; 2015. p. 66–71. Exclusion Code: X1. [PubMed: 25228126]

Keystone E, Haraoui B, Bykerk V. Role of adalimumab in the treatment of early rheumatoid arthritis. Clin Exp Rheumatol; 2012. p. S198–9. Exclusion Code: X1. [PubMed: 14969077]

Mohan AK, Cote TR, Block JA, et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis. 2004 Aug 1;39(3):295–9. PMID: 15306993. Exclusion Code: X1. [PubMed: 15306993]

Pincus T. The clinical efficacy of 3 mg/day prednisone in patients with rheumatoid arthritis: evidence from a randomized, double-blind, placebo-controlled withdrawal clinical trial. Clin Exp Rheumatol; 2012. p. S73–6. Exclusion Code: X1. [PubMed: 22018188]

Rantalaiho V, Puolakka K, Korpela M, et al. Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis. Clin Exp Rheumatol. 2012 Jul-Aug;30(4 Suppl 73):S27–31. PMID: 23073350. Exclusion Code: X1. [PubMed: 23073350]

Riel P. Leflunomide improves the clinical response in patients with active rheumatoid arthritis treated with methotrexate. Clin Exp Rheumatol; 2012. p. 695–6. Exclusion Code: X1. [PubMed: 14740446]

Schafer JA, Kjesbo NK, Gleason PP. Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis. J Manag Care Pharm. 2010 Jul-Aug;16(6):402–16. doi: 10.18553/jmcp.2010.16.6.402. PMID: 20635831. Exclusion Code: X1. [PMC free article: PMC10437992] [PubMed: 20635831] [CrossRef]

Sokka T, Mäkinen H, Puolakka K, et al. Remission as the treatment goal--the FINRACo trial. Clin Exp Rheumatol; 2012. p. S-74–6. Exclusion Code: X1. [PubMed: 17083766]

van den Broek M, Lems WF, Allaart CF. BeSt practice: the success of early-targeted treatment in rheumatoid arthritis. Clin Exp Rheumatol. 2012 Jul-Aug;30(4 Suppl 73):S35–8. PMID: 23078756. Exclusion Code: X1. [PubMed: 23078756]

Verstappen S, Jacobs J, Bijlsma J. The Utrecht experience with different treatment strategies in early rheumatoid arthritis. Clin Exp Rheumatol; 2012. p. S165–8. Exclusion Code: X1. [PubMed: 14969070]

Woude D, Visser K, Klarenbeek N, et al. Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: A comparison of two cohort studies. Rheumatology (United Kingdom); 2012. p. 1120–8. Exclusion Code: X1. [PubMed: 22337939]

Aberumand B, Bykerk V, Schieir O, et al. Treatment response to conventional disease modifying anti-rheumatic drugs (DMARDS) and biologics in seropositive and seronegative patients with early rheumatoid arthritis: Results from catch (Canadian early arthritis cohort). Ann Rheum Dis. 2016;75:683–4. doi: 10.1136/annrheumdis-2016-eular.4483. Exclusion Code: X2. [CrossRef]

Acurcio FA, Machado MA, Moura CS, et al. Medication Persistence of Disease-Modifying Antirheumatic Drugs and Anti-Tumor Necrosis Factor Agents in a Cohort of Patients With Rheumatoid Arthritis in Brazil. Arthritis Care Res (Hoboken). 2016 Oct;68(10):1489–96. doi: 10.1002/acr.22840. PMID: 26814681. Exclusion Code: X2. [PubMed: 26814681] [CrossRef]

Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2005 Oct;64(10):1414–20. PMID: 15843454. Exclusion Code: X2. [PMC free article: PMC1755232] [PubMed: 15843454]

Brunner H, Ruperto N, Martini A, et al. Identification of optimal subcutaneous doses of tocilizumab in children with polyarticular-course juvenile idiopathic arthritis. Arthritis and Rheumatology. 2017;69:60–1. doi: 10.1002/art.v69.S4. Exclusion Code: X2. [CrossRef]

Cho SK, Sung YK, Kim D, et al. Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2016;17(1):1–8 doi: 10.1186/s12891-016-1185-6. Exclusion Code: X2. [PMC free article: PMC4977640] [PubMed: 27507033] [CrossRef]

Desai RJ, Bateman BT, Huybrechts KF, et al. Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study. BMJ. 2017 Mar 06;356:j895. doi: 10.1136/bmj.j895. PMID: 28264814. Exclusion Code: X2. [PMC free article: PMC6168035] [PubMed: 28264814] [CrossRef]

Eccleston C, Cooper TE, Fisher E, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. Cochrane Database of Systematic Reviews: John Wiley & Sons, Ltd; 2017. Exclusion Code: X2. [PMC free article: PMC6460508] [PubMed: 28770976]

Ghosh B, Halder S, Ghosh A, et al. Early rheumatoid arthritis: Clinical and therapeutic evaluation in a tertiary care centre in India. Indian Journal of Rheumatology; 2008. p. 48–51. Exclusion Code: X2.

Gilani ST, Khan DA, Khan FA, et al. Adverse effects of low dose methotrexate in rheumatoid arthritis patients. J Coll Physicians Surg Pak. 2012 Feb;22(2):101–4. . PMID: 22313647. Exclusion Code: X2. [PubMed: 22313647]

Ishiguro N, Atsumi T, Harigai M, et al. Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study. Mod Rheumatol. 2017;27(2):217–26. doi: 10.1080/14397595.2016.1206507. Exclusion Code: X2. [PubMed: 27414105] [CrossRef]

Machado-Alba JE, Ruiz AF, Machado-Duque ME. Adverse drug reactions associated with the use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Rev Panam Salud Publica. 2014 Dec;36(6):396–401. PMID: 25711751. Exclusion Code: X2. [PubMed: 25711751]

Mera-Varela A, Perez-Pampin E. Abatacept therapy in rheumatoid arthritis with interstitial lung disease. J Clin Rheumatol. 2014 Dec;20(8):445–6. doi: 10.1097/rhu.0000000000000084. PMID: 25417684 Exclusion Code: X2. [PubMed: 25417684] [CrossRef]

Rojas-Serrano J, Perez LL, Garcia CG, et al. Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study. Clin Rheumatol. 2011 Dec;30(12):1589–93. doi: 10.1007/s10067-011-1775-5. PMID: 21607552 Exclusion Code: X2. [PubMed: 21607552] [CrossRef]

Sirisena D, Marshall T, Deighton C, et al. Multicenter audit on the use of Leflunomide, in isolation or combination and assessment of adverse effects in rheumatoid arthritis patients. Indian Journal of Rheumatology. 2011;6(1):3–6. doi: 10.1016/S0973-3698(11)60044-7. Exclusion Code: X2. [CrossRef]

Widdifield J, Bernatsky S, Paterson JM, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013 Mar;65(3):353–61. doi: 10.1002/acr.21812. PMID: 22833532. Exclusion Code: X2. [PubMed: 22833532] [CrossRef]

Aalbers C, Gerlag D, Vos K, et al. Intraarticular etanercept treatment in inflammatory arthritis: A randomized double-blind placebo-controlled proof of mechanism clinical trial validating TNF as a potential therapeutic target for local treatment. Joint Bone Spine. 2015 Oct;82(5):338–44. doi: 10.1016/j.jbspin.2015.03.002. PMID: 26188879 Exclusion Code: X3. [PubMed: 26188879] [CrossRef]

Aaltonen KJ, Joensuu JT, Pirilä L, et al. Drug survival on tumour necrosis factor inhibitors in patients with rheumatoid arthritis in Finland. Scand J Rheumatol. 2017;46(5):359–63. doi: 10.1080/03009742.2016.1234641. Exclusion Code: X3. [PubMed: 27931158] [CrossRef]

Aaltonen KJ, Joensuu JT, Virkki L, et al. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy. J Rheumatol. 2015 Mar;42(3):372–8. doi: 10.3899/jrheum.140853. PMID: 25593230. Exclusion Code: X3. [PubMed: 25593230] [CrossRef]

Aaltonen KJ, Sokka T, Mottonen T, et al. A nationwide cross-sectional overview of patients with rheumatoid arthritis followed in outpatient specialty clinics in Finland. Scand J Rheumatol. 2014;43(4):286–90. doi: 10.3109/03009742.2013.876512. PMID: 24654994 Exclusion Code: X3. [PubMed: 24654994] [CrossRef]

Aaltonen KJ, Ylikyla S, Tuulikki Joensuu J, et al. Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice. Rheumatology (Oxford).2017 May 01;56(5):725–35. doi: 10.1093/rheumatology/kew467. PMID: 28064209 Exclusion Code: X3. [PubMed: 28064209] [CrossRef]

Abasolo L, Leon L, Rodriguez-Rodriguez L, et al. Safety of disease-modifying antirheumatic drugs and biologic agents for rheumatoid arthritis patients in real-life conditions. Semin Arthritis Rheum. 2015 Apr;44(5):506–13. doi: 10.1016/j.semarthrit.2014.11.003. PMID: 25532946 Exclusion Code: X3. [PubMed: 25532946] [CrossRef]

Abdallah H, Hsu JC, Lu P, et al. Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA. J Clin Pharmacol. 2017 Apr;57(4):459–68. doi: 10.1002/jcph.826. PMID: 27599663. Exclusion Code: X3. [PMC free article: PMC5363244] [PubMed: 27599663] [CrossRef]

Abdulkader R, Dharmapalaiah C, Rose G, et al. Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab. J Rheumatol. 2014 May;41(5):858–61. doi: 10.3899/jrheum.130526. PMID: 24634201. Exclusion Code: X3. [PubMed: 24634201] [CrossRef]

Abe T, Takeuchi T, Miyasaka N, et al. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol. 2006 Jan;33(1):37–44. PMID: 16395748. Exclusion Code: X3. [PubMed: 16395748]

Accortt NA, Bonafede MM, Collier DH, et al. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs. Arthritis Rheumatol. 2016 Jan;68(1):67–76. doi: 10.1002/art.39416. PMID: 26359948. Exclusion Code: X3. [PubMed: 26359948] [CrossRef]

Accortt NA, Chung JB, Bonafede M, et al. Retrospective analysis to describe associations between tumor necrosis factor alpha inhibitors and COPD-related hospitalizations. International Journal of COPD. 2017;12:2085–94. doi: 10.2147/COPD.S127815. Exclusion Code: X3. [PMC free article: PMC5530069] [PubMed: 28790811] [CrossRef]

Ajeganova S, Fiskesund R, de Faire U, et al. Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritis - a one year study. Clin Exp Rheumatol. 2011 Nov-Dec;29(6):942–50 PMID: 22153361. Exclusion Code: X3. [PubMed: 22153361]

Akici A, Aydin V, Kadi E, et al. Increased risk of tuberculosis in patients with rheumatologic diseases managed with anti-TNF-a agents: A nationwide retrospective pharmacoepidemiological cohort study in Turkey. Clin Ther. 2017;39(8):e57. Exclusion Code: X3.

Akiyama M, Kaneko Y, Yamaoka K, et al. Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study. Rheumatol Int. 2016 Jun;36(6):881–9. doi: 10.1007/s00296-016-3478-3. PMID: 27072347. Exclusion Code: X3. [PubMed: 27072347] [CrossRef]

Alañón Pardo MM, Areas Del Águila VL, Cuadra Díaz JL, et al. Adherence to disease modifying antirheumatic drugs in patients with rheumatoid arthritis. European Journal of Hospital Pharmacy. 2016;23:A45–A6. doi: 10.1136/ejhpharm-2016-000875.104. Exclusion Code: X3. [CrossRef]

Alawneh KM, Ayesh MH, Khassawneh BY, et al. Anti-TNF therapy in Jordan: A focus on severe infections and tuberculosis. Biologics: Targets and Therapy. 2014;8:193–8. doi: 10.2147/BTT.S59574. Exclusion Code: X3. [PMC free article: PMC4003144] [PubMed: 24790412] [CrossRef]

Albattal BM. Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs or anti-tumor necrosis factor. Ann Saudi Med. 2016;36(3):190–6. doi: 10.5144/0256-4947.2016.190. Exclusion Code: X3. [PMC free article: PMC6074539] [PubMed: 27236390] [CrossRef]

Aletaha D, Bingham CO, Tanaka Y, et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. The Lancet. 2017;389(10075):1206–17. doi: 10.1016/S0140-6736(17)30401-4. Exclusion Code: X3. [PubMed: 28215362] [CrossRef]

Alkim H, Koksal AR, Boga S, et al. Etiopathogenesis, Prevention, and Treatment of Thromboembolism in Inflammatory Bowel Disease. Clin Appl Thromb Hemost. 2017;23(6):501–10. doi: 10.1177/1076029616632906. Exclusion Code: X3. [PubMed: 26893444] [CrossRef]

Al-Malaq HM, Al-Arfaj HF, Al-Arfaj AS. Adverse drug reactions caused by methotrexate in Saudi population. Saudi Pharmaceutical Journal. 2012;20(4):301–5. doi: 10.1016/j.jsps.2012.05.004. Exclusion Code: X3. [PMC free article: PMC3745090] [PubMed: 23960804] [CrossRef]

Alonso A, Gonzalez CM, Ballina J, et al. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs in rheumatoid arthritis: results of the GO-MORE study in Spain. Reumatol Clin. 2015 May-Jun;11(3):144–50. doi: 10.1016/j.reuma.2014.05.002. PMID: 25022442 Exclusion Code: X3. [PubMed: 25022442] [CrossRef]

Alten R, Nüßlein HG, Mariette X, et al. Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study. RMD Open. 2017;3(1) doi: 10.1136/rmdopen-2016-000345. Exclusion Code: X3. [PMC free article: PMC5307376] [PubMed: 28243468] [CrossRef]

Alves JA, Fialho SC, Morato EF, et al. Liver toxicity is rare in rheumatoid arthritis patients using combination therapy with leflunomide and methotrexate. Rev Bras Reumatol. 2011 Mar-Apr;51(2):141–4. PMID: 21584420. Exclusion Code: X3. [PubMed: 21584420]

Amann J, Wessels AM, Breitenfeldt F, et al. Quantifying cutaneous adverse effects of systemic glucocorticoids in patients with rheumatoid arthritis: a cross-sectional cohort study. Clin Exp Rheumatol. 2017 May-Jun;35(3):471–6. PMID: 28094753. Exclusion Code: X3. [PubMed: 28094753]

Amano K, Matsubara T, Tanaka T, et al. Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders. Mod Rheumatol. 2015 Sep;25(5):665–71. doi: 10.3109/14397595.2015.1012786. PMID: 25698370 Exclusion Code: X3. [PubMed: 25698370] [CrossRef]

Amari W, Zeringue AL, McDonald JR, et al. Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology (Oxford). 2011 Aug;50(8):1431–9. doi: 10.1093/rheumatology/ker113. PMID: 21415022 Exclusion Code: X3. [PubMed: 21415022] [CrossRef]

Antonelli MA, Moreland LW, Brick JE. Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. Am J Med. 1991 Mar;90(3):295–8. PMID: 2003511. Exclusion Code: X3. [PubMed: 2003511]

Antonio JR, Sanmiguel J, Cagnon GV, et al. Infliximab in patients with psoriasis and other inflammatory diseases: Evaluation of adverse events in the treatment of 168 patients. An Bras Dermatol. 2016;91(3):306–10 doi: 10.1590/abd1806-4841.20164292. Exclusion Code: X3. [PMC free article: PMC4938274] [PubMed: 27438197] [CrossRef]

Arida A, Protogerou AD, Konstantonis G, et al. Atherosclerosis is not accelerated in rheumatoid arthritis of low activity or remission, regardless of antirheumatic treatment modalities. Rheumatology (Oxford). 2017 Jun 01;56(6):934–9. doi: 10.1093/rheumatology/kew506. PMID: 28160488 Exclusion Code: X3. [PubMed: 28160488] [CrossRef]

Arroyo-Ávila M, Fred-Jiménez R, Pérez-Ríos N, et al. Incident hypertension and associated factors in a hispanic group with rheumatoid arthritis. Arthritis and Rheumatology. 2016;68:1855. doi: 10.1002/art.39977. Exclusion Code: X3. [CrossRef]

Arshad N, Ahmad NM, Saeed MA, et al. Adherence to methotrexate therapy in Rheumatoid Arthritis. Pakistan Journal of Medical Sciences. 2016;32(2):413–7. doi: 10.12669/pjms.322.9566. Exclusion Code: X3. [PMC free article: PMC4859034] [PubMed: 27182251] [CrossRef]

Asai S, Kojima T, Oguchi T, et al. Effects of Concomitant Methotrexate on Large Joint Replacement in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors: A Multicenter Retrospective Cohort Study in Japan. Arthritis Care Res (Hoboken). 2015 Oct;67(10):1363–70. doi: 10.1002/acr.22596. PMID: 25832554. Exclusion Code: X3. [PubMed: 25832554] [CrossRef]

Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005 Jul;52(7):1986–92. PMID: 15986370. Exclusion Code: X3. [PubMed: 15986370]

Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis. 2005 Oct;64(10):1421–6. PMID: 15829572. Exclusion Code: X3. [PMC free article: PMC1755244] [PubMed: 15829572]

Askling J, van Vollenhoven RF, Granath F, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum; 2009. p. 3180–9. Exclusion Code: X3. [PubMed: 19877027]

Atzeni F, Sarzi-Puttini P, Botsios C, et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev. 2012 Dec;12(2):225–9. doi: 10.1016/j.autrev.2012.06.008. PMID: 22796281 Exclusion Code: X3. [PubMed: 22796281] [CrossRef]

Avila-Pedretti G, Tornero J, Fernández-Nebro A, et al. Variation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritis. PLoS One. 2015;10(4) doi: 10.1371/journal.pone.0122088. Exclusion Code: X3. [PMC free article: PMC4388501] [PubMed: 25848939] [CrossRef]

Avouac J, Koumakis E, Toth E, et al. Increased risk of osteoporosis and fracture in women with systemic sclerosis: a comparative study with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012 Dec;64(12):1871–8. doi: 10.1002/acr.21761. PMID: 22730393. Exclusion Code: X3. [PubMed: 22730393] [CrossRef]

Backhaus M, Kaufmann J, Richter C, et al. Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice. Clin Rheumatol. 2015 Apr;34(4):673–81. doi: 10.1007/s10067-015-2879-0. PMID: 25630309. Exclusion Code: X3. [PMC free article: PMC4365186] [PubMed: 25630309] [CrossRef]

Baddley JW, Winthrop KL, Chen L, et al. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study. Ann Rheum Dis. 2014 Nov;73(11):1942–8. doi: 10.1136/annrheumdis-2013-203407. PMID: 23852763 Exclusion Code: X3. [PMC free article: PMC4273901] [PubMed: 23852763] [CrossRef]

Bae SC, Gun SC, Mok CC, et al. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis. BMC Musculoskelet Disord. 2013 Jan 08;14:13. doi: 10.1186/1471-2474-14-13 PMID: 23294908. Exclusion Code: X3. [PMC free article: PMC3606371] [PubMed: 23294908] [CrossRef]

Bae SC, Kim J, Choe JY, et al. A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study. Ann Rheum Dis. 2017 Jan;76(1):65–71. doi: 10.1136/annrheumdis-2015-207613. PMID: 26905864 Exclusion Code: X3. [PubMed: 26905864] [CrossRef]

Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006 Mar;54(3):692–701. PMID: 16508929. Exclusion Code: X3. [PubMed: 16508929]

Baker J, Conaghan P, Emery P, et al. Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis. Ann Rheum Dis; 2016. p. 1114–9. Exclusion Code: X3. [PMC free article: PMC4826311] [PubMed: 26091907]

Baker N, Boers M, Hochberg M, et al. Risk of hospitalized infections in patients with rheumatoid arthritis initiating abatacept and other biologics: Analysis of a United States claims database. Ann Rheum Dis. 2016;75:516. doi: 10.1136/annrheumdis-2016-eular.1322. Exclusion Code: X3. [CrossRef]

Balasubramanian A, Wade S, Adler RA, et al. Glucocorticoid exposure and fracture risk in a large cohort of commercially-insured rheumatoid arthritis patients under age 65. Arthritis and Rheumatology. 2014;66:S408. doi: 10.1002/art.38914. Exclusion Code: X3. [CrossRef]

Balsa A, Tovar Beltran JV, Caliz Caliz R, et al. Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study. Rheumatol Int. 2015 Sep;35(9):1525–34. doi: 10.1007/s00296-015-3237-x. PMID: 25773655. Exclusion Code: X3. [PubMed: 25773655] [CrossRef]

Bankhurst A. Etanercept and methotrexate combination therapy. Clin Exp Rheumatol; 2012. p. S69–72. Exclusion Code: X3.

Bartoli F, Bruni C, Tesei G, et al. Incidence of malignancies in patients with inflammatory rheumatic diseases and biological drugs: Experience from one center in Italy. Ann Rheum Dis. 2016;75:880. doi: 10.1136/annrheumdis-2016-eular.5769. Exclusion Code: X3. [CrossRef]

Bay-Jensen AC, Byrjalsen I, Siebuhr AS, et al. Serological biomarkers of joint tissue turnover predict tocilizumab response at baseline. J Clin Rheumatol. 2014 Sep;20(6):332–5. doi: 10.1097/rhu.0000000000000150. PMID: 25160020 Exclusion Code: X3. [PMC free article: PMC4154839] [PubMed: 25160020] [CrossRef]

Bazzani C, Filippini M, Caporali R, et al. Anti-TNFalpha therapy in a cohort of rheumatoid arthritis patients: Clinical outcomes. Autoimmunity Reviews; 2009. p. 260–5. Exclusion Code: X3. [PubMed: 19027090]

Bazzichi L, Biasi D, Tinazzi E, et al. Safety of rituximab in the routine treatment of rheumatoid arthritis in Italy in patients refractory to anti-TNFa drugs: results from the observational retrospective-prospective RUBINO study. Reumatismo. 2014 Nov 06;66(3):224–32. doi: 10.4081/reumatismo.2014.748. PMID: 25376957 Exclusion Code: X3. [PubMed: 25376957] [CrossRef]

Behrens F, Rossmanith T, Koehm M, et al. Effectiveness of different dosages of retreatment of rituximab in combination with leflunomide: Results from a multicenter randomized placebo controlled investigator initiated clinical trial in active rheumatoid arthritis (amara-study). Arthritis and Rheumatology. 2016;68:1262–3. doi: 10.1002/art.39977. Exclusion Code: X3. [CrossRef]

Bejerano C, Oreiro N, Fernandez-Lopez C, et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The optibio study. Arthritis and Rheumatology. 2016;68:853–5. doi: 10.1002/art.39977. Exclusion Code: X3. [CrossRef]

Belghali S, Ben Abderrahim K, Mahmoud I, et al. Brief Michigan Hand Outcomes Questionnaire in rheumatoid arthritis: A cross-sectional study of 100 patients. Hand Surgery and Rehabilitation. 2017;36(1):24–9 doi: 10.1016/j.hansur.2016.09.003. Exclusion Code: X3. [PubMed: 28137438] [CrossRef]

Benucci M, Meacci F, Grossi V, et al. Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab. Biologics: Targets and Therapy. 2016;10:53–8. doi: 10.2147/BTT.S97234. Exclusion Code: X3. [PMC free article: PMC4795572] [PubMed: 27041992] [CrossRef]

Benucci M, Saviola G, Baiardi P, et al. Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis. Int J Immunopathol Pharmacol; 2012. p. 269–74. Exclusion Code: X3. [PubMed: 21496415]

Berghen N, Teuwen LA, Westhovens R, et al. Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study. Clin Rheumatol. 2015 Oct;34(10):1687–95. doi: 10.1007/s10067-015-3026-7. PMID: 26219489 Exclusion Code: X3. [PubMed: 26219489] [CrossRef]

Bergstrom L, Yocum DE, Ampel NM, et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum. 2004 Jun;50(6):1959–66. PMID: 15188373. Exclusion Code: X3. [PubMed: 15188373]

Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford); 2007. p. 1157–60. Exclusion Code: X3. [PubMed: 17478469]

Berthelot JM, Benoist-Gerard S, le Goff B, et al. Outcome and safety of TNFalpha antagonist therapy in 475 consecutive outpatients (with rheumatoid arthritis or spondyloarthropathies) treated by a single physician according to their eligibility for clinical trials. Joint Bone Spine. 2010 Dec;77(6):564–9. doi: 10.1016/j.jbspin.2010.05.011. PMID: 20621538 Exclusion Code: X3. [PubMed: 20621538] [CrossRef]

Bili A, Sartorius JA, Kirchner HL, et al. Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients. J Clin Rheumatol. 2011 Apr;17(3):115–20. doi: 10.1097/RHU.0b013e318214b6b5. PMID: 21441823. Exclusion Code: X3. [PubMed: 21441823] [CrossRef]

Bili A, Tang X, Kirchner HL, et al. Prolonged hydroxychloroquine use is associated with decreased incidence of cardiovascular disease in rheumatoid arthritis patients. Arthritis Rheum. 2011;63(10). Exclusion Code: X3.

Bingham C, Mendelsohn A, Kim L, et al. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial. Arthritis Care Res (Hoboken); 2016. p. 1627–36. Exclusion Code: X3. [PMC free article: PMC5063174] [PubMed: 25623393]

Bingham CO, 3rd, Weinblatt M, Han C, et al. The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial. J Rheumatol. 2014 Jun;41(6):1067–76. doi: 10.3899/jrheum.130864. PMID: 24786931. Exclusion Code: X3. [PubMed: 24786931] [CrossRef]

Bird P, Griffiths H, Tymms K, et al. The SMILE study -- safety of methotrexate in combination with leflunomide in rheumatoid arthritis. J Rheumatol. 2013 Mar;40(3):228–35 doi: 10.3899/jrheum.120922. PMID: 23322457. Exclusion Code: X3. [PubMed: 23322457] [CrossRef]

Bird P, Peterfy C, DiCarlo J, et al. Ac-cute: An open-label study to evaluate non-progression of structural joint damage in patients with moderate to severe active rheumatoid arthritis treated with subcutaneous tocilizumab. Ann Rheum Dis. 2016;75:1029–30. doi: 10.1136/annrheumdis-2016-eular.3780. Exclusion Code: X3. [CrossRef]

Bird P, Rischmueller M, Feletar M, et al. Real world treat to target strategy in rheumatoid arthritis: Radiograph and MRI outcomes in three cohorts with 18 month follow up. Arthritis and Rheumatology. 2016;68:3299–300. doi: 10.1002/art.39977. Exclusion Code: X3. [CrossRef]

Blum MA, Koo D, Doshi JA. Measurement and Rates of Persistence With and Adherence to Biologics for Rheumatoid Arthritis: A Systematic Review. p. 901. Exclusion Code: X3. [PubMed: 21715007]

Blumenauer B, Judd M, Wells G, et al. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews. 2002(3):CD003785. Exclusion Code: X3. [PMC free article: PMC8729322] [PubMed: 12137712]

Blumentals WA, Arreglado A, Napalkov P, et al. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord. 2012 Aug 27;13:158. doi: 10.1186/1471-2474-13-158. PMID: 22925480. Exclusion Code: X3. [PMC free article: PMC3495205] [PubMed: 22925480] [CrossRef]

Boerbooms AM, Kerstens PJ, van Loenhout JW, et al. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum. 1995 Jun;24(6):411–21. PMID: 7667645. Exclusion Code: X3. [PubMed: 7667645]

Bonafede M, Fox KM, Wilson KL, et al. Anti-tumor necrosis factor dose escalation among biologic nave rheumatoid arthritis patients in commercial managed care plans in the two years following therapy initiation. Arthritis Rheum. 2011;63(10). Exclusion Code: X3.

Bonafede M, Johnson BH, Tang D, et al. Adherence and persistence with triple nonbiologic disease modifying antirheumatic drug therapy and etanercept-methotrexate combination therapy in us patients with rheumatoid arthritis. Ann Rheum Dis. 2014;73 doi: 10.1136/annrheumdis-2014-eular.1913. Exclusion Code: X3. [CrossRef]

Bonafede M, Johnson BH, Tang DH, et al. Etanercept-Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2015 Dec;67(12):1656–63. doi: 10.1002/acr.22638. PMID: 26097194. Exclusion Code: X3. [PMC free article: PMC5063099] [PubMed: 26097194] [CrossRef]

Boughrara W, Benzaoui A, Aberkane M, et al. No correlation between MTHFR c.677 C > T, MTHFR c.1298 A > C, and ABCB1 c.3435 C > T polymorphisms and methotrexate therapeutic outcome of rheumatoid arthritis in West Algerian population. Inflamm Res. 2017;66(6):505–13 doi: 10.1007/s00011-017-1034-6. Exclusion Code: X3. [PubMed: 28299396] [CrossRef]

Boyapati A, Msihid J, Fiore S, et al. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: A biomarker study of MOBILITY. Arthritis Research and Therapy. 2016;18(1) doi: 10.1186/s13075-016-1132-9. Exclusion Code: X3. [PMC free article: PMC5052933] [PubMed: 27716324] [CrossRef]

Boyle DL, Soma K, Hodge J, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis. 2015 Jun;74(6):1311–6. doi: 10.1136/annrheumdis-2014-206028. PMID: 25398374 Exclusion Code: X3. [PMC free article: PMC4431345] [PubMed: 25398374] [CrossRef]

Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis; 2006. p. 717–22 Exclusion Code: X3. [PubMed: 16912945]

Brassard P, Lowe AM, Bernatsky S, et al. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum; 2009. p. 300–4. Exclusion Code: X3. [PubMed: 19248128]

Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum; 1998. p. 2196–204. Exclusion Code: X3. [PubMed: 9870876]

Brode SK, Jamieson FB, Ng R, et al. Increased risk of mycobacterial infections associated with anti-rheumatic medications. Thorax. 2015 Jul;70(7):677–82. doi: 10.1136/thoraxjnl-2014-206470. PMID: 25911222 Exclusion Code: X3. [PubMed: 25911222] [CrossRef]

Bröms G, Granath F, Ekbom A, et al. Low Risk of Birth Defects for Infants Whose Mothers Are Treated With Anti-Tumor Necrosis Factor Agents During Pregnancy. Clin Gastroenterol Hepatol. 2016;14(2):234–41 doi: 10.1016/j.cgh.2015.08.039. Exclusion Code: X3. [PubMed: 26375613] [CrossRef]

Brouwer J, Laven JS, Hazes JM, et al. Brief Report: Miscarriages in Female Rheumatoid Arthritis Patients: Associations With Serologic Findings, Disease Activity, and Antirheumatic Drug Treatment. Arthritis Rheumatol. 2015 Jul;67(7):1738–43. doi: 10.1002/art.39137. PMID: 25930951. Exclusion Code: X3. [PubMed: 25930951] [CrossRef]

Brown S, Navarro CN, Pitzalis C, et al. The TRACTISS protocol: a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjögren’s Syndrome. BMC Musculoskelet Disord; 2014. p. 21. Exclusion Code: X3. [PMC free article: PMC3937118] [PubMed: 24438039]

Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002 Dec;46(12):3151–8. PMID: 12483718. Exclusion Code: X3. [PubMed: 12483718]

Buchbinder R, Barber M, Heuzenroeder L, et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 2008 Jun 15;59(6):794–9. PMID: 18512713. Exclusion Code: X3. [PubMed: 18512713]

Buchbinder R, Van Doornum S, Staples M, et al. Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study. BMC Musculoskelet Disord. 2015 Oct 20;16:309. doi: 10.1186/s12891-015-0772-2 PMID: 26481039. Exclusion Code: X3. [PMC free article: PMC4615333] [PubMed: 26481039] [CrossRef]

Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013 Feb 09;381(9865):451–60. doi: 10.1016/s0140-6736(12)61424-x. PMID: 23294500 Exclusion Code: X3. [PubMed: 23294500] [CrossRef]

Burmester GR, Feist E, Kellner H, et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis. 2011 May;70(5):755–9. doi: 10.1136/ard.2010.139725. PMID: 21187298 Exclusion Code: X3. [PMC free article: PMC3070275] [PubMed: 21187298] [CrossRef]

Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017 May;76(5):840–7. doi: 10.1136/annrheumdis-2016-210310. PMID: 27856432 Exclusion Code: X3. [PMC free article: PMC5530335] [PubMed: 27856432] [CrossRef]

Burmester GR, Mariette X, Montecucco C, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis; 2007. p. 732–9. Exclusion Code: X3. [PMC free article: PMC1954645] [PubMed: 17329305]

Burmester GR, Matucci-Cerinic M, Mariette X, et al. Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study. Arthritis Res Ther. 2014 Jan 27;16(1):R24. doi: 10.1186/ar4452. PMID: 24460746. Exclusion Code: X3. [PMC free article: PMC3979145] [PubMed: 24460746] [CrossRef]

Burmester GR, Mease P, Dijkmans BA, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis. 2009 Dec;68(12):1863–9. PMID: 19147611. Exclusion Code: X3. [PMC free article: PMC2770105] [PubMed: 19147611]

Burmester GR, Rubbert-Roth A, Cantagrel A, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis. 2014 Jan;73(1):69–74. doi: 10.1136/annrheumdis-2013-203523. PMID: 23904473 Exclusion Code: X3. [PMC free article: PMC3888614] [PubMed: 23904473] [CrossRef]

Burton MJ, Curtis JR, Yang S, et al. Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis c virus infection. J Rheumatol. 2017;44(5):565–70. doi: 10.3899/jrheum.160983. Exclusion Code: X3. [PubMed: 28250142] [CrossRef]

Busquets-Pérez N, Ponce A, Ortiz-Santamaria V, et al. How many patients with rheumatic diseases and TNF inhibitors treatment have latent tuberculosis? Reumatol Clin. 2017;13(5):282–6. doi: 10.1016/j.reuma.2016.05.006. Exclusion Code: X3. [PubMed: 27394672] [CrossRef]

Buttgereit F, Kent JD, Holt RJ, et al. Improvement Thresholds for Morning Stiffness Duration in Patients Receiving Delayed-Versus Immediate-Release Prednisone for Rheumatoid Arthritis. Bull Hosp Jt Dis (2013). 2015 Jul;73(3):168–77. PMID: 26535595. Exclusion Code: X3. [PubMed: 26535595]

Buttgereit F, Mehta D, Kirwan J, et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis. 2013 Feb;72(2):204–10. doi: 10.1136/annrheumdis-2011-201067. PMID: 22562974 Exclusion Code: X3. [PMC free article: PMC3553491] [PubMed: 22562974] [CrossRef]

Buttgereit F, Strand V, Lee EB, et al. Efficacy and safety of PF-04171327, a novel dissociated agonist of the glucocorticoid receptor (DAGR): Results of a phase 2, randomized, double-blind study. Ann Rheum Dis. 2015;74:737–8. doi: 10.1136/annrheumdis-2015-eular.4897. Exclusion Code: X3. [CrossRef]

Calasan MB, van den Bosch OF, Creemers MC, et al. Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis. Arthritis Res Ther. 2013;15(6):R217. doi: 10.1186/ar4413. PMID: 24345416. Exclusion Code: X3. [PMC free article: PMC3978699] [PubMed: 24345416] [CrossRef]

Calgüneri M, Pay S, Cali?kaner Z, et al. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin Exp Rheumatol; 2012. p. 699–704. Exclusion Code: X3.

Calip GS, Adimadhyam S, Xing S, et al. Medication adherence and persistence over time with self-administered TNF-alpha inhibitors among young adult, middle-aged, and older patients with rheumatologic conditions. Semin Arthritis Rheum. 2017 doi: 10.1016/j.semarthrit.2017.03.010. Exclusion Code: X3. [PubMed: 28410817] [CrossRef]

Calip GS, Lee WJ, Lee TA, et al. Tumor necrosis factor-alpha inhibitor medications for inflammatory conditions and incidence of multiple myeloma. Blood. 2015;126(23):2954. Exclusion Code: X3.

Calip GS, Lee WJ, Lee TA, et al. Risk of non-hodgkin lymphoma following treatment of inflammatory conditions with tumor necrosis factor-alpha inhibitors. Blood. 2015;126(23):2653. Exclusion Code: X3.

Caliz R, del Amo J, Balsa A, et al. The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population. Scand J Rheumatol. 2012 Feb;41(1):10–4. doi: 10.3109/03009742.2011.617312. PMID: 22044028 Exclusion Code: X3. [PubMed: 22044028] [CrossRef]

Canhao H, Rodrigues AM, Mourao AF, et al. Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. Rheumatology (Oxford). 2012 Nov;51(11):2020–6. doi: 10.1093/rheumatology/kes184. PMID: 22843791 Exclusion Code: X3. [PMC free article: PMC3475979] [PubMed: 22843791] [CrossRef]

Cannon GW, Holden WL, Juhaeri J, et al. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. J Rheumatol. 2004 Oct;31(10):1906–11. PMID: 15468352. Exclusion Code: X3. [PubMed: 15468352]

Cannon GW, Wang BC, Park GS, et al. Remission in rheumatoid arthritis patients treated with etanercept monotherapy: clinical practice and clinical trial experience. Clin Exp Rheumatol. 2013 Nov-Dec;31(6):919–25. PMID: 24237999. Exclusion Code: X3. [PubMed: 24237999]

Cantini F, Niccoli L, Goletti D. Adalimumab, Etanercept, Infliximab, and the Risk of Tuberculosis: Data from Clinical Trials, National Registries, and Postmarketing Surveillance. p. 47. Exclusion Code: X3. [PubMed: 24789000]

Cantini F, Niccoli L, Nannini C, et al. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Semin Arthritis Rheum; 2017. Exclusion Code: X3. [PubMed: 28413099]

Capell H, Madhok R, Hunter J, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis; 2012. p. 797–803. Exclusion Code: X3. [PMC free article: PMC1755058] [PubMed: 15194574]

Cardiel MH, Tak PP, Bensen W, et al. A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis. Arthritis Res Ther. 2010;12(5):R192. doi: 10.1186/ar3163. PMID: 20950476. Exclusion Code: X3. [PMC free article: PMC2991028] [PubMed: 20950476] [CrossRef]

Carmona L, Descalzo MÃ, Perez-Pampin E, et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis. 2007;66(7):880–5. Exclusion Code: X3. [PMC free article: PMC1955107] [PubMed: 17324968]

Carubbi F, Zugaro L, Cipriani P, et al. Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare. Int J Immunopathol Pharmacol. 2015;29(2):252–66. doi: 10.1177/0394632015593220. Exclusion Code: X3. [PMC free article: PMC5806711] [PubMed: 26684633] [CrossRef]

Cascino MD, Pei J, Haselkorn T, et al. Incident malignancies following initiation of rituximab for rheumatoid arthritis: Analysis from the sunstone registry. Ann Rheum Dis. 2016;75:503. doi: 10.1136/annrheumdis-2016-eular.5119. Exclusion Code: X3. [CrossRef]

Castañeda OM, Romero FJ, Salinas A, et al. Safety of tofacitinib in the treatment of rheumatoid arthritis in Latin America compared with the rest of the world population. J Clin Rheumatol. 2017;23(4):193–9. doi: 10.1097/RHU.0000000000000498. Exclusion Code: X3. [PubMed: 28145906] [CrossRef]

Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol. 2005 Nov;32(11):2130–5. PMID: 16265690. Exclusion Code: X3. [PubMed: 16265690]

Chang HC, Chen LC, Tseng HL, et al. The long-term utilization and safety of biological agents in treating rheumatoid arthritis patients - A population-based case study in Southern Taiwan. Value Health. 2010;13(7):A557. Exclusion Code: X3.

Chastek B, Becker LK, Chen CI, et al. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis. J Med Econ. 2017;20(5):464–73. doi: 10.1080/13696998.2016.1275653. Exclusion Code: X3. [PubMed: 28010149] [CrossRef]

Chatzidionysiou K, Askling J, Eriksson J, et al. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Ann Rheum Dis. 2015 May;74(5):890–6. doi: 10.1136/annrheumdis-2013-204714. PMID: 24431398 Exclusion Code: X3. [PubMed: 24431398] [CrossRef]

Chatzidionysiou K, Kristensen LE, Eriksson J, et al. Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register. Scand J Rheumatol. 2015;44(6):431–7. doi: 10.3109/03009742.2015.1026840. PMID: 26084325 Exclusion Code: X3. [PubMed: 26084325] [CrossRef]

Chatzidionysiou K, Lie E, Lukina G, et al. Rituximab retreatment in rheumatoid arthritis in a real-life cohort: Data from the CERERRA collaboration. J Rheumatol. 2017;44(2):162–9. doi: 10.3899/jrheum.160460. Exclusion Code: X3. [PubMed: 28089978] [CrossRef]

Chen DY, Chen YM, Hsieh TY, et al. Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis. Arthritis Res Ther. 2015 Mar 07;17:52. doi: 10.1186/s13075-015-0559-8. PMID: 25889426 Exclusion Code: X3. [PMC free article: PMC4384305] [PubMed: 25889426] [CrossRef]

Chen DY, Chou SJ, Hsieh TY, et al. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. 2009. Exclusion Code: X3. [PubMed: 19369178]

Chen HH, Chen DY, Chen YM, et al. Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis? Patient Preference and Adherence. 2016;10:123–34. doi: 10.2147/PPA.S94396. Exclusion Code: X3. [PMC free article: PMC4751906] [PubMed: 26917952] [CrossRef]

Chen HH, Chen DY, Lin CC, et al. Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/psoriatic arthritis: A nationwide, population-based cohort study of 84,989 patients. Ther Clin Risk Manag. 2017;13:583–92. doi: 10.2147/TCRM.S130666. Exclusion Code: X3. [PMC free article: PMC5422572] [PubMed: 28496328] [CrossRef]

Chen JS, Makovey J, Lassere M, et al. Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis. Arthritis Care Res (Hoboken). 2014 Mar;66(3):464–72. doi: 10.1002/acr.22151. PMID: 24022870. Exclusion Code: X3. [PubMed: 24022870] [CrossRef]

Chen L, Qi H, Jiang D, et al. The new use of an ancient remedy: a double-blinded randomized study on the treatment of rheumatoid arthritis. Am J Chin Med. 2013;41(2):263–80. doi: 10.1142/s0192415x13500195. PMID: 23548118 Exclusion Code: X3. [PubMed: 23548118] [CrossRef]

Chen YC. Prevalence of residual inflammation in rheumatoid arthritis patient after one year of adalimumab therapy. Int J Rheum Dis. 2016;19:169–70. doi: 10.1111/1756-185X.12962. Exclusion Code: X3. [CrossRef]

Chester Wasko M, Dasgupta A, Ilse Sears G, et al. Prednisone Use and Risk of Mortality in Patients with Rheumatoid Arthritis: Moderation by Use of Disease-Modifying Antirheumatic Drugs. Arthritis Care Res. 2016;68(5):706–10. doi: 10.1002/acr.22722. Exclusion Code: X3. [PMC free article: PMC4809799] [PubMed: 26415107] [CrossRef]

Chew BH, Vos RC, Metzendorf M-I, et al. Psychological interventions for diabetes-related distress in adults with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews: John Wiley & Sons, Ltd; 2017. Exclusion Code: X3. [PMC free article: PMC6483710] [PubMed: 28954185]

Chiang YC, Kuo LN, Yen YH, et al. Infection risk in patients with rheumatoid arthritis treated with etanercept or adalimumab. Comput Methods Programs Biomed. 2014 Oct;116(3):319–27. doi: 10.1016/j.cmpb.2014.06.008. PMID: 25022467. Exclusion Code: X3. [PubMed: 25022467] [CrossRef]

Chimenti MS, Graceffa D, Di Muzio G, et al. Discontinuation of anti-TNFα therapy due to remission in rheumatoid arthritis: A retrospective study. Clin Drug Investig. 2013;33(SUPPL.2):S122–S5. doi: 10.1007/s40261-012-0036-y. Exclusion Code: X3. [CrossRef]

Chiu YM, Lang HC, Lin HY, et al. Incidence of tuberculosis, serious infections, and lymphoma in patients with rheumatoid arthritis who received biologics and nonbiologic treatment in taiwan. Annals of the Rheumatic Disease. 2013;71 doi: 10.1136/annrheumdis-2012-eular.3430. Exclusion Code: X3. [CrossRef]

Chiu YM, Lang HC, Lin HY, et al. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan. Int J Rheum Dis. 2014 Dec;17 Suppl 3:9–19. doi: 10.1111/1756-185x.12539. PMID: 25496045. Exclusion Code: X3. [PubMed: 25496045] [CrossRef]

Cho SK, Kim D, Won S, et al. Safety of resuming biologic DMARDs in patients who develop tuberculosis after anti-TNF treatment. Semin Arthritis Rheum. 2017;47(1):102–7. doi: 10.1016/j.semarthrit.2017.01.004. Exclusion Code: X3. [PubMed: 28216194] [CrossRef]

Cho SK, Sung YK, Choi CB, et al. Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data. Rheumatol Int. 2012 Dec;32(12):3851–6. doi: 10.1007/s00296-011-2312-1. PMID: 22193228. Exclusion Code: X3. [PubMed: 22193228] [CrossRef]

Cho SK, Sung YK, Park S, et al. Etanercept treatment in rheumatoid arthritis patients with chronic kidney failure on predialysis. Rheumatol Int. 2010 Sep;30(11):1519–22. doi: 10.1007/s00296-009-1108-z. PMID: 19705121. Exclusion Code: X3. [PubMed: 19705121] [CrossRef]

Choe JY, Prodanovic N, Niebrzydowski J, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017 Jan;76(1):58–64. doi: 10.1136/annrheumdis-2015-207764. PMID: 26318384. Exclusion Code: X3. [PMC free article: PMC5264229] [PubMed: 26318384] [CrossRef]

Choi M, Barnabe C, Pope J, et al. A systematic review and appraisal of the ‘pragmaticism’ of randomized trials of biologic therapy in combination with methotrexate for rheumatoid arthritis. Journal of rheumatology. Conference: 72nd annual meeting of the canadian rheumatology association, CRA 2017. Canada; 2017. p. 927. Exclusion Code: X3.

Chopra A, Saluja M, Lagu-Joshi V, et al. Leflunomide (Arava) is a useful DMARD in Indian (Asian) patients: a clinic-based observational study of 1-year treatment. Clin Rheumatol; 2008. p. 1039–44. Exclusion Code: X3. [PubMed: 18470473]

Choquette D, Coupal L, Laliberté M, et al. Biologic discontinuation in rheumatoid arthritis: Experience from Canadian clinics. Value Health. 2015;18(3):A163. Exclusion Code: X3.

Chou MH, Wang JY, Lin CL, et al. DMARD use is associated with a higher risk of dementia in patients with rheumatoid arthritis: A propensity score-matched case– control study. Toxicol Appl Pharmacol. 2017;334:217–22. doi: 10.1016/j.taap.2017.09.014. Exclusion Code: X3. [PubMed: 28927738] [CrossRef]

Chou RC, Kane M, Ghimire S, et al. Treatment for Rheumatoid Arthritis and Risk of Alzheimer’s Disease: A Nested Case-Control Analysis. CNS Drugs. 2016;30(11):1111–20. doi: 10.1007/s40263-016-0374-z. Exclusion Code: X3. [PMC free article: PMC5585782] [PubMed: 27470609] [CrossRef]

Choy E, McKenna F, Vencovsky J, et al. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. Rheumatology (Oxford). 2012 Jul;51(7):1226–34. doi: 10.1093/rheumatology/ker519. PMID: 22344576 Exclusion Code: X3. [PubMed: 22344576] [CrossRef]

Christina CS, Burmester G, Nash P, et al. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2016;75(7):1293–301. doi: 10.1136/annrheumdis-2014-207178. Exclusion Code: X3. [PMC free article: PMC4941182] [PubMed: 26275429] [CrossRef]

Chu LH, Kawatakar AA. Long term medication adherence of adalimumab and etanercept among rheumatoid arthritis patients in kaiser permanente Soutern California. Value Health. 2012;15(4):A40. doi: 10.1016/j.jval.2012.03.228. Exclusion Code: X3. [CrossRef]

Chu LH, Kawatkar AA, Gabriel SE. Medication adherence and attrition to biologic treatment in rheumatoid arthritis patients. Clin Ther. 2015 Mar 01;37(3):660–6.e8. doi: 10.1016/j.clinthera.2014.10.022. PMID: 25618317. Exclusion Code: X3. [PubMed: 25618317] [CrossRef]

Cipriani P, Berardicurti O, Masedu F, et al. Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study. Clin Rheumatol. 2017;36(2):251–60. doi: 10.1007/s10067-016-3444-1. Exclusion Code: X3. [PubMed: 27783237] [CrossRef]

Cisternas MG, Michaud K. Comparative improvement in health-related quality of life for RA patients between TNF-α inhibitors, other biologics, and tofacitinib: Results from a US-wide observational study. Arthritis and Rheumatology. 2016;68:828–30. doi: 10.1002/art.39977. Exclusion Code: X3. [CrossRef]

Codreanu C, Mogoşan C, Ionescu R, et al. Biologic therapy in rheumatoid arthritis: Results from the Romanian registry of rheumatic diseases one year after initiation. Farmacia. 2014;62(6):1089–96. Exclusion Code: X3.

Codreanu C, Sirova K, Jarosova K, et al. Effectiveness and safety of CT-p13 (biosimilar reference infliximab) in a real-life setting in 151 patients with rheumatoid arthritis and ankylosing spondylitis: A mid-term interim analysis. Arthritis and Rheumatology. 2016;68:814–5. doi: 10.1002/art.39977. Exclusion Code: X3. [CrossRef]

Cohen S, Cannon G, Schiff M, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of leflunomide in the treatment of rheumatoid arthritis. Arthritis Rheum. 2001;44(9):1984–92. Exclusion Code: X3. [PubMed: 11592358]

Cohen S, Genovese MC, Choy E, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017 Oct;76(10):1679–87. doi: 10.1136/annrheumdis-2016-210459. PMID: 28584187 Exclusion Code: X3. [PMC free article: PMC5629940] [PubMed: 28584187] [CrossRef]

Cohen S, Keystone E, Genovese M, et al. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Ann Rheum Dis; 2010. p. 1158–61. Exclusion Code: X3. [PMC free article: PMC2935326] [PubMed: 20439295]

Cohen S, Radominski SC, Gomez-Reino JJ, et al. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014 Nov;66(11):2924–37. doi: 10.1002/art.38779. PMID: 25047021. Exclusion Code: X3. [PubMed: 25047021] [CrossRef]

Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793–806. PMID: 2006485778. Exclusion Code: X3. [PubMed: 16947627]

Cole J, Busti A, Kazi S. The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran’s Affairs patients receiving tumor necrosis factor alpha antagonists. Rheumatol Int; 2007. p. 369–73. Exclusion Code: X3. [PubMed: 17028862]

Colin O, Favrelière S, Quillet A, et al. Drug-induced progressive multifocal leukoencephalopathy: a case/noncase study in the French pharmacovigilance database. Fundam Clin Pharmacol. 2017;31(2):237–44 doi: 10.1111/fcp.12247. Exclusion Code: X3. [PubMed: 27736027] [CrossRef]

Combe B, Codreanu C, Fiocco U, et al. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. Ann Rheum Dis; 2009. p. 1146–52. Exclusion Code: X3. [PMC free article: PMC2689524] [PubMed: 18794178]

Combe B, Codreanu C, Fiocco U, et al. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis. 2006;65(10):1357–62. Exclusion Code: X3. [PMC free article: PMC1798315] [PubMed: 16606651]

Combe B, Dasgupta B, Louw I, et al. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study. Ann Rheum Dis. 2014 Aug;73(8):1477–86. doi: 10.1136/annrheumdis-2013-203229. PMID: 23740226 Exclusion Code: X3. [PMC free article: PMC4112444] [PubMed: 23740226] [CrossRef]

Combe B, Furst D, Keystone E, et al. Certolizumab Pegol Efficacy Across Methotrexate Regimens: a Pre-Specified Analysis of Two Phase III Trials. Arthritis Care Res (Hoboken); 2016. p. 299–307. Exclusion Code: X3. [PMC free article: PMC5067694] [PubMed: 26238672]

Combe BG, Codreanu C, Fiocco U, et al. Double-blind comparison of Etanercept and Sulphasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving Sulphasalazine. Ann Rheum Dis. 2006 Apr 10 PMID: 16606651. Exclusion Code: X3. [PMC free article: PMC1798315] [PubMed: 16606651]

Conaghan PG, Durez P, Alten RE, et al. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Ann Rheum Dis. 2013 Aug;72(8):1287–94. doi: 10.1136/annrheumdis-2012-201611. PMID: 22915624 Exclusion Code: X3. [PMC free article: PMC3711370] [PubMed: 22915624] [CrossRef]

Conaghan PG, Emery P, Ostergaard M, et al. Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial. Ann Rheum Dis. 2011 Nov;70(11):1968–74. doi: 10.1136/ard.2010.146068. PMID: 21784729 Exclusion Code: X3. [PMC free article: PMC3184239] [PubMed: 21784729] [CrossRef]

Conaghan PG, Østergaard M, Wu C, et al. Effects of tofacitinib on bone marrow edema, synovitis, and erosive damage in methotrexate-naïve patients with early active rheumatoid arthritis (duration ≤2 years): Results of an exploratory phase 2 MRI study. Arthritis and Rheumatology. 2014;66:S519–S20. doi: 10.1002/art.38914. Exclusion Code: X3. [CrossRef]

Conaghan PG, Peterfy C, Olech E, et al. The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy. Ann Rheum Dis. 2014 May;73(5):810–6. doi: 10.1136/annrheumdis-2013-204762. PMID: 24525910 Exclusion Code: X3. [PMC free article: PMC3995246] [PubMed: 24525910] [CrossRef]

Conigliaro P, Ciccacci C, Politi C, et al. Polymorphisms in STAT4, PTPN2, PSORS1C1 and TRAF3IP2 genes are associated with the response to TNF inhibitors in patients with rheumatoid arthritis. PLoS One. 2017;12(1) doi: 10.1371/journal.pone.0169956. Exclusion Code: X3. [PMC free article: PMC5249113] [PubMed: 28107378] [CrossRef]

Conigliaro P, Tonelli M, Triggianese P, et al. Predictive risk factors of remission and low-disease activity in rheumatoid arthritis patients treated with anti-TNF drugs in real practice: Results from a single centre. Ann Rheum Dis. 2016;75:978. doi: 10.1136/annrheumdis-2016-eular.3629. Exclusion Code: X3. [CrossRef]

Corominas H, Sanchez-Eslava L, Garcia G, et al. Safety profile of biological intravenous therapy in a rheumatoid arthritis patients cohort. Clinical nursing monitoring (Sebiol study). Reumatol Clin. 2013 Mar-Apr;9(2):80–4. doi: 10.1016/j.reuma.2012.06.001. PMID: 23099285 Exclusion Code: X3. [PubMed: 23099285] [CrossRef]

Courvoisier D, Rodriguez DA, Gottenberg JE, et al. Drug retention of biologics in rheumatoid arthritis patients: The role of baseline characteristics and impact of time-varying factors. Arthritis and Rheumatology. 2016;68:3380–3. doi: 10.1002/art.39977. Exclusion Code: X3. [CrossRef]

Curtis JR, Churchill M, Kivitz A, et al. A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol. Arthritis Rheumatol. 2015 Dec;67(12):3104–12. doi: 10.1002/art.39322. PMID: 26316013. Exclusion Code: X3. [PMC free article: PMC5063165] [PubMed: 26316013] [CrossRef]

Curtis JR, Kramer JM, Martin C, et al. Heart failure among younger rheumatoid arthritis and Crohn’s patients exposed to TNF-alpha antagonists. Rheumatology (Oxford); 2007. p. 1688–93. Exclusion Code: X3. [PMC free article: PMC2442887] [PubMed: 17938138]

Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum; 2007. p. 1125–33. Exclusion Code: X3. [PubMed: 17393394]

Curtis JR, Sarsour K, Napalkov P, et al. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor alpha agents, a retrospective cohort study. Arthritis Res Ther. 2015 Nov 11;17:319. doi: 10.1186/s13075-015-0835-7 PMID: 26555431. Exclusion Code: X3. [PMC free article: PMC4641344] [PubMed: 26555431] [CrossRef]

Curtis JR, Xi J, Patkar N, et al. Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum; 2007. p. 4226–7. Exclusion Code: X3. [PMC free article: PMC2561262] [PubMed: 18050253]

Curtis JR, Xie F, Chen L, et al. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1480–9. doi: 10.1002/acr.21805. PMID: 22833479. Exclusion Code: X3. [PMC free article: PMC3687540] [PubMed: 22833479] [CrossRef]

Curtis JR, Xie F, MacKey D, et al. Patient’s experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis. BMC Musculoskelet Disord. 2016;17(1) doi: 10.1186/s12891-016-1254-x. Exclusion Code: X3. [PMC free article: PMC5037591] [PubMed: 27669978] [CrossRef]

Curtis JR, Xie F, Yun H, et al. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated rheumatoid arthritis patients. Pharmacoepidemiol Drug Saf. 2016;25:513–4 doi: 10.1002/pds.4070. Exclusion Code: X3. [CrossRef]

Curtis JR, Xie F, Yun H, et al. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016 doi: 10.1136/annrheumdis-2016-209131. Exclusion Code: X3. [PMC free article: PMC5553444] [PubMed: 27113415] [CrossRef]

Curtis JR, Yang S, Chen L, et al. Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial. Ann Rheum Dis. 2012 Feb;71(2):206–12. doi: 10.1136/ard.2011.153551. PMID: 21998118 Exclusion Code: X3. [PMC free article: PMC3698970] [PubMed: 21998118] [CrossRef]

Curtis JR, Yang S, Patkar NM, et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Jul;66(7):990–7. doi: 10.1002/acr.22281. PMID: 24470378. Exclusion Code: X3. [PMC free article: PMC5059836] [PubMed: 24470378] [CrossRef]

Curtis JR, Zhang J, Xie F, et al. Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States. Arthritis Care Res (Hoboken). 2014 Nov;66(11):1604–11. doi: 10.1002/acr.22383. PMID: 24942466. Exclusion Code: X3. [PubMed: 24942466] [CrossRef]

da Cunha BM, de Oliveira SB, dos Santos-Neto LL. Sarar cohort: Disease activity, functional capacity, and radiological damage in rheumatoid arthritis patients undergoing total hip and knee arthroplasty. Revista Brasileira de Reumatologia. 2015;55(5):420–6 doi: 10.1016/j.rbre.2015.05.005. Exclusion Code: X3. [PubMed: 26071986] [CrossRef]

Dasgupta B, Combe B, Louw I, et al. Patient and physician expectations of add-on treatment with golimumab for rheumatoid arthritis: relationships between expectations and clinical and quality of life outcomes. Arthritis Care Res (Hoboken). 2014 Dec;66(12):1799–807. doi: 10.1002/acr.22371. PMID: 24839031. Exclusion Code: X3. [PubMed: 24839031] [CrossRef]

David JA, Sankarapandian V, Christopher PR, et al. Injected corticosteroids for treating plantar heel pain in adults. Cochrane Database of Systematic Reviews: John Wiley & Sons, Ltd; 2017. Exclusion Code: X3.

De Bandt M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7(3):R545–51. PMID: 15899041. Exclusion Code: X3. [PMC free article: PMC1174953] [PubMed: 15899041]

De Cuyper E, De Gucht V, Maes S, et al. Determinants of methotrexate adherence in rheumatoid arthritis patients. Clin Rheumatol. 2016 May;35(5):1335–9. doi: 10.1007/s10067-016-3182-4. PMID: 26781783 Exclusion Code: X3. [PubMed: 26781783] [CrossRef]

De Filippis L, Caliri A, Anghelone S, et al. Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis. Panminerva Med; 2006. p. 129–35. Exclusion Code: X3. [PubMed: 16953150]

de Jong TD, Vosslamber S, Blits M, et al. Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab. Arthritis Res Ther. 2015 Mar 23;17:78. doi: 10.1186/s13075-015-0564-y. PMID: 25889713. Exclusion Code: X3. [PMC free article: PMC4416246] [PubMed: 25889713] [CrossRef]

de Nijs RN, Jacobs JW, Bijlsma JW, et al. Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. Rheumatology (Oxford). 2001 Dec;40(12):1375–83. PMID: 11752508. Exclusion Code: X3. [PubMed: 11752508]

de Rotte MC, de Jong PH, Pluijm SM, et al. Association of low baseline levels of erythrocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate. Arthritis Rheum. 2013 Nov;65(11):2803–13. doi: 10.1002/art.38113. PMID: 24166792. Exclusion Code: X3. [PubMed: 24166792] [CrossRef]

de Rotte MC, den Boer E, de Jong PH, et al. Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis. Ann Rheum Dis. 2015 Feb;74(2):408–14. doi: 10.1136/annrheumdis-2013-203725. PMID: 24297383 Exclusion Code: X3. [PubMed: 24297383] [CrossRef]

de Steenwinkel FD, Hokken-Koelega AC, Hazes JM, et al. The influence of foetal prednisone exposure on the cortisol levels in the offspring. Clin Endocrinol (Oxf). 2014 Jun;80(6):804–10. doi: 10.1111/cen.12388. PMID: 24350658. Exclusion Code: X3. [PubMed: 24350658] [CrossRef]

de Thurah A, Norgaard M, Harder I, et al. Compliance with methotrexate treatment in patients with rheumatoid arthritis: influence of patients’ beliefs about the medicine. A prospective cohort study. Rheumatol Int. 2010 Sep;30(11):1441–8. doi: 10.1007/s00296-009-1160-8. PMID: 19823840. Exclusion Code: X3. [PubMed: 19823840] [CrossRef]

Deepak P, Sifuentes H, Sherid M, et al. T-cell non-Hodgkin’s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013 Jan;108(1):99–105. doi: 10.1038/ajg.2012.334. PMID: 23032984. Exclusion Code: X3. [PubMed: 23032984] [CrossRef]

Dehestani V, Shariati-Sarabi Z, Mohiti S, et al. Liver toxicity in rheumatoid arthritis patients treated with methotrexate. Asia Pacific Journal of Medical Toxicology. 2015;4(3):102–5. Exclusion Code: X3.

del Rincon I, Battafarano DF, Restrepo JF, et al. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol. 2014 Feb;66(2):264–72. doi: 10.1002/art.38210. PMID: 24504798. Exclusion Code: X3. [PubMed: 24504798] [CrossRef]

den Broeder AA, Creemers MC, Fransen J, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol; 2007. p. 689–95. Exclusion Code: X3. [PubMed: 17117492]

Deodhar A, Bitman B, Yang Y, et al. The effect of etanercept on traditional metabolic risk factors for cardiovascular disease in patients with rheumatoid arthritis. Clin Rheumatol. 2016;35(12):3045–52. doi: 10.1007/s10067-016-3422-7. Exclusion Code: X3. [PMC free article: PMC5118390] [PubMed: 27704313] [CrossRef]

Deodhar AA, Bitman B, Yang Y, et al. Etanercept treatment does not adversely affect traditional cardiovascular risk factors in patients with rheumatoid arthritis. Arthritis and Rheumatology. 2016;68:3472–3 doi: 10.1002/art.39977. Exclusion Code: X3. [CrossRef]

Desai RJ, Eddings W, Liao KP, et al. Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study. Arthritis Care Res (Hoboken). 2015 Apr;67(4):457–66. doi: 10.1002/acr.22483. PMID: 25302481. Exclusion Code: X3. [PMC free article: PMC4751079] [PubMed: 25302481] [CrossRef]

Desai RJ, Solomon DH, Schneeweiss S, et al. Tumor Necrosis Factor-alpha Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis. Epidemiology. 2016 May;27(3):414–22. doi: 10.1097/ede.0000000000000446. PMID: 26808597 Exclusion Code: X3. [PMC free article: PMC5497216] [PubMed: 26808597] [CrossRef]

Desborough MJ, Oakland K, Brierley C, et al. Desmopressin use for minimising perioperative blood transfusion. Cochrane Database of Systematic Reviews: John Wiley & Sons, Ltd; 2017. Exclusion Code: X3. [PMC free article: PMC5546394] [PubMed: 28691229]

Dewedar AM, Shalaby MA, Al-Homaid S, et al. Lack of adverse effect of anti-tumor necrosis factor-alpha biologics in treatment of rheumatoid arthritis: 5 years follow-up. Int J Rheum Dis. 2012 Jun;15(3):330–5. doi: 10.1111/j.1756-185X.2012.01715.x. PMID: 22709496 Exclusion Code: X3. [PubMed: 22709496] [CrossRef]

Dhir V, Aggarwal A. Methotrexate-related minor adverse effects in rheumatoid arthritis: more than a nuisance. J Clin Rheumatol. 2012 Jan;18(1):44–6. doi: 10.1097/RHU.0b013e31823ee540. PMID: 22157277 Exclusion Code: X3. [PubMed: 22157277] [CrossRef]

Dixon WG, Abrahamowicz M, Beauchamp ME, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in patients with rheumatoid arthritis: A nested case-control analysis using a weighted cumulative dose model. Arthritis Rheum. 2011;63(10). Exclusion Code: X3. [PMC free article: PMC3375584] [PubMed: 22241902]

Dixon WG, Abrahamowicz M, Beauchamp ME, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis. 2012 Jul;71(7):1128–33. doi: 10.1136/annrheumdis-2011-200702. PMID: 22241902 Exclusion Code: X3. [PMC free article: PMC3375584] [PubMed: 22241902] [CrossRef]

Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis; 2010. p. 522–8. Exclusion Code: X3. [PMC free article: PMC2927681] [PubMed: 19854715]

Dixon WG, Kezouh A, Bernatsky S, et al. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis. 2011 Jun;70(6):956–60. doi: 10.1136/ard.2010.144741. PMID: 21285116 Exclusion Code: X3. [PMC free article: PMC3086054] [PubMed: 21285116] [CrossRef]

Dixon WG, Symmons DP, Lunt M, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum; 2007. p. 2896–904. Exclusion Code: X3. [PMC free article: PMC2435418] [PubMed: 17763441]

Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006 Jul 25;54(8):2368–76. PMID: 16868999. Exclusion Code: X3. [PubMed: 16868999]

Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum; 2007. p. 2905–12 Exclusion Code: X3. [PMC free article: PMC2435427] [PubMed: 17763428]

Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002 Sep;46(9):2294–300. PMID: 12355476. Exclusion Code: X3. [PubMed: 12355476]

Dos Santos JB, Godman BB, Almeida AM, et al. Effectiveness of adalimumab and etanercept for the treatment of rheumatoid arthritis in the public health system (SUS) Belo Horizonte, Minas Gerais, Brazil. Pharmacoepidemiol Drug Saf. 2016;25:554–5 doi: 10.1002/pds.4070. Exclusion Code: X3. [CrossRef]

Dos Santos JBR, Almeida AM, Acurcio FDA, et al. Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System. Journal of Comparative Effectiveness Research. 2016;5(6):539–49. doi: 10.2217/cer-2016-0027. Exclusion Code: X3. [PMC free article: PMC5097454] [PubMed: 27641309] [CrossRef]

Dougados M, Huizinga T, Choy E, et al. Evaluation of the Disease Activity Score in Twenty-Eight Joints-Based Flare Definitions in Rheumatoid Arthritis: data From a Three-Year Clinical Trial. Arthritis Care Res (Hoboken); 2017. p. 1762–6. Exclusion Code: X3. [PMC free article: PMC5132117] [PubMed: 26037777]

Dougados M, Kissel K, Conaghan PG, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis. 2014 May;73(5):803–9. doi: 10.1136/annrheumdis-2013-204761. PMID: 24473673 Exclusion Code: X3. [PMC free article: PMC3995223] [PubMed: 24473673] [CrossRef]

Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013 Jan;72(1):43–50. doi: 10.1136/annrheumdis-2011-201282. PMID: 22562983 Exclusion Code: X3. [PMC free article: PMC3551223] [PubMed: 22562983] [CrossRef]

Dubey L, Chatterjee S, Ghosh A. Hepatic and hematological adverse effects of long-term low-dose methotrexate therapy in rheumatoid arthritis: An observational study. Indian J Pharmacol. 2016;48(5):591–4. doi: 10.4103/0253-7613.190761. Exclusion Code: X3. [PMC free article: PMC5051257] [PubMed: 27721549] [CrossRef]

Duclos M, Gossec L, Ruyssen-Witrand A, et al. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol; 2006. p. 2433–8. Exclusion Code: X3. [PubMed: 17014004]

Duquenne C, Wendling D, Sibilia J, et al. Glucocorticoid-sparing effect of first-year anti-TNFalpha treatment in rheumatoid arthritis (CORPUS Cohort). Clin Exp Rheumatol. 2017 Jul-Aug;35(4):638–46. PMID: 28516872. Exclusion Code: X3. [PubMed: 28516872]

Edwards CJ, Cooper C, Fisher D, et al. The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis. Arthritis Rheum; 2007. p. 1151–7. Exclusion Code: X3. [PubMed: 17907232]

Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004 Jun 17;350(25):2572–81. PMID: 15201414. Exclusion Code: X3. [PubMed: 15201414]

Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2000;39(6):655–65. Exclusion Code: X3. [PubMed: 10888712]

Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010 Sep;69(9):1629–35. doi: 10.1136/ard.2009.119933. PMID: 20488885 Exclusion Code: X3. [PMC free article: PMC2938895] [PubMed: 20488885] [CrossRef]

Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006 May 1;54(May):1390–400. Exclusion Code: X3. [PubMed: 16649186]

Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum; 2006. p. 1390–400. Exclusion Code: X3. [PubMed: 16649186]

Emery P, Fleischmann RM, Doyle MK, et al. Golimumab, a human anti-tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Care Res (Hoboken). 2013 Nov;65(11):1732–42. doi: 10.1002/acr.22072. PMID: 23861303. Exclusion Code: X3. [PubMed: 23861303] [CrossRef]

Emery P, Fleischmann RM, Hsia EC, et al. Efficacy of golimumab plus methotrexate in methotrexate-naive patients with severe active rheumatoid arthritis. Clin Rheumatol. 2014 Sep;33(9):1239–46. doi: 10.1007/s10067-014-2731-y. PMID: 25005327 Exclusion Code: X3. [PubMed: 25005327] [CrossRef]

Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum; 2009. p. 2272–83. Exclusion Code: X3. [PubMed: 19644849]

Emery P, Fleischmann RM, Strusberg I, et al. Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients with Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial. Arthritis Care Res. 2016;68(6):744–52. doi: 10.1002/acr.22759. Exclusion Code: X3. [PMC free article: PMC5089605] [PubMed: 26474452] [CrossRef]

Emery P, Gallo G, Boyd H, et al. Association between disease activity and risk of serious infections in subjects with rheumatoid arthritis treated with etanercept or disease-modifying anti-rheumatic drugs. Clin Exp Rheumatol. 2014 Sep-Oct;32(5):653–60. PMID: 25190189. Exclusion Code: X3. [PubMed: 25190189]

Emery P, Gottenberg JE, Rubbert-Roth A, et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis. 2015 Jun;74(6):979–84. doi: 10.1136/annrheumdis-2013-203993. PMID: 24442884 Exclusion Code: X3. [PMC free article: PMC4431330] [PubMed: 24442884] [CrossRef]

Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis; 2008. p. 1516–23. Exclusion Code: X3. [PMC free article: PMC3811149] [PubMed: 18625622]

Emery P, Kosinski M, Li T, et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. J Rheumatol. 2006 Apr;33(4):681–9. PMID: 16568505. Exclusion Code: X3. [PubMed: 16568505]

Emery P, Vencovsky J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017 Jan;76(1):51–7. doi: 10.1136/annrheumdis-2015-207588. PMID: 26150601. Exclusion Code: X3. [PMC free article: PMC5264222] [PubMed: 26150601] [CrossRef]

England BR, Pedro S, Mikuls TR, et al. Risk of incident cancer with biologic and tofacitinib therapy in rheumatoid arthritis. Arthritis and Rheumatology. 2016;68:4094–5. doi: 10.1002/art.39977. Exclusion Code: X3. [CrossRef]

Ertz-Archambault N, Taylor G, Kosiorek HE, et al. Myelodysplastic syndromes and acute myelogenous leukemia resulting from therapy for autoimmune disease, a case-control cohort study of 40,011 patients. Blood. 2016;128(22). Exclusion Code: X3.

Escudero-Vilaplana V, Ramirez-Herraiz E, Trovato-Lopez N, et al. Influence on effectiveness of early treatment with anti-TNF therapy in rheumatoid arthritis. J Pharm Pharm Sci. 2012;15(3):355–60. PMID: 22974785. Exclusion Code: X3. [PubMed: 22974785]

Espino-Lorenzo P, Manrique-Arija S, Urena I, et al. Baseline comorbidities in patients with rheumatoid arthritis who have been prescribed biological therapy: a case control study. Reumatol Clin. 2013 Jan-Feb;9(1):18–23 doi: 10.1016/j.reuma.2012.05.012. PMID: 22938792. Exclusion Code: X3. [PubMed: 22938792] [CrossRef]

Espinoza F, Le Blay P, Combe B. Biologic disease-modifying antirheumatic drug (bdmard)-induced neutropenia: A registry from a retrospective cohort of patients with rheumatic diseases treated with 3 classes of intravenous bdmard. J Rheumatol. 2017;44(6):844–9. doi: 10.3899/jrheum.150457. Exclusion Code: X3. [PubMed: 28412711] [CrossRef]

Esposti LD, Sangiorgi D, Perrone V, et al. Adherence and resource use among patients treated with biologic drugs: Findings from BEETLE study. ClinicoEconomics and Outcomes Research. 2014;6:401–7. doi: 10.2147/CEOR.S66338. Exclusion Code: X3. [PMC free article: PMC4171999] [PubMed: 25258545] [CrossRef]

Faarvang K, Egsmose C, Kryger P, et al. Hydroxychloroquine and Sulphasalazine Alone and in Combination in Rheumatoid Arthritis: a Randomised Double Blind Trial. Annals of the rheumatic diseases. 1993;52(10):711–5. Exclusion Code: X3. [PMC free article: PMC1005166] [PubMed: 7903034]

Fafa BP, Louzada-Junior P, Titton DC, et al. Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL. Clin Rheumatol. 2015 May;34(5):921–7. doi: 10.1007/s10067-015-2929-7. PMID: 25851594. Exclusion Code: X3. [PubMed: 25851594] [CrossRef]

Fautrel B, Joubert JM, Cukierman G, et al. Rheumatoid Arthritis (RA), Comorbidities and biological agents uptake in France: Analysis of a national claims database. Ann Rheum Dis. 2013;72 doi: 10.1136/annrheumdis-2013-eular.1040. Exclusion Code: X3. [CrossRef]

Favalli EG, Biggioggero M, Marchesoni A, et al. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology (Oxford). 2014 Sep;53(9):1664–8. doi: 10.1093/rheumatology/keu158. PMID: 24729445 Exclusion Code: X3. [PubMed: 24729445] [CrossRef]

Favalli EG, Pregnolato F, Biggioggero M, et al. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry. Arthritis Care Res (Hoboken). 2016 Apr;68(4):432–9. doi: 10.1002/acr.22788. PMID: 26556048. Exclusion Code: X3. [PubMed: 26556048] [CrossRef]

Fehlauer CS, Carson CW, Cannon GW, et al. Methotrexate therapy in rheumatoid arthritis: 2-year retrospective followup study. J Rheumatol. 1989 Mar;16(3):307–12. PMID: 2724249. Exclusion Code: X3. [PubMed: 2724249]

Feltelius N, Fored CM, Blomqvist P, et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis. 2005 Feb;64(2):246–52. PMID: 15208177. Exclusion Code: X3. [PMC free article: PMC1755333] [PubMed: 15208177]

Fernández Díaz C, Cervantes EC, Castañeda S, et al. Abatacept in rheumatoid arthritis with interstitial lung disease: A multicentre study in 34 patients. Ann Rheum Dis. 2016;75:722. doi: 10.1136/annrheumdis-2016-eular.5255. Exclusion Code: X3. [CrossRef]

Fernández-Díaz C, Loricera J, Castañeda S, et al. Abatacept in rheumatoid arthritis with interstitial lung disease: A multicenter study of 55 patients. Arthritis and Rheumatology. 2016;68:3477–80. doi: 10.1002/art.39977. Exclusion Code: X3. [CrossRef]

Fernandez-Nebro A, Irigoyen MV, Urena I, et al. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis. J Rheumatol; 2007. p. 2334–42. Exclusion Code: X3. [PubMed: 17985409]

Finckh A, Ciurea A, Brulhart L, et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum; 2007. p. 1417–23. Exclusion Code: X3. [PubMed: 17469098]

Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis; 2010. p. 387–93. Exclusion Code: X3. [PMC free article: PMC2800201] [PubMed: 19416802]

Finckh A, Dehler S, Gabay C. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. Ann Rheum Dis; 2009. p. 33–9. Exclusion Code: X3. [PubMed: 18230627]

Fisher MD, Watson C, Fox KM, et al. Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population. Curr Med Res Opin. 2013 May;29(5):561–8. doi: 10.1185/03007995.2013.786693. PMID: 23489410 Exclusion Code: X3. [PubMed: 23489410] [CrossRef]

Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2012 Mar;64(3):617–29. doi: 10.1002/art.33383. PMID: 21952978. Exclusion Code: X3. [PubMed: 21952978] [CrossRef]

Fleischmann R, Koenig AS, Szumski A, et al. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis. Rheumatology (Oxford). 2014 Nov;53(11):1984–93. doi: 10.1093/rheumatology/keu235. PMID: 24907147 Exclusion Code: X3. [PubMed: 24907147] [CrossRef]

Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012 Aug 09;367(6):495–507. doi: 10.1056/NEJMoa1109071. PMID: 22873530 Exclusion Code: X3. [PubMed: 22873530] [CrossRef]

Fleischmann R, Mease P, Schwartzman S, et al. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group. Clin Rheumatol. 2017;36(1):15–24. doi: 10.1007/s10067-016-3436-1. Exclusion Code: X3. [PMC free article: PMC5216063] [PubMed: 27734232] [CrossRef]

Fleischmann R, Tongbram V, Van Vollenhoven R, et al. Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis. RMD Open. 2017;3(1) doi: 10.1136/rmdopen-2016-000371. Exclusion Code: X3. [PMC free article: PMC5237767] [PubMed: 28123782] [CrossRef]

Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Arthritis and Rheumatology. 2017;69(2):277–90. doi: 10.1002/art.39944. Exclusion Code: X3. [PMC free article: PMC6207906] [PubMed: 27860410] [CrossRef]

Fleischmann R, Vencovsky J, Vollenhoven R, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis; 2012. p. 805–11. Exclusion Code: X3. [PMC free article: PMC2674555] [PubMed: 19015206]

Fleischmann RM, Baumgartner SW, Tindall EA, et al. Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol. 2003 Apr;30(4):691–6. PMID: 12672185. Exclusion Code: X3. [PubMed: 12672185]

Fleischmann RM, Halland AM, Brzosko M, et al. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results. J Rheumatol. 2013 Feb;40(2):113–26. doi: 10.3899/jrheum.120447. PMID: 23322466. Exclusion Code: X3. [PubMed: 23322466] [CrossRef]

Flendrie M, Creemers MC, Welsing PM, et al. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis. 2003 Nov;62 Suppl 2:ii30–3. PMID: 14532145. Exclusion Code: X3. [PMC free article: PMC1766750] [PubMed: 14532145]

Flendrie M, Creemers MC, Welsing PM, et al. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study. Rheumatology (Oxford). 2005 Apr;44(4):472–8. PMID: 15598707. Exclusion Code: X3. [PubMed: 15598707]

Flendrie M, Vissers WH, Creemers MC, et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7(3):R666–76. PMID: 15899052. Exclusion Code: X3. [PMC free article: PMC1174960] [PubMed: 15899052]

Flipo RM, Gaujoux-Viala C, Hudry C, et al. Prospective observational real-life study (STRATEGE) shows the efficacy of treat-to-target strategy and methotrexate monotherapy optimization in patients with established rheumatoid arthritis. Arthritis and Rheumatology. 2016;68:849–50. doi: 10.1002/art.39977. Exclusion Code: X3. [CrossRef]

Flouri I, Markatseli TE, Voulgari PV, et al. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Semin Arthritis Rheum. 2014 Feb;43(4):447–57. doi: 10.1016/j.semarthrit.2013.07.011. PMID: 24012040. Exclusion Code: X3. [PubMed: 24012040] [CrossRef]

Forsblad-d’Elia H, Bengtsson K, Kristensen LE, et al. Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register. Rheumatology (Oxford). 2015 Jul;54(7):1186–93. doi: 10.1093/rheumatology/keu455. PMID: 25505001 Exclusion Code: X3. [PubMed: 25505001] [CrossRef]

Frazier-Mironer A, Dougados M, Mariette X, et al. Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice. Joint Bone Spine. 2014 Jul;81(4):352–9. doi: 10.1016/j.jbspin.2014.02.014. PMID: 24721422 Exclusion Code: X3. [PubMed: 24721422] [CrossRef]

Fuerst M, Mohl H, Baumgartel K, et al. Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Rheumatol Int; 2006. p. 1138–42. Exclusion Code: X3. [PubMed: 16736164]

Fujibayashi T, Takahashi N, Kida D, et al. Comparison of efficacy and safety of tacrolimus and methotrexate in combination with abatacept in patients with rheumatoid arthritis; a retrospective observational study in the TBC Registry. Mod Rheumatol. 2015;25(6):825–30. doi: 10.3109/14397595.2015.1029238. PMID: 25775147 Exclusion Code: X3. [PubMed: 25775147] [CrossRef]

Furst D, Erikson N, Clute L, et al. Adverse Experience With Methotrexate During 176 Weeks of a Longterm Prospective Trial in Patients With Rheumatoid Arthritis. J Rheumatol. 1990;12:1628–35. Exclusion Code: X3. [PubMed: 2084236]

Furst D, Schiff M, Fleischmann R, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol; 2012. p. 2563–71. Exclusion Code: X3. [PubMed: 14719195]

Furst DE, Gaylis N, Bray V, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis. 2007 Jul;66(7):893–9. doi: 10.1136/ard.2006.068304. PMID: 17412737. Exclusion Code: X3. [PMC free article: PMC1955098] [PubMed: 17412737] [CrossRef]

Gabay C, McInnes IB, Kavanaugh A, et al. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2016 Oct;75(10):1806–12. doi: 10.1136/annrheumdis-2015-207872. PMID: 26613768 Exclusion Code: X3. [PMC free article: PMC5036214] [PubMed: 26613768] [CrossRef]

Gallego-Galisteo M, Villa-Rubio A, Alegredel Rey E, et al. Indirect comparison of biological treatments in refractory rheumatoid arthritis. J Clin Pharm Ther. 2012 Jun;37(3):301–7. doi: 10.1111/j.1365-2710.2011.01292.x. PMID: 21831256. Exclusion Code: X3. [PubMed: 21831256] [CrossRef]

Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011 Jan;50(1):124–31. doi: 10.1093/rheumatology/keq242. PMID: 20675706 Exclusion Code: X3. [PMC free article: PMC3105607] [PubMed: 20675706] [CrossRef]

Galloway JB, Hyrich KL, Mercer LK, et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011 Oct;70(10):1810–4. doi: 10.1136/ard.2011.152769. PMID: 21784730 Exclusion Code: X3. [PMC free article: PMC3168332] [PubMed: 21784730] [CrossRef]

Galloway JB, Mercer LK, Moseley A, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2013 Feb;72(2):229–34. doi: 10.1136/annrheumdis-2011-201108. PMID: 22532633 Exclusion Code: X3. [PMC free article: PMC3595979] [PubMed: 22532633] [CrossRef]

Garcia-Lagunar MH, Gutierrez-Civicos MR, Garcia-Simon MS, et al. Reasons for Discontinuation and Adverse Effects of TNFalpha Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis. Ann Pharmacother. 2017 May;51(5):388–93. doi: 10.1177/1060028016682330. PMID: 27920336 Exclusion Code: X3. [PubMed: 27920336] [CrossRef]

Gardette A, Ottaviani S, Tubach F, et al. High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis. Joint Bone Spine. 2014 Oct;81(5):416–20. doi: 10.1016/j.jbspin.2014.06.001. PMID: 24998790 Exclusion Code: X3. [PubMed: 24998790] [CrossRef]

Gaultney J, Benucci M, Iannazzo S, et al. Trial-based cost-effectiveness of abatacept for rheumatoid arthritis patients in Italy. Expert Rev Pharmacoecon Outcomes Res. 2016 Jun;16(3):409–17. doi: 10.1586/14737167.2016.1102636. PMID: 26495961 Exclusion Code: X3. [PubMed: 26495961] [CrossRef]

Geborek P, Bladstrom A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005 May;64(5):699–703. PMID: 15695534. Exclusion Code: X3. [PMC free article: PMC1755491] [PubMed: 15695534]

Geborek P, Crnkic M, Petersson IF, et al. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis. 2002 Sep;61(9):793–8. PMID: 12176803. Exclusion Code: X3. [PMC free article: PMC1754224] [PubMed: 12176803]

Genant H, Peterfy C, Westhovens R, et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis; 2012. p. 1084–9. Exclusion Code: X3. [PMC free article: PMC2569144] [PubMed: 18086727]

Genovese M, Becker J, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med; 2012. p. 1114–23. Exclusion Code: X3. [PubMed: 16162882]

Genovese M, Sebba A, Youssef P, et al. Long-term safety of tocilizumab in patients with rheumatoid arthritis following a mean treatment duration of 3.9 years (encore). Intern Med J. 2014;44:25. doi: 10.1111/imj.12426. Exclusion Code: X3. [CrossRef]

Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 2004 May;50(5):1412–9. PMID: 15146410. Exclusion Code: X3. [PubMed: 15146410]

Genovese MC, Covarrubias A, Leon G, et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum. 2011 Oct;63(10):2854–64. doi: 10.1002/art.30463. PMID: 21618201. Exclusion Code: X3. [PMC free article: PMC3229984] [PubMed: 21618201] [CrossRef]

Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. Arthritis Rheumatol. 2015 Jun;67(6):1424–37. doi: 10.1002/art.39093. PMID: 25733246. Exclusion Code: X3. [PubMed: 25733246] [CrossRef]

Genovese MC, Han C, Keystone EC, et al. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study. J Rheumatol. 2012 Jun;39(6):1185–91. doi: 10.3899/jrheum.111195. PMID: 22505702. Exclusion Code: X3. [PubMed: 22505702] [CrossRef]

Genovese MC, Kivitz AJ, Campos JAS, et al. Sarilumab for the treatment of moderate-to-severe rheumatoid arthritis: Results of a phase 2, randomized, double-blind, placebo-controlled, international study. Arthritis Rheum. 2011;63(12):4041–2. doi: 10.1002/art.33477. Exclusion Code: X3. [CrossRef]

Genovese MC, Kremer JM, van Vollenhoven RF, et al. Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis. Arthritis Rheumatol. 2017 Sep;69(9):1751–61. doi: 10.1002/art.40176. PMID: 28597609. Exclusion Code: X3. [PubMed: 28597609] [CrossRef]

Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum; 2008. p. 2968–80. Exclusion Code: X3. [PubMed: 18821691]

Ghodke-Puranik Y, Puranik AS, Shintre P, et al. Folate metabolic pathway single nucleotide polymorphisms: a predictive pharmacogenetic marker of methotrexate response in Indian (Asian) patients with rheumatoid arthritis. Pharmacogenomics. 2015 Dec;16(18):2019–34. doi: 10.2217/pgs.15.145. PMID: 26616421. Exclusion Code: X3. [PMC free article: PMC4976849] [PubMed: 26616421] [CrossRef]

Goll GL, Olsen IC, Jorgensen KK, et al. Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: Results from a 52-week randomized switch trial in Norway. Arthritis and Rheumatology. 2016;68:4389–92. doi: 10.1002/art.39977. Exclusion Code: X3. [CrossRef]

Gómez C, García ML, Galindez E, et al. Adherence to DMARD and subcutaneous biological therapy among rheumatoid arthritis and psoriatic arthritis patients at basurto university hospital. Ann Rheum Dis. 2016;75:1004. doi: 10.1136/annrheumdis-2016-eular.3915. Exclusion Code: X3. [CrossRef]

Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003 Aug;48(8):2122–7. PMID: 12905464. Exclusion Code: X3. [PubMed: 12905464]

Goodman SM, Springer B, Guyatt G, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. J Arthroplasty. 2017 doi: 10.1016/j.arth.2017.05.001. Exclusion Code: X3. [PubMed: 28629905] [CrossRef]

Gossec L, Danre A, Combe B, et al. Improvement in patient-reported outcomes after rituximab in rheumatoid arthritis patients: An open-label assessment of 175 patients. Joint Bone Spine. 2015 Dec;82(6):451–4. doi: 10.1016/j.jbspin.2015.02.007. PMID: 26162632 Exclusion Code: X3. [PubMed: 26162632] [CrossRef]

Gottenberg JE, Brocq O, Perdriger A, et al. NonTNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: A randomized clinical trial. JAMA - Journal of the American Medical Association. 2016;316(11):1172–80. doi: 10.1001/jama.2016.13512. Exclusion Code: X3. [PubMed: 27654603] [CrossRef]

Gottenberg JE, Ravaud P, Cantagrel A, et al. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry. Ann Rheum Dis. 2012 Nov;71(11):1815–9. doi: 10.1136/annrheumdis-2011-201109. PMID: 22615458 Exclusion Code: X3. [PubMed: 22615458] [CrossRef]

Grabner M, Boytsov NN, Huang Q, et al. Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: A retrospective claims analysis. Arthritis Research and Therapy. 2017;19(1) doi: 10.1186/s13075-017-1293-1. Exclusion Code: X3. [PMC free article: PMC5433023] [PubMed: 28506320] [CrossRef]

Grace EL, Marmaduke DQ, Motsko SP. Incidence of infections, cardiovascular, and hepatic events among initiators of TNF-α inhibitor therapy compared to methotrexate users. Pharmacoepidemiol Drug Saf. 2012;21:44. doi: 10.1002/pds.3324. Exclusion Code: X3. [CrossRef]

Graudal N, Hubeck-Graudal T, Tarp S, et al. Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials. PLoS One. 2014;9(9):e106408. doi: 10.1371/journal.pone.0106408. PMID: 25244021 Exclusion Code: X3. [PMC free article: PMC4171366] [PubMed: 25244021] [CrossRef]

Greenberg JD, Reed G, Kremer JM, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis; 2010. p. 380–6. Exclusion Code: X3. [PMC free article: PMC2861900] [PubMed: 19359261]

Greenwald MW, Shergy WJ, Kaine JL, et al. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial. Arthritis Rheum. 2011 Mar;63(3):622–32. doi: 10.1002/art.30194. PMID: 21360491. Exclusion Code: X3. [PubMed: 21360491] [CrossRef]

Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011 Dec 07;306(21):2331–9. doi: 10.1001/jama.2011.1692. PMID: 22056398. Exclusion Code: X3. [PMC free article: PMC3428224] [PubMed: 22056398] [CrossRef]

Grijalva CG, Chung CP, Arbogast PG, et al. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care; 2007. p. S66–76. Exclusion Code: X3. [PubMed: 17909386]

Grijalva CG, Kaltenbach L, Arbogast PG, et al. Initiation of rheumatoid arthritis treatments and the risk of serious infections. Rheumatology (Oxford); 2010. p. 82–90. Exclusion Code: X3. [PMC free article: PMC2909794] [PubMed: 19906833]

Guignard S, Gossec L, Bandinelli F, et al. Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients. A systematic review of 2707 patients, 18 vasculitis. Clin Exp Rheumatol; 2008. p. S23–9. Exclusion Code: X3. [PubMed: 18799049]

Han C, Weinblatt ME, Westhovens R, et al. Intravenous golimumab therapy improves hemoglobin, resulting in reduced anemia, improved physical function and fatigue in patients with moderate to severe rheumatoid arthritis: Results from go-further phase Iii clinical trial. Ann Rheum Dis. 2016;75:226. doi: 10.1136/annrheumdis-2016-eular.2012. Exclusion Code: X3. [CrossRef]

Hanrahan PS, Scrivens GA, Russell AS. Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression. Br J Rheumatol. 1989 Apr;28(2):147–53. PMID: 2706419. Exclusion Code: X3. [PubMed: 2706419]

Hansen M, Podenphant J, Florescu A, et al. A Randomised Trial of Differentiated Prednisolone Treatment in Active Rheumatoid Arthritis. Clinical Benefits and Skeletal Side Effects. Annals of the rheumatic diseases. 1999;58(11):713–8. Exclusion Code: X3. [PMC free article: PMC1752793] [PubMed: 10531077]

Haraoui B, Cividino A, Stewart J, et al. Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT study. BMC Musculoskelet Disord. 2011 Nov 17;12:261. doi: 10.1186/1471-2474-12-261. PMID: 22093579 Exclusion Code: X3. [PMC free article: PMC3226526] [PubMed: 22093579] [CrossRef]

Harigai M, Nanki T, Koike R, et al. Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan. Mod Rheumatol. 2016;26(5):642–50. doi: 10.3109/14397595.2016.1141740. Exclusion Code: X3. [PubMed: 26873430] [CrossRef]

Harigai M, Takeuchi T, Tanaka Y, et al. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Mod Rheumatol. 2012 Nov;22(6):814–22. doi: 10.1007/s10165-011-0586-5. PMID: 22270346. Exclusion Code: X3. [PubMed: 22270346] [CrossRef]

Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care. 2003 Oct;9(6 Suppl):S136–43. PMID: 14577718. Exclusion Code: X3. [PubMed: 14577718]

Harnett J, Curtis JR, Gerber R, et al. Initial Experience with Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination with Conventional Synthetic DMARDs in 2 US Health Care Claims Databases. Clin Ther. 2016;38(6):1451–63. doi: 10.1016/j.clinthera.2016.03.038. Exclusion Code: X3. [PubMed: 27112534] [CrossRef]

Harnett J, Gerber R, Gruben D, et al. Real-world experience with tofacitinib vs adalimumab (ADA), etanercept (ETN) and abatacept (ABA) in biologic-experienced patients with rheumatoid arthritis (RA): Data from a US administrative claims database. Ann Rheum Dis. 2016;75:1042–3. doi: 10.1136/annrheumdis-2016-eular.1837. Exclusion Code: X3. [CrossRef]

Harnett J, Gerber R, Gruben D, et al. Evaluation of real-world experience with tofacitinib compared with adalimumab, etanercept, and abatacept in Ra patients with 1 previous biologic DMARD: Data from a U.S. administrative claims database. Journal of Managed Care and Specialty Pharmacy. 2016;22(12):1457–71. doi: 10.18553/jmcp.2016.22.12.1457. Exclusion Code: X3. [PMC free article: PMC10397820] [PubMed: 27882833] [CrossRef]

Haroon M, Adeeb F, Devlin J, et al. A comparative study of renal dysfunction in patients with inflammatory arthropathies: strong association with cardiovascular diseases and not with anti-rheumatic therapies, inflammatory markers or duration of arthritis. Int J Rheum Dis. 2011 Aug;14(3):255–60. doi: 10.1111/j.1756-185X.2011.01594.x. PMID: 21816021. Exclusion Code: X3. [PubMed: 21816021] [CrossRef]

Haroon N, Srivastava R, Misra R, et al. A novel predictor of clinical response to methotrexate in patients with rheumatoid arthritis: a pilot study of in vitro T cell cytokine suppression. J Rheumatol. 2008 Jun;35(6):975–8. PMID: 18464312. Exclusion Code: X3. [PubMed: 18464312]

Harris ED, Jr., Emkey RD, Nichols JE, et al. Low dose prednisone therapy in rheumatoid arthritis: a double blind study. J Rheumatol. 1983 Oct;10(5):713–21. PMID: 6358491. Exclusion Code: X3. [PubMed: 6358491]

Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis; 2009. p. 209–15. Exclusion Code: X3. [PMC free article: PMC2605571] [PubMed: 18385277]

Harrold LR, Litman HJ, Connolly SE, et al. Impact of anti-cyclic citrullinated peptide and rheumatoid factor status on response to abatacept therapy: Findings from a us observational cohort. Ann Rheum Dis. 2016;75:123–4. doi: 10.1136/annrheumdis-2016-eular.1277. Exclusion Code: X3. [CrossRef]

Harrold LR, Litman HJ, Saunders KC, et al. The real world comparative safety of certolizumab pegol (CZP) as compared to other TNFI in a national us cohort. Arthritis and Rheumatology. 2016;68:3489–91. doi: 10.1002/art.39977. Exclusion Code: X3. [CrossRef]

Harrold LR, Reed GW, Karki C, et al. Risk of Infection Associated With Subsequent Biologic Agent Use After Rituximab: Results From a National Rheumatoid Arthritis Patient Registry. Arthritis Care Res. 2016;68(12):1888–93. doi: 10.1002/acr.22912. Exclusion Code: X3. [PMC free article: PMC5132134] [PubMed: 27111064] [CrossRef]

Harrold LR, Reed GW, Kremer JM, et al. The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Ann Rheum Dis. 2015 Feb;74(2):430–6. doi: 10.1136/annrheumdis-2013-203936. PMID: 24297378 Exclusion Code: X3. [PMC free article: PMC4316858] [PubMed: 24297378] [CrossRef]

Harrold LR, Reed GW, Magner R, et al. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry. Arthritis Res Ther. 2015 Sep 18;17:256. doi: 10.1186/s13075-015-0776-1. PMID: 26382589 Exclusion Code: X3. [PMC free article: PMC4574482] [PubMed: 26382589] [CrossRef]

Harrold LR, Reed GW, Solomon DH, et al. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry. Arthritis Research and Therapy. 2016;18(1) doi: 10.1186/s13075-016-1179-7. Exclusion Code: X3. [PMC free article: PMC5134270] [PubMed: 27906048] [CrossRef]

Haschka J, Englbrecht M, Hueber AJ, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis. 2016 Jan;75(1):45–51. doi: 10.1136/annrheumdis-2014-206439. PMID: 25660991 Exclusion Code: X3. [PubMed: 25660991] [CrossRef]

Hashimoto J, Garnero P, Heijde D, et al. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. Mod Rheumatol; 2011. p. 10–5. Exclusion Code: X3. [PMC free article: PMC3036807] [PubMed: 20574648]

Hashimoto M, Fujii T, Hamaguchi M, et al. Increase of hemoglobin levels by anti-IL-6 receptor antibody (tocilizumab) in rheumatoid arthritis. PLoS One. 2014;9(5):e98202. doi: 10.1371/journal.pone.0098202. PMID: 24878740. Exclusion Code: X3. [PMC free article: PMC4039447] [PubMed: 24878740] [CrossRef]

Hassett AL, Li T, Buyske S, et al. The multi-faceted assessment of independence in patients with rheumatoid arthritis: preliminary validation from the ATTAIN study. Curr Med Res Opin; 2008. p. 1443–53 Exclusion Code: X3. [PubMed: 18402714]

Hattori Y, Kojima T, Kaneko A, et al. Longterm retention rate and risk factors for adalimumab discontinuation due to efficacy and safety in Japanese patients with rheumatoid arthritis: An observational cohort study. J Rheumatol. 2016;43(8):1475–9. doi: 10.3899/jrheum.151006. Exclusion Code: X3. [PubMed: 27307531] [CrossRef]

Hayashi M, Kobayakawa T, Takanashi T, et al. Golimumab reduces disease activity of rheumatoid arthritis for 1 year and strongly inhibits radiographic progression in Japanese patients: partial but detailed results of the GO-FORTH and GO-MONO studies. Clin Rheumatol. 2013 Jul;32(7):961–7. doi: 10.1007/s10067-013-2210-x. PMID: 23397148 Exclusion Code: X3. [PubMed: 23397148] [CrossRef]

Heiberg MS, Rødevand E, Mikkelsen K, et al. Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: Results from a 6-month longitudinal, observational, multicentre study. Ann Rheum Dis; 2006. p. 1379–83. Exclusion Code: X3. [PMC free article: PMC1798316] [PubMed: 16679432]

Herrinton LJ, Liu L, Chen L, et al. Association between anti-TNF-alpha therapy and all-cause mortality. Pharmacoepidemiol Drug Saf. 2012 Dec;21(12):1311–20. doi: 10.1002/pds.3354. PMID: 23065964. Exclusion Code: X3. [PMC free article: PMC3565563] [PubMed: 23065964] [CrossRef]

Herwaarden N, Maas A, Minten M, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ (Clinical research ed.); 2015. p. h1389. Exclusion Code: X3. [PMC free article: PMC4391970] [PubMed: 25858265]

Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab results from eight years of surveillance of clinical practice in the Nationwide Danish DANBIO Registry. Arthritis Rheum. 2010;62(1):22–32. Exclusion Code: X3. [PubMed: 20039405]

Higuchi T, Higuchi Y, Fuke S, et al. Maximum methotrexate dose seem to be an only risk factor for development of MTX-associated lymphoproliferative disorders. Ann Rheum Dis. 2016;75:714–5. doi: 10.1136/annrheumdis-2016-eular.4193. Exclusion Code: X3. [CrossRef]

Hirabayashi Y, Munakata Y, Miyata M, et al. Clinical and structural remission rates increased annually and radiographic progression was continuously inhibited during a 3-year administration of tocilizumab in patients with rheumatoid arthritis: A multi-center, prospective cohort study by the Michinoku Tocilizumab Study Group. Mod Rheumatol. 2016;26(6):828–35. doi: 10.3109/14397595.2016.1160991. Exclusion Code: X3. [PubMed: 26934116] [CrossRef]

Hirata S, Saito K, Kubo S, et al. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study. Arthritis Res Ther. 2013 Sep 25;15(5):R135. doi: 10.1186/ar4315. PMID: 24286472. Exclusion Code: X3. [PMC free article: PMC3978613] [PubMed: 24286472] [CrossRef]

Hiroshima R, Kawakami K, Iwamoto T, et al. Analysis of C-reactive protein levels and febrile tendency after joint surgery in rheumatoid arthritis patients treated with a perioperative 4-week interruption of tocilizumab. Mod Rheumatol. 2011 Feb;21(1):109–11. doi: 10.1007/s10165-010-0343-1. PMID: 20824299. Exclusion Code: X3. [PubMed: 20824299] [CrossRef]

Hishitani Y, Ogata A, Shima Y, et al. Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis. Scand J Rheumatol. 2013;42(4):253–9. doi: 10.3109/03009742.2012.762037. PMID: 23470089 Exclusion Code: X3. [PubMed: 23470089] [CrossRef]

Hjardem E, Ostergaard M, Podenphant J, et al. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? Ann Rheum Dis; 2007. p. 1184–9. Exclusion Code: X3. [PMC free article: PMC1955158] [PubMed: 17389656]

Hone D, Cheng A, Watson C, et al. Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States. Arthritis Care Res (Hoboken). 2013 Oct;65(10):1564–72. doi: 10.1002/acr.22022. PMID: 23554320. Exclusion Code: X3. [PubMed: 23554320] [CrossRef]

Hooper M, Wenkert D, Bitman B, et al. Malignancies in children and young adults on etanercept: Summary of cases from clinical trials and post marketing reports. Pediatric Rheumatology. 2013;11(1) doi: 10.1186/1546-0096-11-35. Exclusion Code: X3. [PMC free article: PMC3851136] [PubMed: 24225257] [CrossRef]

Hoshi D, Nakajima A, Inoue E, et al. Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab. Mod Rheumatol. 2012 Feb;22(1):122–7. doi: 10.1007/s10165-011-0488-6. PMID: 21735355. Exclusion Code: X3. [PubMed: 21735355] [CrossRef]

Hu C, Xu Z, Zhang Y, et al. Population approach for exposure-response modeling of golimumab in patients with rheumatoid arthritis. J Clin Pharmacol. 2011 May;51(5):639–48. doi: 10.1177/0091270010372520. PMID: 20622199 Exclusion Code: X3. [PubMed: 20622199] [CrossRef]

Huffstutter JE, Kafka S, Brent LH, et al. Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study. Curr Med Res Opin. 2017 Apr;33(4):657–66. doi: 10.1080/03007995.2016.1277195. PMID: 28035867 Exclusion Code: X3. [PubMed: 28035867] [CrossRef]

Huizinga T, Fleischmann R, Jasson M, et al. Sarilumab, a fully human monoclonal antibody against IL-6R? in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARILRA-MOBILITY Part A trial. Ann Rheum Dis; 2016. p. 1626–34. Exclusion Code: X3. [PMC free article: PMC4145418] [PubMed: 24297381]

Huizinga TW, Conaghan PG, Martin-Mola E, et al. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis. 2015 Jan;74(1):35–43. doi: 10.1136/annrheumdis-2014-205752. PMID: 25169728. Exclusion Code: X3. [PMC free article: PMC4283697] [PubMed: 25169728] [CrossRef]

Huizinga TW, Fleischmann RM, Jasson M, et al. Sarilumab, a fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARILRA-MOBILITY Part A trial. Ann Rheum Dis. 2014 Sep;73(9):1626–34. doi: 10.1136/annrheumdis-2013-204405. PMID: 24297381 Exclusion Code: X3. [PMC free article: PMC4145418] [PubMed: 24297381] [CrossRef]

Hung YM, Lin L, Chen CM, et al. The effect of anti-rheumatic medications for coronary artery diseases risk in patients with rheumatoid arthritis might be changed over time: A nationwide population-based cohort study. PLoS One. 2017;12(6) doi: 10.1371/journal.pone.0179081. Exclusion Code: X3. [PMC free article: PMC5489160] [PubMed: 28658301] [CrossRef]

Hwang YG, Balasubramani GK, Metes ID, et al. Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker. Arthritis Research and Therapy. 2016;18(1) doi: 10.1186/s13075-016-1009-y. Exclusion Code: X3. [PMC free article: PMC4869396] [PubMed: 27188329] [CrossRef]

Hyrich KL, Lunt M, Watson KD, et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum; 2007. p. 13–20. Exclusion Code: X3. [PubMed: 17195186]

Hyrich KL, Symmons DP, Watson KD, et al. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006 May 30;54(6):1786–94. PMID: 16736520. Exclusion Code: X3. [PubMed: 16736520]

Hyrich KL, Watson KD, Silman AJ, et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology; 2006. p. 1558–65. Exclusion Code: X3. [PubMed: 16705046]

Iannone F, Courvoisier DS, Gottenberg JE, et al. Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the “pan-European registry collaboration for abatacept (PANABA). Clin Rheumatol. 2017;36(4):773–9. doi: 10.1007/s10067-016-3505-5. Exclusion Code: X3. [PubMed: 27966068] [CrossRef]

Iannone F, Fanizzi R, Notarnicola A, et al. Obesity reduces the drug survival of second line biological drugs following a first TNF-alpha inhibitor in rheumatoid arthritis patients. Joint Bone Spine. 2015 May;82(3):187–91. doi: 10.1016/j.jbspin.2014.12.006. PMID: 25619156 Exclusion Code: X3. [PubMed: 25619156] [CrossRef]

Iannone F, Gremese E, Atzeni F, et al. Longterm retention of tumor necrosis factor-alpha inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol. 2012 Jun;39(6):1179–84. doi: 10.3899/jrheum.111125. PMID: 22467933. Exclusion Code: X3. [PubMed: 22467933] [CrossRef]

Iannone F, Gremese E, Gallo G, et al. High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register. Clin Rheumatol. 2014 Jan;33(1):31–7 doi: 10.1007/s10067-013-2348-6. PMID: 23954923. Exclusion Code: X3. [PubMed: 23954923] [CrossRef]

Iannone F, La Montagna G, Bagnato G, et al. Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial. J Rheumatol. 2014 Feb;41(2):286–92. doi: 10.3899/jrheum.130658. PMID: 24429167. Exclusion Code: X3. [PubMed: 24429167] [CrossRef]

Iking-Konert C, von Hinuber U, Richter C, et al. ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany. Rheumatology (Oxford). 2016 Apr;55(4):624–35. doi: 10.1093/rheumatology/kev372. PMID: 26515959 Exclusion Code: X3. [PubMed: 26515959] [CrossRef]

Ince-Askan H, Hazes JMW, Dolhain R. Identifying Clinical Factors Associated With Low Disease Activity and Remission of Rheumatoid Arthritis During Pregnancy. Arthritis Care Res (Hoboken). 2017 Sep;69(9):1297–303. doi: 10.1002/acr.23143. PMID: 27813290. Exclusion Code: X3. [PubMed: 27813290] [CrossRef]

Ishaq M, Muhammad JS, Hameed K, et al. Leflunomide or methotrexate? Comparison of clinical efficacy and safety in low socioeconomic rheumatoid arthritis patients. Mod Rheumatol. 2011 Aug;21(4):375–80. doi: 10.1007/s10165-010-0405-4. PMID: 21229373 Exclusion Code: X3. [PubMed: 21229373] [CrossRef]

Isik M, Halacli B, Atmaca O, et al. Triple DMARD combination for rheumatoid arthritis resistant to methotrexate and steroid combination: a single-center experience. Rheumatol Int. 2013 Jun;33(6):1425–7. doi: 10.1007/s00296-012-2546-6. PMID: 23152085 Exclusion Code: X3. [PubMed: 23152085] [CrossRef]

Islam M, Alam M, Haq S, et al. Efficacy of Sulphasalazine Plus Methotrexate in Rheumatoid Arthritis. Bangladesh Medical Research Council bulletin. 2000;26(1):1–7. Exclusion Code: X3. [PubMed: 11192489]

Isvy A, Meunier M, Gobeaux-Chenevier C, et al. Safety of rituximab in rheumatoid arthritis: a long-term prospective single-center study of gammaglobulin concentrations and infections. Joint Bone Spine. 2012 Jul;79(4):365–9. doi: 10.1016/j.jbspin.2011.12.004. PMID: 22285615 Exclusion Code: X3. [PubMed: 22285615] [CrossRef]

Iwatani M, Inoue E, Nakamura T, et al. Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA. Mod Rheumatol; 2006. p. 376–80. Exclusion Code: X3. [PubMed: 17165000]

Izumi K, Kaneko Y, Hashizume M, et al. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naive Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study). PLoS One. 2015;10(12):e0145468. doi: 10.1371/journal.pone.0145468. PMID: 26698858 Exclusion Code: X3. [PMC free article: PMC4689361] [PubMed: 26698858] [CrossRef]

Izumi K, Kaneko Y, Yasuoka H, et al. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52. Mod Rheumatol. 2015 Jan;25(1):31–7. doi: 10.3109/14397595.2014.897793. PMID: 24684408 Exclusion Code: X3. [PubMed: 24684408] [CrossRef]

Jacobsson LT, Turesson C, Gulfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol. 2005 Jul;32(7):1213–8. PMID: 15996054. Exclusion Code: X3. [PubMed: 15996054]

Jagoda JS, Rajapakse CN. Leflunomide in clinical practice. A retrospective observational study on use of leflunomide in New Zealand. Int J Rheum Dis. 2011 Oct;14(4):340–4. doi: 10.1111/j.1756-185X.2011.01637.x. PMID: 22004230. Exclusion Code: X3. [PubMed: 22004230] [CrossRef]

Jaimes-Hernandez J, Melendez-Mercado CI, Mendoza-Fuentes A, et al. Efficacy of leflunomide 100mg weekly compared to low dose methotrexate in patients with active rheumatoid arthritis. Double blind, randomized clinical trial. Reumatol Clin. 2012 Sep-Oct;8(5):243–9. doi: 10.1016/j.reuma.2012.03.013. PMID: 22763150 Exclusion Code: X3. [PubMed: 22763150] [CrossRef]

Jani M, Chinoy H, Warren RB, et al. Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheumatol. 2015 May;67(8):2011–9. doi: 10.1002/art.39169. PMID: 26109489. Exclusion Code: X3. [PMC free article: PMC4843946] [PubMed: 26109489] [CrossRef]

Javed S, Kamili QU, Mendoza N, et al. Possible association of lower rate of postherpetic neuralgia in patients on anti-tumor necrosis factor-alpha. J Med Virol. 2011 Nov;83(11):2051–5. doi: 10.1002/jmv.22182. PMID: 21915882. Exclusion Code: X3. [PubMed: 21915882] [CrossRef]

Jiang L, Liu Y, Zhang L, et al. Rituximab for treating inhibitors in people with inherited severe hemophilia. Cochrane Database of Systematic Reviews: John Wiley & Sons, Ltd; 2017. Exclusion Code: X3.

Jiang Y, Genant HK, Watt I, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 2000 May;43(5):1001–9. PMID: 10817552. Exclusion Code: X3. [PubMed: 10817552]

Jin Y, Desai RJ, Liu J, et al. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis. Arthritis Research and Therapy. 2017;19(1) doi: 10.1186/s13075-017-1366-1. Exclusion Code: X3. [PMC free article: PMC5499035] [PubMed: 28679392] [CrossRef]

Jobanputra P, Barton P, Bryan S, et al. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2002;6(21):1–110. PMID: 12387732. Exclusion Code: X3. [PubMed: 12387732]

Jobanputra P, Maggs F, Deeming A, et al. A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: A pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: Outcomes over 2 years. BMJ Open. 2012;2(6) doi: 10.1136/bmjopen-2012-001395. Exclusion Code: X3. [PMC free article: PMC3532970] [PubMed: 23148339] [CrossRef]

Joensuu JT, Aaltonen KJ, Aronen P, et al. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study. Rheumatology (Oxford). 2016 Oct;55(10):1803–11. doi: 10.1093/rheumatology/kew264. PMID: 27354689 Exclusion Code: X3. [PubMed: 27354689] [CrossRef]

John A, Prehn AW, Tawfik H, et al. Incidence of non alcoholic fatty liver disease by key risk factors among patients with rheumatoid arthritis. Arthritis and Rheumatology. 2016;68:37–40. doi: 10.1002/art.39977. Exclusion Code: X3. [CrossRef]

Johnston SS, Turpcu A, Shi N, et al. Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis. Semin Arthritis Rheum. 2013 Aug;43(1):39–47. doi: 10.1016/j.semarthrit.2012.12.024. PMID: 23453683 Exclusion Code: X3. [PubMed: 23453683] [CrossRef]

Jones G. The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis. Expert Rev Clin Immunol; 2010. p. 189–95. Exclusion Code: X3. [PubMed: 20402381]

Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis; 2010. p. 88–96. Exclusion Code: X3. [PMC free article: PMC3747519] [PubMed: 19297346]

Jones G, Wallace T, McIntosh MJ, et al. Five-year Efficacy and safety of tocilizumab monotherapy in patients with rheumatoid arthritis who were methotrexate-And biologic-naive or free of methotrexate for 6 months: The ambition study. J Rheumatol. 2017;44(2):142–6. doi: 10.3899/jrheum.160287. Exclusion Code: X3. [PubMed: 27909081] [CrossRef]

Joost I, Kaasch A, Pausch C, et al. Staphylococcus aureus bacteremia in patients with rheumatoid arthritis – Data from the prospective INSTINCT cohort. J Infect. 2017;74(6):575–84. doi: 10.1016/j.jinf.2017.03.003. Exclusion Code: X3. [PubMed: 28322887] [CrossRef]

Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017 Jun 10;389(10086):2304–16 doi: 10.1016/s0140-6736(17)30068-5. PMID: 28502609. Exclusion Code: X3. [PubMed: 28502609] [CrossRef]

Jorgensen TS, Kristensen LE, Christensen R, et al. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry. Rheumatology (Oxford). 2015 Dec;54(12):2156–65. doi: 10.1093/rheumatology/kev216. PMID: 26175471 Exclusion Code: X3. [PubMed: 26175471] [CrossRef]

Jørgensen TS, Turesson C, Kapetanovic M, et al. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry. PLoS One. 2017;12(2) doi: 10.1371/journal.pone.0169946. Exclusion Code: X3. [PMC free article: PMC5289416] [PubMed: 28151971] [CrossRef]

Kameda H, Kanbe K, Sato E, et al. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. J Rheumatol. 2011 Aug;38(8):1585–92. doi: 10.3899/jrheum.110014. PMID: 21572151. Exclusion Code: X3. [PubMed: 21572151] [CrossRef]

Kameda H, Ueki Y, Saito K, et al. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. Mod Rheumatol. 2010 Dec;20(6):531–8. doi: 10.1007/s10165-010-0324-4. PMID: 20574649 Exclusion Code: X3. [PubMed: 20574649] [CrossRef]

Kanayama Y, Kaneko A, Takahashi N, et al. Clinical efficacy of certolizumab pegol therapy in patients with japanese active rheumatoid arthritis 52 week result ∼a multicenter registry study ∼. Ann Rheum Dis. 2016;75:1015–6. doi: 10.1136/annrheumdis-2016-eular.3146. Exclusion Code: X3. [CrossRef]

Kanayama Y, Kojima T, Hirano Y, et al. Efficacy of infliximab for suppressing radiographic progression of cervical lesions in patients with rheumatoid arthritis comparison with methotrexate; two years of follow-up-a multicenter registry study. Ann Rheum Dis. 2016;75:242–3. doi: 10.1136/annrheumdis-2016-eular.2487. Exclusion Code: X3. [CrossRef]

Kaneko A, Hirano Y, Fujibayashi T, et al. Twenty-four-week clinical results of adalimumab therapy in Japanese patients with rheumatoid arthritis: retrospective analysis for the best use of adalimumab in daily practice. Mod Rheumatol. 2013 May;23(3):466–77. doi: 10.1007/s10165-012-0705-y. PMID: 22895833. Exclusion Code: X3. [PubMed: 22895833] [CrossRef]

Kaneko Y, Atsumi T, Tanaka Y, et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Ann Rheum Dis. 2016;75(11):1917–23 doi: 10.1136/annrheumdis-2015-208426. Exclusion Code: X3. [PMC free article: PMC5099201] [PubMed: 26733110] [CrossRef]

Kang JH, Park DJ, Lee JW, et al. Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis. J Korean Med Sci. 2014 Sep;29(9):1205–11. doi: 10.3346/jkms.2014.29.9.1205. PMID: 25246737. Exclusion Code: X3. [PMC free article: PMC4168172] [PubMed: 25246737] [CrossRef]

Karlsson JA, Kristensen LE, Kapetanovic MC, et al. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford); 2008. p. 507–13. Exclusion Code: X3. [PubMed: 18304941]

Katikireddi V, Hadwen T, Kubler P, et al. Patterns of biologic agent use, efficacy, safety and retention rates in a public hospital and private practice setting. Intern Med J. 2011;41:26. doi: 10.1111/j.1445-5994.2010.02466.x. Exclusion Code: X3. [CrossRef]

Kaufmann J, Feist E, Roske AE, et al. Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. Clin Rheumatol. 2013 Sep;32(9):1347–55. doi: 10.1007/s10067-013-2281-8. PMID: 23703358 Exclusion Code: X3. [PubMed: 23703358] [CrossRef]

Kavanaugh A, Klareskog L, Heijde D, et al. Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate. Ann Rheum Dis; 2012. p. 1444–7. Exclusion Code: X3. [PMC free article: PMC2566536] [PubMed: 18535115]

Kavanaugh A, Smolen JS, Emery P, et al. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis Rheum; 2009. p. 1592–600. Exclusion Code: X3. [PubMed: 19877104]

Kavanaugh A, St Clair EW, McCune WJ, et al. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol. 2000 Apr;27(4):841–50. PMID: 10782805. Exclusion Code: X3. [PubMed: 10782805]

Kawai VK, Grijalva CG, Arbogast PG, et al. Initiation of tumor necrosis factor alpha antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases. Arthritis Care Res (Hoboken). 2013 Jul;65(7):1085–94. doi: 10.1002/acr.21937. PMID: 23281339. Exclusion Code: X3. [PMC free article: PMC3631448] [PubMed: 23281339] [CrossRef]

Kawakami K, Ikari K, Kawamura K, et al. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications? Rheumatology (Oxford); 2010. p. 341–7. Exclusion Code: X3. [PubMed: 19965973]

Kawashima H, Kagami SI, Kashiwakuma D, et al. Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis. Rheumatol Int. 2017;37(3):369–76. doi: 10.1007/s00296-016-3631-z. Exclusion Code: X3. [PMC free article: PMC5310556] [PubMed: 27999943] [CrossRef]

Kawashiri SY, Kawakami A, Yamasaki S, et al. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int. 2011 Apr;31(4):451–6. doi: 10.1007/s00296-009-1303-y. PMID: 20024554 Exclusion Code: X3. [PubMed: 20024554] [CrossRef]

Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum; 2008. p. 964–75. Exclusion Code: X3. [PubMed: 18383539]

Ke WM, Chen LS, Parng IM, et al. Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan. Int J Tuberc Lung Dis. 2013 Dec;17(12):1590–5. doi: 10.5588/ijtld.13.0368. PMID: 24200274. Exclusion Code: X3. [PubMed: 24200274] [CrossRef]

Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001 Oct 11;345(15):1098–104. PMID: 11596589. Exclusion Code: X3. [PubMed: 11596589]

Kelsall J, Rogers P, Galindo G, et al. Safety of infliximab treatment in patients with rheumatoid arthritis in a real-world clinical setting: description and evaluation of infusion reactions. J Rheumatol. 2012 Aug;39(8):1539–45. doi: 10.3899/jrheum.110956. PMID: 22589260. Exclusion Code: X3. [PubMed: 22589260] [CrossRef]

Kerr G, Aujero M, Richards J, et al. Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications. Arthritis Care Res (Hoboken). 2014 Nov;66(11):1619–26. doi: 10.1002/acr.22341. PMID: 24692402. Exclusion Code: X3. [PubMed: 24692402] [CrossRef]

Keystone E, Burmester GR, Furie R, et al. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum; 2008. p. 785–93. Exclusion Code: X3. [PubMed: 18512710]

Keystone E, Emery P, Peterfy CG, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis; 2009. p. 216–21. Exclusion Code: X3. [PubMed: 18388156]

Keystone E, Freundlich B, Schiff M, et al. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA. J Rheumatol; 2009. p. 522–31. Exclusion Code: X3. [PubMed: 19228659]

Keystone E, Genovese M, Hall S, et al. Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial. The Journal of rheumatology; 2016. p. 298–306. Exclusion Code: X3. [PubMed: 26669912]

Keystone E, Genovese M, Klareskog L, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis; 2010. p. 1129–35. Exclusion Code: X3. [PubMed: 20444749]

Keystone E, Heijde D, Mason D, Jr., et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum; 2008. p. 3319–29. Exclusion Code: X3. [PubMed: 18975346]

Keystone E, Landewe R, van Vollenhoven R, et al. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. Ann Rheum Dis. 2014 Dec;73(12):2094–100. doi: 10.1136/annrheumdis-2013-203695. PMID: 23918037 Exclusion Code: X3. [PMC free article: PMC4251202] [PubMed: 23918037] [CrossRef]

Keystone E, Pope J, Thorne J, et al. Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis. Rheumatology (Oxford); 2016. p. 327–34. Exclusion Code: X3. [PMC free article: PMC4710802] [PubMed: 26361879]

Keystone EC, Anisfeld A, Ogale S, et al. Continued benefit of tocilizumab plus disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatment. J Rheumatol. 2014 Feb;41(2):216–26. doi: 10.3899/jrheum.130489. PMID: 24429164. Exclusion Code: X3. [PubMed: 24429164] [CrossRef]

Keystone EC, Combe B, Smolen J, et al. Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. Rheumatology (Oxford). 2012 Sep;51(9):1628–38. doi: 10.1093/rheumatology/kes082. PMID: 22596211 Exclusion Code: X3. [PubMed: 22596211] [CrossRef]

Keystone EC, Curtis JR, Fleischmann RM, et al. Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial. J Rheumatol. 2011 Jun;38(6):990–6. doi: 10.3899/jrheum.100935. PMID: 21362764. Exclusion Code: X3. [PubMed: 21362764] [CrossRef]

Keystone EC, Genovese MC, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension. J Rheumatol. 2013 Jul;40(7):1097–103. doi: 10.3899/jrheum.120584. PMID: 23678153. Exclusion Code: X3. [PubMed: 23678153] [CrossRef]

Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis; 2009. p. 789–96. Exclusion Code: X3. [PMC free article: PMC2674549] [PubMed: 19066176]

Keystone EC, Kavanaugh A, Weinblatt ME, et al. Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis. J Rheumatol. 2011 May;38(5):855–62. doi: 10.3899/jrheum.100752. PMID: 21285171. Exclusion Code: X3. [PubMed: 21285171] [CrossRef]

Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004 May;50(5):1400–11. PMID: 15146409. Exclusion Code: X3. [PubMed: 15146409]

Kievit W, Adang EM, Fransen J, et al. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis; 2008. p. 1229–34. Exclusion Code: X3. [PubMed: 18174220]

Kihara M, Davies R, Kearsley-Fleet L, et al. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. Clin Rheumatol. 2017;36(2):241–50. doi: 10.1007/s10067-016-3485-5. Exclusion Code: X3. [PMC free article: PMC5290047] [PubMed: 27913894] [CrossRef]

Kim G, Barner JC, Rascati K, et al. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis. Clin Ther. 2016 Mar;38(3):646–54. doi: 10.1016/j.clinthera.2016.01.022. PMID: 26899313 Exclusion Code: X3. [PubMed: 26899313] [CrossRef]

Kim HY, Hsu PN, Barba M, et al. Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial. Int J Rheum Dis. 2012 Apr;15(2):188–96 doi: 10.1111/j.1756-185X.2011.01680.x. PMID: 22462423. Exclusion Code: X3. [PubMed: 22462423] [CrossRef]

Kim HY, Lee SK, Song YW, et al. A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. APLAR J Rheumatol. 2007;10(1):9–16. Exclusion Code: X3.

Kim J, Ryu H, Yoo DH, et al. A clinical trial and extension study of infliximab in Korean patients with active rheumatoid arthritis despite methotrexate treatment. J Korean Med Sci. 2013 Dec;28(12):1716–22. doi: 10.3346/jkms.2013.28.12.1716. PMID: 24339699 Exclusion Code: X3. [PMC free article: PMC3857365] [PubMed: 24339699] [CrossRef]

Kim JW, Choi IA, Lee EY, et al. Tofacitinib prevents radiographic progression in rheumatoid arthritis. J Korean Med Sci. 2013 Aug;28(8):1134–8. doi: 10.3346/jkms.2013.28.8.1134. PMID: 23960438 Exclusion Code: X3. [PMC free article: PMC3744699] [PubMed: 23960438] [CrossRef]

Kim SC, Solomon DH, Liu J, et al. Risk of venous thromboembolism and use of disease-modifying antirheumatic drugs for rheumatoid arthritis. Arthritis Rheum. 2013;65:S156–S7. doi: 10.1002/art.38216. Exclusion Code: X3. [CrossRef]

Kim SC, Solomon DH, Rogers JR, et al. Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis. Arthritis and Rheumatology. 2016;68:3532–3. doi: 10.1002/art.39977. Exclusion Code: X3. [PMC free article: PMC5573926] [PubMed: 28245350] [CrossRef]

Kim SC, Solomon DH, Rogers JR, et al. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study. Arthritis Rheumatol. 2017 Jun;69(6):1154–64. doi: 10.1002/art.40084. PMID: 28245350. Exclusion Code: X3. [PMC free article: PMC5573926] [PubMed: 28245350] [CrossRef]

Kim SY, Schneeweiss S, Liu J, et al. Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study. J Bone Miner Res. 2012 Apr;27(4):789–96. doi: 10.1002/jbmr.1489. PMID: 22162140. Exclusion Code: X3. [PMC free article: PMC3725780] [PubMed: 22162140] [CrossRef]

Kim YJ, Kim YG, Shim TS, et al. Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors. Rheumatology (Oxford). 2014 Aug;53(8):1477–81. doi: 10.1093/rheumatology/keu041. PMID: 24681840 Exclusion Code: X3. [PubMed: 24681840] [CrossRef]

Kimura N, Suzuki K, Takeuchi T. Time lag between the initiation of adalimumab after methotrexate correlates with the efficacy of adalimumab in rheumatoid arthritis patients. Mod Rheumatol. 2016;26(5):676–80. doi: 10.3109/14397595.2015.1132952. Exclusion Code: X3. [PubMed: 26708943] [CrossRef]

Kirwan JR, Hallgren R, Mielants H, et al. A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis. Ann Rheum Dis. 2004;63(6):688–95. Exclusion Code: X3. [PMC free article: PMC1755023] [PubMed: 15140776]

Kisiel B, Kruszewski R, Juszkiewicz A, et al. Methotrexate, Cyclosporine A, and Biologics Protect against Atherosclerosis in Rheumatoid Arthritis. J Immunol Res. 2015;2015:759610. doi: 10.1155/2015/759610. PMID: 26090499. Exclusion Code: X3. [PMC free article: PMC4452098] [PubMed: 26090499] [CrossRef]

Kitada A, Min C, Kataoka Y, et al. Verification of antibacterial effect of sulfasalazine in rheumatoid arthritis patients. Ann Rheum Dis. 2016;75:989. doi: 10.1136/annrheumdis-2016-eular.5309. Exclusion Code: X3. [CrossRef]

Kivitz A, Olech E, Borofsky M, et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Nov;66(11):1653–61. doi: 10.1002/acr.22384. PMID: 24942540. Exclusion Code: X3. [PMC free article: PMC4276289] [PubMed: 24942540] [CrossRef]

Klareskog L, Gaubitz M, Rodriguez-Valverde V, et al. A Long-Term, Open-Label Trial of the Safety and Efficacy of Etanercept (ENBREL(R)) In Patients With Rheumatoid Arthritis Not Treated With Other DMARDs (3-year Interim Report). Ann Rheum Dis. 2006 Mar 15 PMID: 16540554. Exclusion Code: X3. [PMC free article: PMC1798461] [PubMed: 16540554]

Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004 Feb 28;363(9410):675–81. PMID: 15001324. Exclusion Code: X3. [PubMed: 15001324]

Kobayashi M, Miyamoto S, Kashiwagura T, et al. Profiles of patients aged over 80 years with rheumatoid arthritis in aora registry. Ann Rheum Dis. 2016;75:1254–5. doi: 10.1136/annrheumdis-2016-eular.1567. Exclusion Code: X3. [CrossRef]

Kodama S, Ito S, Murasawa A, et al. Efficacy and safety of etanercept in rheumatoid arthritis patients over 75 years old. Arthritis and Rheumatology. 2014;66:S207. doi: 10.1002/art.38914. Exclusion Code: X3. [CrossRef]

Koike T, Harigai M, Inokuma S, et al. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol. 2014 Jan;41(1):15–23. doi: 10.3899/jrheum.130466. PMID: 24187110. Exclusion Code: X3. [PubMed: 24187110] [CrossRef]

Koike T, Harigai M, Inokuma S, et al. Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study. Rheumatol Int. 2012 Jun;32(6):1617–24. doi: 10.1007/s00296-011-1807-0. PMID: 21331576 Exclusion Code: X3. [PMC free article: PMC3364424] [PubMed: 21331576] [CrossRef]

Kojima T, Takahashi N, Funahashi K, et al. Improved safety of biologic therapy for rheumatoid arthritis over the 8-year period since implementation in Japan: long-term results from a multicenter observational cohort study. Clin Rheumatol. 2016 Apr;35(4):863–71. doi: 10.1007/s10067-016-3201-5. PMID: 26846135. Exclusion Code: X3. [PubMed: 26846135] [CrossRef]

Kojima T, Yabe Y, Kaneko A, et al. Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study. Rheumatology (Oxford). 2015 Jan;54(1):113–20. doi: 10.1093/rheumatology/keu302. PMID: 25102861 Exclusion Code: X3. [PubMed: 25102861] [CrossRef]

Komano Y, Tanaka M, Nanki T, et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol. 2011 Jul;38(7):1258–64. doi: 10.3899/jrheum.101009. PMID: 21498482. Exclusion Code: X3. [PubMed: 21498482] [CrossRef]

Korswagen LA, Bartelds GM, Krieckaert CL, et al. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum. 2011 Apr;63(4):877–83. doi: 10.1002/art.30209. PMID: 21452312. Exclusion Code: X3. [PubMed: 21452312] [CrossRef]

Kotak S, Mardekian J, Horowicz-Mehler N, et al. Impact of Etanercept Therapy on Disease Activity and Health-Related Quality of Life in Moderate Rheumatoid Arthritis Patients Population from a National British Observational Cohort. Value Health. 2015 Sep;18(6):817–23. doi: 10.1016/j.jval.2015.05.005. PMID: 26409609 Exclusion Code: X3. [PubMed: 26409609] [CrossRef]

Krause C, Herborn G, Braun J, et al. Response to methotrexate predicts long-term mortality of patients with rheumatoid arthritis independent of the degree of response: results of a re-evaluation 30 years after baseline. Clin Exp Rheumatol. 2017 May-Jun;35(3):384–9. PMID: 27974101. Exclusion Code: X3. [PubMed: 27974101]

Kremer J, Li ZG, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013 Aug 20;159(4):253–61. doi: 10.7326/0003-4819-159-4-201308200-00006. PMID: 24026258. Exclusion Code: X3. [PubMed: 24026258] [CrossRef]

Kremer J, Ritchlin C, Mendelsohn A, et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum; 2010. p. 917–28. Exclusion Code: X3. [PubMed: 20131276]

Kremer JL, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate at 1 year: The LITHE study. Arthritis Rheum; 2010. Exclusion Code: X3.

Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011 Mar;63(3):609–21. doi: 10.1002/art.30158. PMID: 21360490. Exclusion Code: X3. [PubMed: 21360490] [CrossRef]

Kremer JM, Cohen S, Wilkinson BE, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 2012 Apr;64(4):970–81. doi: 10.1002/art.33419. PMID: 22006202. Exclusion Code: X3. [PubMed: 22006202] [CrossRef]

Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005 Aug;52(8):2263–71. PMID: 16052582. Exclusion Code: X3. [PubMed: 16052582]

Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis - a randomized trial. Ann Intern Med. 2006 Dec;144:865–76. Exclusion Code: X3. [PubMed: 16785475]

Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;137(9):726–33. Exclusion Code: X3. [PubMed: 12416946]

Kremer JM, Peterfy C, Russell AS, et al. Longterm safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in inadequate responders to methotrexate trial. J Rheumatol. 2014 Jun;41(6):1077–87. doi: 10.3899/jrheum.130263. PMID: 24786925. Exclusion Code: X3. [PubMed: 24786925] [CrossRef]

Kremer JM, Russell AS, Emery P, et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis. 2011 Oct;70(10):1826–30. doi: 10.1136/ard.2010.139345. PMID: 21893583 Exclusion Code: X3. [PMC free article: PMC3171107] [PubMed: 21893583] [CrossRef]

Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med; 2003. p. 1907–15. Exclusion Code: X3. [PubMed: 14614165]

Krieckaert CL, Jamnitski A, Nurmohamed MT, et al. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum. 2012 Dec;64(12):3850–5. doi: 10.1002/art.34680. PMID: 22933315. Exclusion Code: X3. [PubMed: 22933315] [CrossRef]

Krintel SB, Essioux L, Wool A, et al. CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis. PLoS One. 2012;7(6):e38539. doi: 10.1371/journal.pone.0038539. PMID: 22685579 Exclusion Code: X3. [PMC free article: PMC3369852] [PubMed: 22685579] [CrossRef]

Krintel SB, Grunert VP, Hetland ML, et al. The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure. Rheumatology (Oxford). 2013 Jul;52(7):1245–53. doi: 10.1093/rheumatology/ket017. PMID: 23459699 Exclusion Code: X3. [PubMed: 23459699] [CrossRef]

Kristensen LE, Bliddal H, Christensen R, et al. Is swollen to tender joint count ratio a new and useful clinical marker for biologic drug response in rheumatoid arthritis? Results from a Swedish cohort. Arthritis Care Res (Hoboken). 2014 Feb;66(2):173–9. doi: 10.1002/acr.22107. PMID: 23982986. Exclusion Code: X3. [PubMed: 23982986] [CrossRef]

Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum. 2006 Feb;54(2):600–6. PMID: 16447237. Exclusion Code: X3. [PubMed: 16447237]

Kristensen LE, Saxne T, Nilsson JA, et al. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther; 2006. p. R174. Exclusion Code: X3. [PMC free article: PMC1794519] [PubMed: 17121678]

Kubo S, Nakayamada S, Nakano K, et al. Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching. Ann Rheum Dis. 2016;75(7):1321–7. doi: 10.1136/annrheumdis-2015-207784. Exclusion Code: X3. [PubMed: 26245754] [CrossRef]

Kuriachan MA, Revikumar KG, Jolly A. Comparison of treatment outcome in rheumatoid arthritis patients treated with single and two DMARDs in combination with corticosteroids. International Journal of Drug Development and Research. 2012;4(3):228–35. Exclusion Code: X3.

Kuriya B, Hernandez-Diaz S, Liu J, et al. Patterns of medication use during pregnancy in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011 May;63(5):721–8. doi: 10.1002/acr.20422. PMID: 21557526. Exclusion Code: X3. [PubMed: 21557526] [CrossRef]

Kuriya B, Xiong J, Boire G, et al. Earlier time to remission predicts sustained clinical remission in early rheumatoid arthritis--results from the Canadian Early Arthritis Cohort (CATCH). J Rheumatol. 2014 Nov;41(11):2161–6. doi: 10.3899/jrheum.140137. PMID: 25274902. Exclusion Code: X3. [PubMed: 25274902] [CrossRef]

Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003 May 20;138(10):807–11. PMID: 12755552. Exclusion Code: X3. [PubMed: 12755552]

Lacaille D, Guh DP, Abrahamowicz M, et al. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum; 2008. p. 1074–81. Exclusion Code: X3. [PubMed: 18668604]

Lagacé S, Bessette L, Coupal L, et al. The clinical response to biologic and nonbiologic disease modifying antirheumatic drugs (DMARDs) according to gender in a French-Canadian population with rheumatoid arthritis (RA). Arthritis and Rheumatology. 2016;68:795–6. doi: 10.1002/art.39977. Exclusion Code: X3. [CrossRef]

Lahaye C, Soubrier M, Mulliez A, et al. Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology’s ORA registry. Rheumatology (Oxford). 2016 May;55(5):874–82. doi: 10.1093/rheumatology/kev437. PMID: 26822072 Exclusion Code: X3. [PubMed: 26822072] [CrossRef]

l’Ami MJ, Kneepkens EL, Nurmohamed MT, et al. Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate. Clin Exp Rheumatol. 2017 May-Jun;35(3):431–7. PMID: 28079512. Exclusion Code: X3. [PubMed: 28079512]

Lan JL, Tseng CH, Chen JH, et al. Reduced risk of all-cancer and solid cancer in Taiwanese patients with rheumatoid arthritis treated with etanercept, a TNF-alpha inhibitor. Medicine (Baltimore). 2017 Feb;96(7):e6055. doi: 10.1097/md.0000000000006055. PMID: 28207513 Exclusion Code: X3. [PMC free article: PMC5319502] [PubMed: 28207513] [CrossRef]

Landewe R, Ostergaard M, Keystone EC, et al. Analysis of integrated radiographic data from two long-term, open-label extension studies of adalimumab for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2015 Feb;67(2):180–6. doi: 10.1002/acr.22426. PMID: 25073879. Exclusion Code: X3. [PubMed: 25073879] [CrossRef]

Lane MA, McDonald JR, Zeringue AL, et al. TNF-alpha antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis. Medicine (Baltimore). 2011 Mar;90(2):139–45 doi: 10.1097/MD.0b013e318211106a. PMID: 21358439. Exclusion Code: X3. [PMC free article: PMC3076552] [PubMed: 21358439] [CrossRef]

Lange E, Blizzard L, Venn A, et al. Disease-modifying anti-rheumatic drugs and nonmelanoma skin cancer in inflammatory arthritis patients: A retrospective cohort study. Rheumatology (United Kingdom). 2016;55(9):1594–600. doi: 10.1093/rheumatology/kew214. Exclusion Code: X3. [PubMed: 27185957] [CrossRef]

Larsen A, Kvien TK, Schattenkirchner M, et al. Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. Scand J Rheumatol. 2001;30(3):135–42. Exclusion Code: X3. [PubMed: 11469522]

Lathia U, Ewara EM, Nantel F. Impact of adherence to biological agents on health care resource utilization for patients over the age of 65 years with rheumatoid arthritis. Patient Preference and Adherence. 2017;11:1133–42 doi: 10.2147/PPA.S137206. Exclusion Code: X3. [PMC free article: PMC5505619] [PubMed: 28740368] [CrossRef]

Lau AN, Shah A, Deamude M, et al. Does etanercept maintain its efficacy in the elderly population. A single center retrospective analysis. Ann Rheum Dis. 2014;73 doi: 10.1136/annrheumdis-2014-eular.6068. Exclusion Code: X3. [CrossRef]

Lebwohl M, Blum R, Berkowitz E, et al. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Arch Dermatol. 2005 Jul;141(7):861–4. PMID: 16027301. Exclusion Code: X3. [PubMed: 16027301]

Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014 Jun 19;370(25):2377–86. doi: 10.1056/NEJMoa1310476. PMID: 24941177 Exclusion Code: X3. [PubMed: 24941177] [CrossRef]

Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002 Oct;46(10):2565–70. PMID: 12384912. Exclusion Code: X3. [PubMed: 12384912]

Lee MY, Shin JY, Park SY, et al. Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: An analysis of the South Korean National Health Insurance Database. Semin Arthritis Rheum. 2017 doi: 10.1016/j.semarthrit.2017.08.007. Exclusion Code: X3. [PubMed: 28939234] [CrossRef]

Lee SJ, Park W, Park SH, et al. Low baseline interleukin-17A levels are associated with better treatment response at 12 weeks to tocilizumab therapy in rheumatoid arthritis patients. J Immunol Res. 2015;2015:487230. doi: 10.1155/2015/487230. PMID: 25922848. Exclusion Code: X3. [PMC free article: PMC4398953] [PubMed: 25922848] [CrossRef]

Lee YH, Woo JH, Rho YH, et al. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. Rheumatol Int; 2008. p. 553–9. Exclusion Code: X3. [PubMed: 17943257]

Leon L, Rodriguez-Rodriguez L, Rosales Z, et al. Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice. Scand J Rheumatol. 2016 Nov;45(6):456–60. doi: 10.3109/03009742.2016.1141979. PMID: 27115843 Exclusion Code: X3. [PubMed: 27115843] [CrossRef]

Li C, Wang XR, Ji HJ, et al. Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China. Clin Rheumatol. 2017;36(5):1023–9. doi: 10.1007/s10067-017-3596-7. Exclusion Code: X3. [PubMed: 28342151] [CrossRef]

Li P, Blum MA, Von Feldt J, et al. Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis. Value Health. 2010/11/09 ed; 2010. p. 805–12. Exclusion Code: X3. [PubMed: 21054657]

Li R, Zhao JX, Su Y, et al. High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): A multicenter randomized clinical trial. Medicine (Baltimore). 2016 Jul;95(28):e3968. doi: 10.1097/md.0000000000003968. PMID: 27428186 Exclusion Code: X3. [PMC free article: PMC4956780] [PubMed: 27428186] [CrossRef]

Li T, Gignac M, Wells G, et al. Decreased external home help use with improved clinical status in rheumatoid arthritis: an exploratory analysis of the Abatacept in Inadequate responders to Methotrexate (AIM) trial. Clin Ther; 2008. p. 734–48. Exclusion Code: X3. [PubMed: 18498922]

Li T, Wells G, Westhovens R, et al. Improvements in participation in usual daily activities in patients with rheumatoid arthritis treated with abatacept. Value Health. 2011 Mar-Apr;14(2):361–70. doi: 10.1016/j.jval.2010.10.008. PMID: 21296603 Exclusion Code: X3. [PubMed: 21296603] [CrossRef]

Li Z, Zhang F, Kay J, et al. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy. Int J Rheum Dis. 2016;19(11):1143–56. doi: 10.1111/1756-185X.12723. Exclusion Code: X3. [PubMed: 26259617] [CrossRef]

Liao TL, Chen YM, Chen DY. Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications. Clin Microbiol Infect. 2016 Sep;22(9):815.e1–.e3. doi: 10.1016/j.cmi.2016.05.030. PMID: 27297321. Exclusion Code: X3. [PubMed: 27297321] [CrossRef]

Liao TL, Chen YM, Liu HJ, et al. Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: A case-control study in Asia. BMJ Open. 2017;7(1) doi: 10.1136/bmjopen-2016-014032. Exclusion Code: X3. [PMC free article: PMC5223706] [PubMed: 28057661] [CrossRef]

Liao TL, Lin CH, Chen YM, et al. Different Risk of Tuberculosis and Efficacy of Isoniazid Prophylaxis in Rheumatoid Arthritis Patients with Biologic Therapy: A Nationwide Retrospective Cohort Study in Taiwan. PLoS One. 2016;11(4):e0153217. doi: 10.1371/journal.pone.0153217. PMID: 27064275. Exclusion Code: X3. [PMC free article: PMC4827833] [PubMed: 27064275] [CrossRef]

Lim CH, Chen HH, Chen YH, et al. The risk of tuberculosis disease in rheumatoid arthritis patients on biologics and targeted therapy: A 15-year real world experience in Taiwan. PLoS One. 2017;12(6) doi: 10.1371/journal.pone.0178035. Exclusion Code: X3. [PMC free article: PMC5453436] [PubMed: 28570568] [CrossRef]

Lim CH, Lin CH, Chen DY, et al. One-year tuberculosis risk in rheumatoid arthritis patients starting their first tumor necrosis factor inhibitor therapy from 2008 to 2012 in Taiwan: A nationwide population-based cohort study. PLoS One. 2016;11(11) doi: 10.1371/journal.pone.0166339. Exclusion Code: X3. [PMC free article: PMC5104359] [PubMed: 27832150] [CrossRef]

Lima A, Bernardes M, Azevedo R, et al. SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients. Toxicol Sci. 2014 Nov;142(1):196–209. doi: 10.1093/toxsci/kfu162. PMID: 25124723. Exclusion Code: X3. [PubMed: 25124723] [CrossRef]

Lin KM, Cheng TT, Lin JC, et al. Tumor necrosis factor-alpha antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study. Clin Rheumatol. 2015 Jun;34(6):1039–46. doi: 10.1007/s10067-015-2962-6. PMID: 25939523. Exclusion Code: X3. [PubMed: 25939523] [CrossRef]

Lin ND, Seeger JD, Ng E, et al. Safety surveillance study of abatacept therapy among patients with rheumatoid arthritis. Pharmacoepidemiol Drug Saf. 2011;20:S14. doi: 10.1002/pds.2206. Exclusion Code: X3. [CrossRef]

Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000 Nov 30;343(22):1594–602. PMID: 11096166. Exclusion Code: X3. [PubMed: 11096166]

Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005 Nov;52(11):3403–12. PMID: 16255017. Exclusion Code: X3. [PubMed: 16255017]

Listing J, Strangfeld A, Kekow J, et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum; 2008. p. 667–77. Exclusion Code: X3. [PubMed: 18311816]

Listing J, Strangfeld A, Rau R, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register. Arthritis Res Ther. 2006;8(3):R66. PMID: 16600016. Exclusion Code: X3. [PMC free article: PMC1526636] [PubMed: 16600016]

Ljung L, Rantapää-Dahlqvist S, Jacobsson LTH, et al. Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. Ann Rheum Dis. 2016;75(12):2087–94. doi: 10.1136/annrheumdis-2015-208995. Exclusion Code: X3. [PubMed: 26984007] [CrossRef]

Low ASL, Lunt M, Mercer LK, et al. Association between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients with Rheumatoid Arthritis. Arthritis and Rheumatology. 2016;68(6):1337–45. doi: 10.1002/art.39582. Exclusion Code: X3. [PMC free article: PMC4982051] [PubMed: 26749043] [CrossRef]

Low ASL, Symmons DPM, Lunt M, et al. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76(4):654–60 doi: 10.1136/annrheumdis-2016-209784. Exclusion Code: X3. [PMC free article: PMC5530342] [PubMed: 28073800] [CrossRef]

Lukas C, Heijde D, Fatenajad S, et al. Repair of erosions occurs almost exclusively in damaged joints without swelling. Ann Rheum Dis; 2010. p. 851–5. Exclusion Code: X3. [PubMed: 19846407]

Lurati A, Marrazza M, Angela K, et al. Safety of etanercept in elderly subjects with rheumatoid arthritis. Biologics: Targets and Therapy. 2010;4:1–4. Exclusion Code: X3. [PMC free article: PMC2819897] [PubMed: 20161980]

Lyu R, Ding Q, Govoni M, et al. Persistence rate with subcutaneous biologic therapies in patients with rheumatoid arthritis (RA). Value Health. 2014;17(7):A384. doi: 10.1016/j.jval.2014.08.2634. Exclusion Code: X3. [PubMed: 27200864] [CrossRef]

Lyu R, Govoni M, Ding Q, et al. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany. Rheumatol Int. 2016;36(1):143–53. doi: 10.1007/s00296-015-3348-4. Exclusion Code: X3. [PubMed: 26314368] [CrossRef]

Maas A, Kievit W, Bemt B, et al. Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study (Provisional abstract). Ann Rheum Dis; 2012. p. 1849–54 Exclusion Code: X3. [PubMed: 22504561]

Machado DA, Guzman R, Xavier RM, et al. Two-year safety and efficacy experience in patients with methotrexate-resistant active rheumatoid arthritis treated with etanercept and conventional disease-modifying anti-rheumatic drugs in the Latin American region. Open Rheumatol J. 2016;10:13–25. doi: 10.2174/1874312901610010013. Exclusion Code: X3. [PMC free article: PMC4780479] [PubMed: 27006728] [CrossRef]

Machado DA, Guzman RM, Xavier RM, et al. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region. J Clin Rheumatol. 2014 Jan;20(1):25–33. doi: 10.1097/rhu.0000000000000055. PMID: 24356474 Exclusion Code: X3. [PubMed: 24356474] [CrossRef]

Machado M, Moura CS, Behlouli H, et al. Comparative effectiveness of tofacitinib, biologic drugs and traditional disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis and Rheumatology. 2016;68:3387–9. doi: 10.1002/art.39977. Exclusion Code: X3. [CrossRef]

Machado NP, Reis Neto ET, Soares MR, et al. The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis. Clinics (Sao Paulo). 2013 Sep;68(9):1189–96. doi: 10.6061/clinics/2013(09)03. PMID: 24141833 Exclusion Code: X3. [PMC free article: PMC3782714] [PubMed: 24141833] [CrossRef]

Machado-Alba JE, Ruiz AF, Machado-Duque ME. Effectiveness of treatment with biologic- and disease-modifying antirheumatic drugs in rheumatoid arthritis patients in Colombia. Int J Clin Pract. 2016;70(6):506–11. doi: 10.1111/ijcp.12809. Exclusion Code: X3. [PubMed: 27238964] [CrossRef]

Machold K, Landewé R, Smolen J, et al. The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Ann Rheum Dis; 2010. p. 495–502. Exclusion Code: X3. [PubMed: 20223838]

Mahdi-Rogers M, Brassington R, Gunn AA, et al. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews: John Wiley & Sons, Ltd; 2017. Exclusion Code: X3. [PMC free article: PMC6481566] [PubMed: 28481421]

Maid P, Real R, Pedersen R, et al. Incidence of anti-drug antibodies in patients with rheumatoid arthritis from argentina treated with adalimumab, etanercept, or infliximab in a real-world setting. J Clin Rheumatol. 2016;22(3):131. doi: 10.1097/RHU.0000000000000372. Exclusion Code: X3. [PubMed: 29232322] [CrossRef]

Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999 Dec 4;354(9194):1932–9 PMID: 10622295. Exclusion Code: X3. [PubMed: 10622295]

Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 2004 Apr;50(4):1051–65. PMID: 15077287. Exclusion Code: X3. [PubMed: 15077287]

Malaviya AN. Methotrexate intolerance in the treatment of rheumatoid arthritis (RA): effect of adding caffeine to the management regimen. Clin Rheumatol. 2017 Feb;36(2):279–85. doi: 10.1007/s10067-016-3398-3. PMID: 27596742. Exclusion Code: X3. [PubMed: 27596742] [CrossRef]

Malysheva OA, Wahle M, Wagner U, et al. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. J Rheumatol; 2008. p. 979–85. Exclusion Code: X3. [PubMed: 18412314]

Manders SH, Kievit W, Adang E, et al. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. Arthritis Res Ther. 2015 May 22;17:134. doi: 10.1186/s13075-015-0630-5. PMID: 25997746. Exclusion Code: X3. [PMC free article: PMC4489004] [PubMed: 25997746] [CrossRef]

Marchesoni A, Zaccara E, Gorla R, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci; 2009. p. 837–46. Exclusion Code: X3. [PubMed: 19758236]

Mariette X, Alten R, Nüßlein HG, et al. The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study. Joint Bone Spine. 2017;84(5):571–6. doi: 10.1016/j.jbspin.2016.10.011. Exclusion Code: X3. [PubMed: 28043761] [CrossRef]

Mariette X, Tubach F, Bagheri H, et al. Lymphoma in patients treated with anti-TNF: Results of the 3-year prospective French RATIO registry. Ann Rheum Dis; 2010. p. 400–8. Exclusion Code: X3. [PMC free article: PMC2925048] [PubMed: 19828563]

Mathias SD, Colwell HH, Miller DP, et al. Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin Ther. 2000 Jan;22(1):128–39. PMID: 10688396. Exclusion Code: X3. [PubMed: 10688396]

Matsubara H, Kojima T, Kaneko A, et al. Longterm retention rate and risk factor for discontinuation due to insufficient efficacy and adverse events in Japanese patients with rheumatoid arthritis receiving etanercept therapy. J Rheumatol. 2014 Aug;41(8):1583–9. doi: 10.3899/jrheum.130901. PMID: 25028370. Exclusion Code: X3. [PubMed: 25028370] [CrossRef]

Matsudaira R, Tamura N, Sekiya F, et al. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J Rheumatol. 2011 Nov;38(11):2346–54. doi: 10.3899/jrheum.101295. PMID: 21965648. Exclusion Code: X3. [PubMed: 21965648] [CrossRef]

Mattey DL, Brownfield A, Dawes PT. Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis. J Rheumatol; 2009. p. 1180–7. Exclusion Code: X3. [PubMed: 19447930]

Mazzantini M, Talarico R, Doveri M, et al. Incident comorbidity among patients with rheumatoid arthritis treated or not with low-dose glucocorticoids: a retrospective study. J Rheumatol. 2010 Nov;37(11):2232–6. doi: 10.3899/jrheum.100461. PMID: 20843913. Exclusion Code: X3. [PubMed: 20843913] [CrossRef]

McDonald JR, Zeringue AL, Caplan L, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis; 2009. p. 1364–71. Exclusion Code: X3. [PMC free article: PMC2743911] [PubMed: 19368499]

McErlane F, Foster HE, Davies R, et al. Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2013 Oct;52(10):1905–13. doi: 10.1093/rheumatology/ket248. PMID: 23873820 Exclusion Code: X3. [PMC free article: PMC3775296] [PubMed: 23873820] [CrossRef]

McInnes IB, Thompson L, Giles JT, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2015 Apr;74(4):694–702. doi: 10.1136/annrheumdis-2013-204345. PMID: 24368514 Exclusion Code: X3. [PMC free article: PMC4392313] [PubMed: 24368514] [CrossRef]

Mease PJ, Revicki DA, Szechinski J, et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial. J Rheumatol; 2008. p. 20–30. Exclusion Code: X3. [PubMed: 18050385]

Meissner Y, Zink A, Kekow J, et al. Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis. Arthritis Research and Therapy. 2016;18(1) doi: 10.1186/s13075-016-1077-z. Exclusion Code: X3. [PMC free article: PMC4975917] [PubMed: 27495156] [CrossRef]

Mercer LK, Askling J, Raaschou P, et al. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: Results from a collaborative project of 11 European biologic registers. Ann Rheum Dis. 2017;76(2):386–91. doi: 10.1136/annrheumdis-2016-209285. Exclusion Code: X3. [PMC free article: PMC5284347] [PubMed: 27307502] [CrossRef]

Mercer LK, Galloway JB, Lunt M, et al. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2017;76(3):497–503. doi: 10.1136/annrheumdis-2016-209389. Exclusion Code: X3. [PMC free article: PMC5446004] [PubMed: 27502891] [CrossRef]

Mercer LK, Green AC, Galloway JB, et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2012 Jun;71(6):869–74. doi: 10.1136/annrheumdis-2011-200622. PMID: 22241900 Exclusion Code: X3. [PMC free article: PMC3371225] [PubMed: 22241900] [CrossRef]

Mercer LK, Lunt M, Low AL, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2015 Jun;74(6):1087–93. doi: 10.1136/annrheumdis-2013-204851. PMID: 24685910. Exclusion Code: X3. [PMC free article: PMC4431340] [PubMed: 24685910] [CrossRef]

Mertz LE, Blair JE. Coccidioidomycosis in rheumatology patients: incidence and potential risk factors. Ann N Y Acad Sci; 2007. p. 343–57. Exclusion Code: X3. [PubMed: 17363440]

Migita K, Akeda Y, Akazawa M, et al. Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients. Arthritis Res Ther. 2015 Dec 10;17:357. doi: 10.1186/s13075-015-0863-3. PMID: 26653668. Exclusion Code: X3. [PMC free article: PMC4675027] [PubMed: 26653668] [CrossRef]

Migita K, Sasaki Y, Ishizuka N, et al. Glucocorticoid therapy and the risk of infection in patients with newly diagnosed autoimmune disease. Medicine (United States). 2013;92(5):285–93. doi: 10.1097/MD.0b013e3182a72299. Exclusion Code: X3. [PMC free article: PMC4553976] [PubMed: 23982055] [CrossRef]

Migliore A, Bizzi E, Lagana B, et al. The safety of anti-TNF agents in the elderly. Int J Immunopathol Pharmacol. 2009/06/10 ed; 2009. p. 415–26. Exclusion Code: X3. [PubMed: 19505394]

Milic V, Jekic B, Lukovic L, et al. Association of dihydrofolate reductase (DHFR) -317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2012 Mar-Apr;30(2):178–83. PMID: 22324981. Exclusion Code: X3. [PubMed: 22324981]

Mittal N, Mittal R, Sharma A, et al. Treatment failure with disease-modifying antirheumatic drugs in rheumatoid arthritis patients. Singapore Med J. 2012 Aug;53(8):532–6. PMID: 22941131. Exclusion Code: X3. [PubMed: 22941131]

Mittal N, Sharma A, Jose V, et al. Causes of DMARD withdrawal following ADR within 6 months of initiation among Indian rheumatoid arthritis patients. Rheumatol Int. 2012 Mar;32(3):743–8. doi: 10.1007/s00296-010-1646-4. PMID: 21161534 Exclusion Code: X3. [PubMed: 21161534] [CrossRef]

Miura K, Morita O, Hirano T, et al. Sagittal spinopelvic alignment in patients with rheumatoid arthritis: A cross-sectional study. Eur Spine J. 2016;25:S287. doi: 10.1007/s00586-016-4722-y. Exclusion Code: X3. [CrossRef]

Miwa Y, Isojima S, Saito M, et al. Comparative Study of Infliximab Therapy and Methotrexate Monotherapy to Improve the Clinical Effect in Rheumatoid Arthritis Patients. Intern Med. 2016;55(18):2581–5. doi: 10.2169/internalmedicine.55.6872. PMID: 27629950. Exclusion Code: X3. [PubMed: 27629950] [CrossRef]

Miwa Y, Takahashi R, Ikari Y, et al. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission with Six Months of Biological DMARDs Treatment. Intern Med. 2017;56(8):903–6. doi: 10.2169/internalmedicine.56.8039. PMID: 28420837 Exclusion Code: X3. [PMC free article: PMC5465405] [PubMed: 28420837] [CrossRef]

Miyasaka N. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol; 2012. p. 252–62. Exclusion Code: X3. [PMC free article: PMC2668560] [PubMed: 18330677]

Mochizuki T, Yano K, Ikari K, et al. The efficacy of abatacept in Japanese patients with rheumatoid arthritis: 104 weeks radiographic and clinical results in clinical practice. Mod Rheumatol. 2016;26(4):499–506. doi: 10.3109/14397595.2015.1109578. Exclusion Code: X3. [PubMed: 26473281] [CrossRef]

Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001 Dec;44(12):2862–9. PMID: 11762947. Exclusion Code: X3. [PubMed: 11762947]

Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997 Jul 17;337(3):141–7. PMID: 9219699. Exclusion Code: X3. [PubMed: 9219699]

Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999 Mar 16;130(6):478–86. PMID: 10075615. Exclusion Code: X3. [PubMed: 10075615]

Moreland LW, Weinblatt ME, Keystone EC, et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol. 2006 May;33(5):854–61. PMID: 16541481. Exclusion Code: X3. [PubMed: 16541481]

Morgan C, McBeth J, Cordingley L, et al. The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. Rheumatology (Oxford). 2015 Oct;54(10):1780–91. doi: 10.1093/rheumatology/kev105. PMID: 25972390 Exclusion Code: X3. [PMC free article: PMC4571488] [PubMed: 25972390] [CrossRef]

Morgan CL, Emery P, Porter D, et al. Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. Rheumatology (Oxford). 2014 Jan;53(1):186–94. doi: 10.1093/rheumatology/ket333. PMID: 24140761 Exclusion Code: X3. [PubMed: 24140761] [CrossRef]

Mori S. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mod Rheumatol. 2011;21(6):621–7. doi: 10.1007/s10165-011-0458-z. Exclusion Code: X3. [PMC free article: PMC3236827] [PubMed: 21528424] [CrossRef]

Mori S, Yoshitama T, Hidaka T, et al. Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan. PLoS One. 2017;12(6):e0179179. doi: 10.1371/journal.pone.0179179. PMID: 28594905 Exclusion Code: X3. [PMC free article: PMC5464634] [PubMed: 28594905] [CrossRef]

Moura CS, Abrahamowicz M, Beauchamp ME, et al. Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study. Arthritis Res Ther. 2015 Aug 03;17:197. doi: 10.1186/s13075-015-0713-3 PMID: 26235697. Exclusion Code: X3. [PMC free article: PMC4522999] [PubMed: 26235697] [CrossRef]

Movahedi M, Costello R, Lunt M, et al. Oral glucocorticoid therapy and all-cause and cause-specific mortality in patients with rheumatoid arthritis: a retrospective cohort study. Eur J Epidemiol. 2016;31(10):1045–55 doi: 10.1007/s10654-016-0167-1. Exclusion Code: X3. [PMC free article: PMC5065607] [PubMed: 27256352] [CrossRef]

Mueller RB, Gengenbacher M, Richter S, et al. Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK). Arthritis Res Ther. 2016 Apr 14;18:88. doi: 10.1186/s13075-016-0985-2. PMID: 27074795. Exclusion Code: X3. [PMC free article: PMC4831114] [PubMed: 27074795] [CrossRef]

Muller RB, von Kempis J, Haile SR, et al. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort. Semin Arthritis Rheum. 2015 Aug;45(1):28–34. doi: 10.1016/j.semarthrit.2015.02.009. PMID: 25895697 Exclusion Code: X3. [PubMed: 25895697] [CrossRef]

Müller S, Wilke T, Fuchs A, et al. Nonpersistence and non-adherence to MTX therapy in patients with rheumatoid arthritis: A retrospective cohort study based on German RA patients. Patient Preference and Adherence. 2017;11:1253–64. doi: 10.2147/PPA.S134924. Exclusion Code: X3. [PMC free article: PMC5530851] [PubMed: 28790807] [CrossRef]

Muralidharan N, Mariaselvam CM, Jain VK, et al. ATIC 347C>G gene polymorphism may be associated with methotrexate-induced adverse events in south Indian Tamil rheumatoid arthritis. Pharmacogenomics. 2016 Feb;17(3):241–8. doi: 10.2217/pgs.15.170. PMID: 26799664. Exclusion Code: X3. [PubMed: 26799664] [CrossRef]

Mykytenko G, Iaremenko O. Efficiency of non-biological disease-modifying antirheumatic drugs (DMARDS) in rheumatoid arthritis (RA) patients with comorbidity. Ann Rheum Dis. 2016;75:212–3 doi: 10.1136/annrheumdis-2016-eular.1594. Exclusion Code: X3. [CrossRef]

Nadareishvili Z, Michaud K, Hallenbeck JM, et al. Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum; 2008. p. 1090–6. Exclusion Code: X3. [PMC free article: PMC2778069] [PubMed: 18668583]

Nagashima M, Matsuoka T, Saitoh K, et al. Treatment continuation rate in relation to efficacy and toxicity in long-term therapy with low-dose methotrexate, sulfasalazine, and bucillamine in 1,358 Japanese patients with rheumatoid arthritis. Clin Exp Rheumatol; 2006. p. 260–7. Exclusion Code: X3. [PubMed: 16870092]

Nakajima A, Inoue E, Taniguchi A, et al. Effectiveness of tacrolimus in comparison with methotrexate or biologics in propensity score-matched patients with rheumatoid arthritis. Mod Rheumatol. 2016;26(6):836–43 doi: 10.3109/14397595.2016.1160969. Exclusion Code: X3. [PubMed: 26934454] [CrossRef]

Nakajima A, Urano W, Inoue E, et al. Incidence of herpes zoster in Japanese patients with rheumatoid arthritis from 2005 to 2010. Mod Rheumatol. 2015 Jul;25(4):558–61. doi: 10.3109/14397595.2014.984829. PMID: 25648973 Exclusion Code: X3. [PubMed: 25648973] [CrossRef]

Nakashita T, Ando K, Kaneko N, et al. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis. BMJ Open. 2014 Aug 14;4(8):e005615. doi: 10.1136/bmjopen-2014-005615. PMID: 25125479 Exclusion Code: X3. [PMC free article: PMC4139628] [PubMed: 25125479] [CrossRef]

Nam JL, Villeneuve E, Hensor EM, et al. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. Ann Rheum Dis. 2014 Jun;73(6):1027–36. doi: 10.1136/annrheumdis-2013-204882. PMID: 24618266. Exclusion Code: X3. [PubMed: 24618266] [CrossRef]

Nampei A, Shi K, Ebina K, et al. Prevalence of gastroesophageal reflux disease symptoms and related factors in patients with rheumatoid arthritis. J Clin Biochem Nutr. 2013;52(2):179–84. doi: 10.3164/jcbn.12-83. Exclusion Code: X3. [PMC free article: PMC3593137] [PubMed: 23525140] [CrossRef]

Naranjo A, Sokka T, Descalzo MA, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther; 2008. p. R30. Exclusion Code: X3. [PMC free article: PMC2453774] [PubMed: 18325087]

Narvaez J, Diaz-Torne C, Magallares B, et al. Comparative effectiveness of tocilizumab with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. PLoS One. 2015;10(4):e0123392. doi: 10.1371/journal.pone.0123392. PMID: 25830224 Exclusion Code: X3. [PMC free article: PMC4382296] [PubMed: 25830224] [CrossRef]

Narvaez J, Diaz-Torne C, Ruiz JM, et al. Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. Semin Arthritis Rheum. 2011 Dec;41(3):401–5. doi: 10.1016/j.semarthrit.2011.06.005. PMID: 21862107 Exclusion Code: X3. [PubMed: 21862107] [CrossRef]

Nash P, Nayiager S, Genovese MC, et al. Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. Arthritis Care Res (Hoboken). 2013 May;65(5):718–28 doi: 10.1002/acr.21876. PMID: 23097311. Exclusion Code: X3. [PubMed: 23097311] [CrossRef]

Navarro-Millan I, Herrinton LJ, Chen L, et al. Comparative Effectiveness of Etanercept and Adalimumab in Patient Reported Outcomes and Injection-Related Tolerability. PLoS One. 2016;11(3):e0149781. doi: 10.1371/journal.pone.0149781. PMID: 27007811 Exclusion Code: X3. [PMC free article: PMC4805235] [PubMed: 27007811] [CrossRef]

Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, et al. Adalimumab for Treating Rheumatoid Arthritis. Cochrane Database of Systematic Reviews. 2005(3):CD005113. Exclusion Code: X3. [PubMed: 16034967]

Nicholls D, Zochling J, Boers A, et al. A retrospective chart review of the use of rituximab for the treatment of rheumatoid arthritis in Australian rheumatology practice. Int J Rheum Dis. 2014 Sep;17(7):755–61. doi: 10.1111/1756-185x.12164. PMID: 24131467. Exclusion Code: X3. [PubMed: 24131467] [CrossRef]

Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15(12):1677–83. doi: 10.1517/14712598.2015.1103733. PMID: 26549204 Exclusion Code: X3. [PubMed: 26549204] [CrossRef]

Nilsson AC, Christensen AF, Junker P, et al. Tumour necrosis factor-alpha inhibitors are glucocorticoid-sparing in rheumatoid arthritis. Dan Med Bull. 2011 Apr;58(4):A4257. PMID: 21466765. Exclusion Code: X3. [PubMed: 21466765]

Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis; 2007. p. 1162–7. Exclusion Code: X3. [PMC free article: PMC1955155] [PubMed: 17485422]

Nishimoto N, Miyasaka N, Yamamoto K, et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009 Oct;68(10):1580–4. doi: 10.1136/ard.2008.092866. PMID: 19019888. Exclusion Code: X3. [PMC free article: PMC2732899] [PubMed: 19019888] [CrossRef]

Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol; 2009. p. 12–9. Exclusion Code: X3. [PMC free article: PMC2638601] [PubMed: 18979150]

Nurmohamed M, Bao Y, Signorovitch J, et al. Use of anti-tumor necrosis factor therapy is associated with reduced cardiovascular event risk in rheumatoid arthritis. Arthritis Rheum. 2012;64:S531. doi: 10.1002/art.37735. Exclusion Code: X3. [CrossRef]

Nurmohamed MT, Bao Y, Signorovitch J, et al. Use of anti-TNF therapy is associated with reduced cardiovascular event risk in rheumatoid arthritis. Annals of the Rheumatic Disease. 2013;71 doi: 10.1136/annrheumdis-2012-eular.1685. Exclusion Code: X3. [CrossRef]

Nusslein HG, Alten R, Galeazzi M, et al. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. BMC Musculoskelet Disord. 2014 Jan 11;15:14. doi: 10.1186/1471-2474-15-14. PMID: 24410774. Exclusion Code: X3. [PMC free article: PMC3898027] [PubMed: 24410774] [CrossRef]

Oba K, Horie N, Sato N, et al. Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis. Contemporary Clinical Trials Communications. 2017;8:49–54. doi: 10.1016/j.conctc.2017.08.007. Exclusion Code: X3. [PMC free article: PMC5898537] [PubMed: 29696196] [CrossRef]

Ochi K, Go Y, Furuya T, et al. Risk factors associated with the occurrence of distal radius fractures in Japanese patients with rheumatoid arthritis: a prospective observational cohort study. Clin Rheumatol. 2014 Apr;33(4):477–83. doi: 10.1007/s10067-013-2415-z. PMID: 24196989 Exclusion Code: X3. [PubMed: 24196989] [CrossRef]

O’Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. 1996 May 16;334(20):1287–91. PMID: 8609945. Exclusion Code: X3. [PubMed: 8609945]

O’Dell JR, Leff R, Paulsen G, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46(5):1164–70. Exclusion Code: X3. [PubMed: 12115219]

O’Dell JR, Mikuls TR, Taylor TH, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013 Jul 25;369(4):307–18. doi: 10.1056/NEJMoa1303006. PMID: 23755969 Exclusion Code: X3. [PubMed: 23755969] [CrossRef]

O’Dell JR, Petersen K, Leff R, et al. Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis. J Rheumatol. 2006 Feb;33(2):213–8. PMID: 16358366. Exclusion Code: X3. [PubMed: 16358366]

Ogata A, Amano K, Dobashi H, et al. Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study. J Rheumatol. 2015 May;42(5):799–809. doi: 10.3899/jrheum.140665. PMID: 25834203. Exclusion Code: X3. [PubMed: 25834203] [CrossRef]

Ogawa Y, Takahashi N, Kojima T, et al. Association between rheumatoid factor positivity and effects of treatment with a first biologic agent in rheumatoid arthritis. Arthritis and Rheumatology. 2016;68:3584–5 doi: 10.1002/art.39977. Exclusion Code: X3. [CrossRef]

Ogawa Y, Takahashi N, Kojima T, et al. Association between methotrexate use and effects of treatment with a second biologic agent in rheumatoid arthritis. Arthritis and Rheumatology. 2016;68:818–9. doi: 10.1002/art.39977. Exclusion Code: X3. [CrossRef]

Ohta S, Tsuru T, Terao K, et al. Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). J Clin Pharmacol. 2014 Jan;54(1):109–19. doi: 10.1002/jcph.185. PMID: 24115082. Exclusion Code: X3. [PMC free article: PMC3908364] [PubMed: 24115082] [CrossRef]

Okano T, Inui K, Tada M, et al. Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study. Rheumatol Int. 2016 Mar;36(3):349–57. doi: 10.1007/s00296-015-3379-x. PMID: 26438386 Exclusion Code: X3. [PubMed: 26438386] [CrossRef]

Ornbjerg LM, Ostergaard M, Boyesen P, et al. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry. J Rheumatol. 2014 Dec;41(12):2352–60. doi: 10.3899/jrheum.131299. PMID: 25274894. Exclusion Code: X3. [PubMed: 25274894] [CrossRef]

Osiri M, Deesomchok U, Tugwell P. Disease activity and functional changes of RA patients receiving different DMARDs in clinical practice. Clin Rheumatol. 2006;25(5):721–7. PMID: 2006353950. Exclusion Code: X3. [PubMed: 16365685]

Ostergaard M, Emery P, Conaghan PG, et al. Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients. Arthritis Rheum. 2011 Dec;63(12):3712–22. doi: 10.1002/art.30592. PMID: 22127693. Exclusion Code: X3. [PubMed: 22127693] [CrossRef]

Ostergaard M, Jacobsson LT, Schaufelberger C, et al. MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16. Ann Rheum Dis. 2015 Jun;74(6):1156–63. doi: 10.1136/annrheumdis-2014-206359. PMID: 25512675. Exclusion Code: X3. [PMC free article: PMC4431335] [PubMed: 25512675] [CrossRef]

Padovan M, Filippini M, Tincani A, et al. Safety of Abatacept in Rheumatoid Arthritis with Serologic Evidence of Past or Present Hepatitis B Virus Infection. Arthritis Care Res. 2016;68(6):738–43. doi: 10.1002/acr.22786. Exclusion Code: X3. [PubMed: 26555747] [CrossRef]

Pallavicini FB, Caporali R, Sarzi-Puttini P, et al. Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun Rev; 2010. p. 175–80. Exclusion Code: X3. [PubMed: 19647103]

Pan SM, Dehler S, Ciurea A, et al. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum; 2009. p. 560–8. Exclusion Code: X3. [PubMed: 19405000]

Panasyuk E, Nasonov E, Nasonova VA. Tocilizumab improved of the quality of the life patients with severe/moderate RA (LORNET Study). Ann Rheum Dis. 2015;74:722–3. doi: 10.1136/annrheumdis-2015-eular.4371. Exclusion Code: X3. [CrossRef]

Pappas DA, Hooper MM, Kremer JM, et al. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs. Arthritis Care Res (Hoboken). 2015 Dec;67(12):1671–8. doi: 10.1002/acr.22628. PMID: 26018115. Exclusion Code: X3. [PubMed: 26018115] [CrossRef]

Park DJ, Choi SJ, Shin K, et al. Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry. Clin Rheumatol. 2017;36(5):1013–22. doi: 10.1007/s10067-017-3584-y. Exclusion Code: X3. [PubMed: 28243760] [CrossRef]

Park W, Suh CH, Shim SC, et al. Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis. Biodrugs. 2017;31(4):369–77. doi: 10.1007/s40259-017-0233-6. Exclusion Code: X3. [PMC free article: PMC5548826] [PubMed: 28600696] [CrossRef]

Pavelka K, Akkoç N, Al-Maini M, et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access. Rheumatol Int. 2017;37(9):1469–79. doi: 10.1007/s00296-017-3749-7. Exclusion Code: X3. [PubMed: 28597306] [CrossRef]

Pavelka K, Burgos-Vargas R, Miranda P, et al. Etanercept in moderate rheumatoid arthritis: PRESERVE study results from central/eastern Europe, Latin America and Asia. Int J Clin Rheumtol. 2014;9(5):415–30 doi: 10.2217/ijr.14.27. Exclusion Code: X3. [CrossRef]

Payet S, Gottenberg JE, Mariette X, et al. Tolerance and efficacy of rituximab in elderly patients with rheumatoid arthritis enrolled in the french society of rheumatology air registry. Arthritis Rheum. 2012;64:S917. doi: 10.1002/art.37735. Exclusion Code: X3. [CrossRef]

Pecoraro V, De Santis E, Trenti T. Effect of immunogenicity on anti-TNFa response. Clin Chem Lab Med. 2017;55:S344. doi: 10.1515/cclm-2017-5007. Exclusion Code: X3. [CrossRef]

Pedrazas CH, Azevedo MN, Torres SR. Oral events related to low-dose methotrexate in rheumatoid arthritis patients. Braz Oral Res. 2010 Jul-Sep;24(3):368–73. PMID: 20877977. Exclusion Code: X3. [PubMed: 20877977]

Pers YM, Fortunet C, Constant E, et al. Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice. Rheumatology (Oxford). 2014 Jan;53(1):76–84 doi: 10.1093/rheumatology/ket301. PMID: 24056521. Exclusion Code: X3. [PubMed: 24056521] [CrossRef]

Pers YM, Schaub R, Constant E, et al. Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis. Joint Bone Spine. 2015 Jan;82(1):25–30. doi: 10.1016/j.jbspin.2014.07.010. PMID: 25241333 Exclusion Code: X3. [PubMed: 25241333] [CrossRef]

Peterfy C, Emery P, Tak PP, et al. MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study. Ann Rheum Dis. 2016 Jan;75(1):170–7. doi: 10.1136/annrheumdis-2014-206015. PMID: 25355728 Exclusion Code: X3. [PMC free article: PMC4717395] [PubMed: 25355728] [CrossRef]

Peters MJ, Welsh P, McInnes IB, et al. Tumour necrosis factor {alpha} blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. Ann Rheum Dis. 2010 Jul;69(7):1281–5. doi: 10.1136/ard.2009.119412. PMID: 19934107. Exclusion Code: X3. [PubMed: 19934107] [CrossRef]

Pfeiffer BM, Krenzer S, Dockhorn R, et al. Impact of modified-release prednisone on functional ability in patients with rheumatoid arthritis. Rheumatol Int. 2013 Jun;33(6):1447–54. doi: 10.1007/s00296-012-2583-1. PMID: 23179262. Exclusion Code: X3. [PubMed: 23179262] [CrossRef]

Phillips C, Zeringue AL, McDonald JR, et al. Tumor Necrosis Factor Inhibition and Head and Neck Cancer Recurrence and Death in Rheumatoid Arthritis. PLoS One. 2015;10(11):e0143286. doi: 10.1371/journal.pone.0143286. PMID: 26599370 Exclusion Code: X3. [PMC free article: PMC4658068] [PubMed: 26599370] [CrossRef]

Plasencia C, Wolbink G, Krieckaert CL, et al. Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity. Clin Exp Rheumatol. 2016 Jul-Aug;34(4):655–62. PMID: 27214767. Exclusion Code: X3. [PubMed: 27214767]

Pope J, Keystone E, Thorne C, et al. Study completion and etanercept retention in patients with rheumatoid arthritis treated with etanercept or etanercept and methotrexate in the Canadian methotrexate and etanercept outcome (CAMEO) study. J Rheumatol. 2016;43(6):1239–40. doi: 10.3899/jrheum.160272. Exclusion Code: X3. [CrossRef]

Pope JE, Haraoui B, Rampakakis E, et al. Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial. Arthritis Care Res (Hoboken). 2013 Sep;65(9):1401–9. doi: 10.1002/acr.22010. PMID: 23509040. Exclusion Code: X3. [PubMed: 23509040] [CrossRef]

Popescu C, Bojinca V, Opris D, et al. Dual X-ray Absorptiometry Whole Body Composition of Adipose Tissue in Rheumatoid Arthritis. Rom J Intern Med. 2015 Jul-Sep;53(3):237–47. doi: 10.1515/rjim-2015-0031. PMID: 26710499. Exclusion Code: X3. [PubMed: 26710499] [CrossRef]

Prioreschi A, Hodkinson B, Tikly M, et al. Changes in physical activity measured by accelerometry following initiation of DMARD therapy in rheumatoid arthritis. Rheumatology (Oxford). 2014 May;53(5):923–6. doi: 10.1093/rheumatology/ket457. PMID: 24459221 Exclusion Code: X3. [PubMed: 24459221] [CrossRef]

Puljak L, Marin A, Vrdoljak D, et al. Celecoxib for osteoarthritis. Cochrane Database of Systematic Reviews: John Wiley & Sons, Ltd; 2017. Exclusion Code: X3.

Pullar T, Hunter J, Capell H. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br Med J (Clin Res Ed); 2012. p. 1102–4. Exclusion Code: X3. [PMC free article: PMC1549364] [PubMed: 6138117]

Punzi L, Matucci Cerinic M, Cantini F, et al. Treatment patterns of anti-TNF agents in Italy: an observational study. Reumatismo. 2011 Mar;63(1):18–28. PMID: 21509346. Exclusion Code: X3. [PubMed: 21509346]

Quach LT, Chang BH, Brophy MT, et al. Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events. Rheumatology (Oxford). 2017 Mar 01;56(3):378–83. doi: 10.1093/rheumatology/kew412. PMID: 27994091 Exclusion Code: X3. [PMC free article: PMC5850115] [PubMed: 27994091] [CrossRef]

Raaschou P, Frisell T, Askling J. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2015 Dec;74(12):2137–43. doi: 10.1136/annrheumdis-2014-205745. PMID: 25107559 Exclusion Code: X3. [PubMed: 25107559] [CrossRef]

Raaschou P, Simard JF, Hagelberg CA, et al. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: Cohort study based on nationwide prospectively recorded data from Sweden. BMJ (Online). 2016;352 doi: 10.1136/bmj.i262. Exclusion Code: X3. [PMC free article: PMC4730989] [PubMed: 26823527] [CrossRef]

Rankin IA, Sargeant H, Rehman H, et al. Low-level laser therapy for carpal tunnel syndrome. Cochrane Database of Systematic Reviews: John Wiley & Sons, Ltd; 2017. Exclusion Code: X3.

Ranza R, Laurindo I, Titton D, et al. Incidence of serious adverse events in patients with rheumatoid arthritis exposed to biologic therapies. Results from biobadabrasil registry. Ann Rheum Dis. 2016;75:422. doi: 10.1136/annrheumdis-2016-eular.1560. Exclusion Code: X3. [CrossRef]

Rashid N, Lin AT, Aranda G, et al. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system. J Med Econ. 2016;19(6):568–75. doi: 10.3111/13696998.2016.1142448. Exclusion Code: X3. [PubMed: 26766553] [CrossRef]

Rendas-Baum R, Kosinski M, Singh A, et al. Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials. Rheumatology (Oxford). 2017 Aug 01;56(8):1386–94. doi: 10.1093/rheumatology/kex087. PMID: 28460083 Exclusion Code: X3. [PMC free article: PMC5850117] [PubMed: 28460083] [CrossRef]

Rentero ML, Amigo E, Chozas N, et al. Prevalence of fractures in women with rheumatoid arthritis and/or systemic lupus erythematosus on chronic glucocorticoid therapy Epidemiology of musculoskeletal disorders. BMC Musculoskelet Disord. 2015;16(1) doi: 10.1186/s12891-015-0733-9. Exclusion Code: X3. [PMC free article: PMC4608160] [PubMed: 26472426] [CrossRef]

Restrepo JF, Del Rincon I, Molina E, et al. Use of Hydroxychloroquine Is Associated with Improved Lipid Profile in Rheumatoid Arthritis Patients. J Clin Rheumatol. 2017;23(3):144–8. doi: 10.1097/RHU.0000000000000502. Exclusion Code: X3. [PMC free article: PMC5364043] [PubMed: 28277344] [CrossRef]

Ribbens C, Vanhoof J, Maertens M, et al. Glucocorticoid dose reduction in patients with low disease activity using tocilizumab: The act-alone study. Ann Rheum Dis. 2014;73 doi: 10.1136/annrheumdis-2014-eular.1992. Exclusion Code: X3. [CrossRef]

Richter A, Strangfeld A, Herzer P, et al. Sustainability of rituximab therapy in different treatment strategies: results of a 3-year followup of a German biologics register. Arthritis Care Res (Hoboken). 2014 Nov;66(11):1627–33. doi: 10.1002/acr.22327. PMID: 24664818. Exclusion Code: X3. [PMC free article: PMC4282041] [PubMed: 24664818] [CrossRef]

Roberts L, Tymms K, De Jager J, et al. The CEDAR Study: A longitudinal study of the clinical effects of conventional DMARDs and biologic DMARDs in Australian rheumatology practice. Int J Rheumatol. 2017;2017 doi: 10.1155/2017/1201450. Exclusion Code: X3. [PMC free article: PMC5463140] [PubMed: 28630629] [CrossRef]

Rodriguez-Rodriguez L, Jover-Jover JA, Fontsere O, et al. Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: a survival analysis. Scand J Rheumatol. 2013;42(6):433–6. doi: 10.3109/03009742.2013.785590. PMID: 23742043 Exclusion Code: X3. [PubMed: 23742043] [CrossRef]

Romao VC, Santos MJ, Polido-Pereira J, et al. Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt. Biomed Res Int. 2015;2015:279890. doi: 10.1155/2015/279890. PMID: 26000286. Exclusion Code: X3. [PMC free article: PMC4427085] [PubMed: 26000286] [CrossRef]

Roshique KK, Ravindran V. Efficacy and safety of a biosimilar rituximab in biologic naive patients with active rheumatoid arthritis. Clin Rheumatol. 2015 Jul;34(7):1289–92. doi: 10.1007/s10067-015-2980-4. PMID: 26032432. Exclusion Code: X3. [PubMed: 26032432] [CrossRef]

Rossini M, Viapiana O, Vitiello M, et al. Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: The glucocorticoid induced OsTeoporosis TOol (GIOTTO) study. Reumatismo. 2017;69(1):30–9. doi: 10.4081/reumatismo.2017.922. Exclusion Code: X3. [PubMed: 28535619] [CrossRef]

Rotar Z, Hocevar A, Rebolj Kodre A, et al. Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry. Clin Rheumatol. 2015 Oct;34(10):1787–93. doi: 10.1007/s10067-015-3066-z. PMID: 26345633 Exclusion Code: X3. [PubMed: 26345633] [CrossRef]

Roussy JP, Bessette L, Bernatsky S, et al. Biologic disease-modifying anti-rheumatic drugs and the risk of non-vertebral osteoporotic fractures in patients with rheumatoid arthritis aged 50 years and over. Arthritis Rheum. 2012;64:S198. doi: 10.1002/art.37735. Exclusion Code: X3. [PubMed: 23504029] [CrossRef]

Ruiz GV, Burls A, Cabello JB, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database of Systematic Reviews: John Wiley & Sons, Ltd; 2017. Exclusion Code: X3. [PMC free article: PMC6483724] [PubMed: 28884785]

Russell AS, Wallenstein GV, Li T, et al. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Ann Rheum Dis. 2007 Feb;66(2):189–94. PMID: 16984942. Exclusion Code: X3. [PMC free article: PMC1798514] [PubMed: 16984942]

Ruyssen-Witrand A, Rouanet S, Combe B, et al. Fcgamma receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis. 2012 Jun;71(6):875–7. doi: 10.1136/annrheumdis-2011-200337. PMID: 22368231 Exclusion Code: X3. [PubMed: 22368231] [CrossRef]

Ruyssen-Witrand A, Rouanet S, Combe B, et al. Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients. Rheumatology (Oxford). 2013 Apr;52(4):636–41. doi: 10.1093/rheumatology/kes344. PMID: 23264555 Exclusion Code: X3. [PubMed: 23264555] [CrossRef]

Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med. 1994 Feb;96(2):115–23. PMID: 8109596. Exclusion Code: X3. [PubMed: 8109596]

Saiki O, Uda H. Successful extension of tocilizumab infusion intervals from 4 weeks to 6 or 5 weeks in 90% of RA patients with good response to 4-week intervals. Clin Exp Rheumatol. 2017 Jul-Aug;35(4):666–70. PMID: 28229812. Exclusion Code: X3. [PubMed: 28229812]

Sakai R, Cho SK, Nanki T, et al. Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. Arthritis Res Ther. 2015 Mar 23;17:74. doi: 10.1186/s13075-015-0583-8. PMID: 25880658. Exclusion Code: X3. [PMC free article: PMC4384380] [PubMed: 25880658] [CrossRef]

Sakai R, Kasai S, Hirano F, et al. Incidence rate and the risk of herpes zoster in patients with rheumatoid arthritis using Japanese health insurance database. Ann Rheum Dis. 2016;75:481. doi: 10.1136/annrheumdis-2016-eular.2414. Exclusion Code: X3. [CrossRef]

Sakai R, Komano Y, Tanaka M, et al. Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012 Aug;64(8):1125–34. doi: 10.1002/acr.21666. PMID: 22422487. Exclusion Code: X3. [PubMed: 22422487] [CrossRef]

Sakai R, Komano Y, Tanaka M, et al. The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8 mg/week in patients with rheumatoid arthritis. Mod Rheumatol. 2011 Aug;21(4):444–8. doi: 10.1007/s10165-011-0421-z. PMID: 21312050 Exclusion Code: X3. [PubMed: 21312050] [CrossRef]

Sakai R, Tanaka M, Nanki T, et al. Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. Ann Rheum Dis. 2012 Nov;71(11):1820–6. doi: 10.1136/annrheumdis-2011-200838. PMID: 22504558 Exclusion Code: X3. [PubMed: 22504558] [CrossRef]

Salliot C, Gossec L, Ruyssen-Witrand A, et al. Infections during tumour necrosis factor-{alpha} blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford). 2007 July 31, 2006;46(2):327–34. doi: 10.1093/rheumatology/kel236. Exclusion Code: X3. [PubMed: 16880188] [CrossRef]

Salmon JH, Gottenberg JE, Ravaud P, et al. Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: Results from the Orencia and Rheumatoid Arthritis (ORA) registry. Ann Rheum Dis. 2016;75(6):1108–13. doi: 10.1136/annrheumdis-2015-207362. Exclusion Code: X3. [PubMed: 26048170] [CrossRef]

Sandooghi M, Zakeri Z, Almasy S, et al. A Comparative Study on Atorvastatin Versus Methotrexate in Rheumatoid Arthritis in a Double Blind Placebo control Trial. Shiraz E Medical Journal. 2011;12(4):189–95. Exclusion Code: X3.

Santoleri F, Sorice P, Lasala R, et al. Medication adherence and persistence in the treatment of rheumatoid arthritis with adalimumab and etanercept. Six years of analysis. J Med Econ. 2014 May;17(5):320–5. doi: 10.3111/13696998.2014.902844. PMID: 24641160. Exclusion Code: X3. [PubMed: 24641160] [CrossRef]

Santos-Moreno P, Sanchez G, Gomez D, et al. Direct Comparative Effectiveness Among 3 Anti-Tumor Necrosis Factor Biologics in a Real-Life Cohort of Patients With Rheumatoid Arthritis. J Clin Rheumatol. 2016 Mar;22(2):57–62. doi: 10.1097/rhu.0000000000000358. PMID: 26886438 Exclusion Code: X3. [PMC free article: PMC4927323] [PubMed: 26886438] [CrossRef]

Santos-Moreno PI, de la Hoz-Valle J, Villarreal L, et al. Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study. Clin Rheumatol. 2015 Feb;34(2):215–20 doi: 10.1007/s10067-014-2794-9. PMID: 25318612. Exclusion Code: X3. [PubMed: 25318612] [CrossRef]

Saraux A, Gossec L, Goupille P, et al. Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France (Structured abstract). Rheumatology; 2010. p. 733–40. Exclusion Code: X3. [PubMed: 20081224]

Sarzi-Puttini P, Filippucci E, Adami S, et al. Multicenter, open-label study to evaluate the predictability of disease control at week 52 based on early response to certolizumab pegol (in combination with methotrexate) in italian patients with moderate to severe rheumatoid arthritis: the CZP-speed study. Ann Rheum Dis. 2016;75:236–7. doi: 10.1136/annrheumdis-2016-eular.2166. Exclusion Code: X3. [CrossRef]

Sato E, Tanaka E, Nakajima A, et al. Assessment of the effectiveness of golimumab 50-mg and 100-mg regimens in patients with rheumatoid arthritis in daily practice. Mod Rheumatol. 2015 Jul;25(4):528–33. doi: 10.3109/14397595.2014.995892. PMID: 25536168 Exclusion Code: X3. [PubMed: 25536168] [CrossRef]

Sato E, Tanaka E, Ochiai M, et al. Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012. Mod Rheumatol. 2015 May;25(3):350–7. doi: 10.3109/14397595.2014.958274. PMID: 25619283 Exclusion Code: X3. [PubMed: 25619283] [CrossRef]

Sauer BC, Teng CC, Tang D, et al. Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2017 Mar;69(3):313–22. doi: 10.1002/acr.22944. PMID: 27273801. Exclusion Code: X3. [PMC free article: PMC6207907] [PubMed: 27273801] [CrossRef]

Schabert VF, Bruce B, Ferrufino CF, et al. Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study. Curr Med Res Opin. 2012 Apr;28(4):569–80. doi: 10.1185/03007995.2012.656844. PMID: 22236091 Exclusion Code: X3. [PubMed: 22236091] [CrossRef]

Schabert VF, Bruce B, Ferrufino CP, et al. Disability outcomes and dose escalation in rheumatoid arthritis patients treated with tumor necrosis factor blockers: A comparative effectiveness analysis. Value Health. 2010;13(7):A302. Exclusion Code: X3.

Schaible TF. Long term safety of infliximab. Can J Gastroenterol. 2000 Sep;14(Suppl C):29C–32C. PMID: 11023558. Exclusion Code: X3. [PubMed: 11023558]

Schiff M, Keiserman M, Codding C, et al. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study. Ann Rheum Dis. 2011 Nov;70(11):2003–7. doi: 10.1136/annrheumdis-2011-200316. PMID: 21914628 Exclusion Code: X3. [PMC free article: PMC3184243] [PubMed: 21914628] [CrossRef]

Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis; 2008. p. 1096–103. Exclusion Code: X3. [PMC free article: PMC2564802] [PubMed: 18055472]

Schiff M, Pritchard C, Huffstutter JE, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis. 2009 Nov;68(11):1708–14. doi: 10.1136/ard.2008.099218. PMID: 19074911. Exclusion Code: X3. [PMC free article: PMC2756956] [PubMed: 19074911] [CrossRef]

Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006 Jul;65(7):889–94. PMID: 16439435. Exclusion Code: X3. [PMC free article: PMC1798196] [PubMed: 16439435]

Schiff MH, von Kempis J, Goldblum R, et al. Rheumatoid arthritis secondary nonresponders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase. Ann Rheum Dis. 2014 Dec;73(12):2174–7. doi: 10.1136/annrheumdis-2014-205325. PMID: 24972708. Exclusion Code: X3. [PubMed: 24972708] [CrossRef]

Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum; 2007. p. 1754–64. Exclusion Code: X3. [PubMed: 17530704]

Schoels M, Kapral T, Stamm T, et al. Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study. Ann Rheum Dis; 2007. p. 1059–65. Exclusion Code: X3. [PMC free article: PMC1954688] [PubMed: 17307765]

Schultz M, Keeling SO, Katz SJ, et al. Clinical effectiveness and safety of leflunomide in inflammatory arthritis: a report from the RAPPORT database with supporting patient survey. Clin Rheumatol. 2017;36(7):1471–8. doi: 10.1007/s10067-017-3687-5. Exclusion Code: X3. [PubMed: 28550389] [CrossRef]

Scott DG, Claydon P, Ellis C. Retrospective evaluation of continuation rates following a switch to subcutaneous methotrexate in rheumatoid arthritis patients failing to respond to or tolerate oral methotrexate: the MENTOR study. Scand J Rheumatol. 2014;43(6):470–6. doi: 10.3109/03009742.2014.910312. PMID: 24898259 Exclusion Code: X3. [PubMed: 24898259] [CrossRef]

Scott DL, Ibrahim F, Farewell V, et al. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. BMJ. 2015 Mar 13;350:h1046. doi: 10.1136/bmj.h1046. PMID: 25769495. Exclusion Code: X3. [PMC free article: PMC4358851] [PubMed: 25769495] [CrossRef]

Scott DL, Smolen JS, Kalden JR, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis. 2001;60(10):913–23. Exclusion Code: X3. [PMC free article: PMC1753377] [PubMed: 11557646]

Scott FI, Mamtani R, Brensinger CM, et al. Risk of non-melanoma skin cancer recurrence with the use of immunosuppressant and biologic agents in autoimmune disease. Pharmacoepidemiol Drug Saf. 2015;24:47–8. doi: 10.1002/pds.3838. Exclusion Code: X3. [CrossRef]

Scott FI, Mamtani R, Brensinger CM, et al. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. JAMA Dermatol. 2016 Feb;152(2):164–72. doi: 10.1001/jamadermatol.2015.3029. PMID: 26510126. Exclusion Code: X3. [PMC free article: PMC5935268] [PubMed: 26510126] [CrossRef]

Segan J, Staples MP, March L, et al. Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-alpha inhibitors. Intern Med J. 2015 Mar;45(3):310–8. doi: 10.1111/imj.12679. PMID: 25565419. Exclusion Code: X3. [PubMed: 25565419] [CrossRef]

Sellam J, Hendel-Chavez H, Rouanet S, et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum. 2011 Apr;63(4):933–8. doi: 10.1002/art.30233. PMID: 21225699. Exclusion Code: X3. [PubMed: 21225699] [CrossRef]

Seong SS, Choi CB, Woo JH, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol. 2007 Apr;34(4):706–11 PMID: 17309133. Exclusion Code: X3. [PubMed: 17309133]

Serelis J, Panagiotakos DB, Mavrommati M, et al. Cardiovascular disease is related to hypertension in patients with rheumatoid arthritis: a greek cohort study. J Rheumatol. 2011 Feb;38(2):236–41. doi: 10.3899/jrheum.100564. PMID: 21078723. Exclusion Code: X3. [PubMed: 21078723] [CrossRef]

Seror R, Richez C, Sordet C, et al. Pattern of demyelination occurring during anti-TNF-alpha therapy: a French national survey. Rheumatology (Oxford). 2013 May;52(5):868–74. doi: 10.1093/rheumatology/kes375. PMID: 23287362. Exclusion Code: X3. [PubMed: 23287362] [CrossRef]

Seto Y, Tanaka E, Inoue E, et al. Studies of the efficacy and safety of methotrexate at dosages over 8 mg/week using the IORRA cohort database. Mod Rheumatol. 2011 Dec;21(6):579–93. doi: 10.1007/s10165-011-0445-4. PMID: 21424533. Exclusion Code: X3. [PMC free article: PMC3236829] [PubMed: 21424533] [CrossRef]

Setoguchi S, Schneeweiss S, Avorn J, et al. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J; 2008. p. 336–41. Exclusion Code: X3. [PMC free article: PMC3257055] [PubMed: 18657665]

Setoguchi S, Solomon DH, Weinblatt ME, et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Sep;54(9):2757–64. PMID: 16947774. Exclusion Code: X3. [PubMed: 16947774]

Shaikh S, Bensen W, Chow A, et al. Safety and effectiveness of TNF-alpha inhibitor therapy with certolizumab pegol observed in daily practice in adult rheumatoid arthritis patients in Canada-first interim analysis of the noninterventional fast can study. J Rheumatol. 2013;40(6):961. doi: 10.3899/jrheum.130301. Exclusion Code: X3. [CrossRef]

Sharp JT, Strand V, Leung H, et al. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum. 2000;43(3):495–505. Exclusion Code: X3. [PubMed: 10728741]

Shashikumar NS, Shivamurthy MC, Chandrashekara S. Evaluation of efficacy of combination of methotrexate and hydroxychloroquine with leflunomide in active rheumatoid arthritis. Indian J Pharmacol. 2010;42(6):358–61. doi: 10.4103/0253-7613.71916. Exclusion Code: X3. [PMC free article: PMC2991692] [PubMed: 21189905] [CrossRef]

Shidara K, Nakajima A, Inoue E, et al. Continual maintenance of remission defined by the ACR/EULAR criteria in daily practice leads to better functional outcomes in patients with rheumatoid arthritis. J Rheumatol. 2017;44(2):147–53. doi: 10.3899/jrheum.160395. Exclusion Code: X3. [PubMed: 27909083] [CrossRef]

Shimizu Y, Nakajima A, Inoue E, et al. Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort. Clin Rheumatol. 2017;36(6):1237–45 doi: 10.1007/s10067-017-3634-5. Exclusion Code: X3. [PubMed: 28455827] [CrossRef]

Shin IS, Baer AN, Kwon HJ, et al. Guillain-Barre and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum. 2006 May;54(5):1429–34. PMID: 16645971. Exclusion Code: X3. [PubMed: 16645971]

Silva-Fernández L, Lunt M, Kearsley-Fleet L, et al. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: Results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. Rheumatology (United Kingdom). 2016;55(11):2033–9. doi: 10.1093/rheumatology/kew314. Exclusion Code: X3. [PMC free article: PMC5088627] [PubMed: 27550304] [CrossRef]

Simard JF, Neovius M, Askling J. Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register. Arthritis Rheum. 2012 Nov;64(11):3502–10. doi: 10.1002/art.34582. PMID: 22886739. Exclusion Code: X3. [PubMed: 22886739] [CrossRef]

Simon TA, Smitten AL, Franklin J, et al. Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis. 2009 Dec;68(12):1819–26. doi: 10.1136/ard.2008.097527. PMID: 19054822. Exclusion Code: X3. [PMC free article: PMC2770103] [PubMed: 19054822] [CrossRef]

Singh JA, Hossain A, Mudano AS, et al. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017 May 08;5:Cd012657. doi: 10.1002/14651858.cd012657. PMID: 28481462 Exclusion Code: X3. [PMC free article: PMC6481641] [PubMed: 28481462] [CrossRef]

Slifman NR, Gershon SK, Lee JH, et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003 Feb;48(2):319–24. PMID: 12571839. Exclusion Code: X3. [PubMed: 12571839]

Slimani S, Lukas C, Combe B, et al. Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort. Joint Bone Spine. 2011 Oct;78(5):484–7. doi: 10.1016/j.jbspin.2010.11.012. PMID: 21196130 Exclusion Code: X3. [PubMed: 21196130] [CrossRef]

Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum; 2007. p. 1431–8. Exclusion Code: X3. [PubMed: 18050184]

Smitten AL, Choi HK, Hochberg MC, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol; 2008. p. 387–93. Exclusion Code: X3. [PubMed: 18260176]

Smolen J, Kay J, Doyle M, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor? inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. Arthritis Res Ther; 2017. p. 14. Exclusion Code: X3. [PMC free article: PMC4382834] [PubMed: 25627338]

Smolen J, Landewé R, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis; 2012. p. 797–804. Exclusion Code: X3. [PMC free article: PMC2674556] [PubMed: 19015207]

Smolen JS. Efficacy and safety of the new DMARD leflunomide: comparison to placebo and sulfasalazine in active rheumatoid arthritis. Scand J Rheumatol. 1999;112(Supplement):15–21. Exclusion Code: X3. [PubMed: 10668523]

Smolen JS, Avila JC, Aletaha D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis. 2012 May;71(5):687–93. doi: 10.1136/annrheumdis-2011-200395. PMID: 22121130 Exclusion Code: X3. [PMC free article: PMC3329225] [PubMed: 22121130] [CrossRef]

Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet; 2008. p. 987–97. Exclusion Code: X3. [PubMed: 18358926]

Smolen JS, Burmester GR, Combe B, et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. The Lancet. 2016;388(10061):2763–74. doi: 10.1016/S0140-6736(16)31651-8. Exclusion Code: X3. [PubMed: 27863807] [CrossRef]

Smolen JS, Emery P, Ferraccioli GF, et al. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Ann Rheum Dis. 2015 May;74(5):843–50. doi: 10.1136/annrheumdis-2013-204632. PMID: 24431394 Exclusion Code: X3. [PMC free article: PMC4392224] [PubMed: 24431394] [CrossRef]

Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 2005 Apr;52(4):1020–30. PMID: 15818697. Exclusion Code: X3. [PubMed: 15818697]

Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet. 1999;353(9149):259–66. Exclusion Code: X3. [PubMed: 9929017]

Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet; 2009. p. 210–21. Exclusion Code: X3. [PubMed: 19560810]

Smolen JS, Kay J, Landewe RB, et al. Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. Ann Rheum Dis. 2012 Oct;71(10):1671–9. doi: 10.1136/annrheumdis-2011-200956. PMID: 22459542 Exclusion Code: X3. [PMC free article: PMC3439650] [PubMed: 22459542] [CrossRef]

Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet. 2013 Mar 16;381(9870):918–29. doi: 10.1016/s0140-6736(12)61811-x. PMID: 23332236 Exclusion Code: X3. [PubMed: 23332236] [CrossRef]

Smolen JS, van Vollenhoven R, Kavanaugh A, et al. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. Arthritis Res Ther. 2015 Sep 10;17:245. doi: 10.1186/s13075-015-0767-2. PMID: 26353833. Exclusion Code: X3. [PMC free article: PMC4565002] [PubMed: 26353833] [CrossRef]

Smolen JS, Weinblatt ME, Sheng S, et al. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2014 Sep;73(9):1616–25. doi: 10.1136/annrheumdis-2013-205137. PMID: 24699939 Exclusion Code: X3. [PMC free article: PMC4145446] [PubMed: 24699939] [CrossRef]

Soderlin MK, Lindroth Y, Jacobsson LT. Trends in medication and health-related quality of life in a population-based rheumatoid arthritis register in Malmo, Sweden. Rheumatology (Oxford); 2007. p. 1355–8. Exclusion Code: X3. [PubMed: 17567634]

Soderlin MK, Petersson IF, Geborek P. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scand J Rheumatol. 2012 Feb;41(1):1–9. doi: 10.3109/03009742.2011.599073. PMID: 22118371 Exclusion Code: X3. [PubMed: 22118371] [CrossRef]

Sokolova MV, Ivanitskiy LV, Elonakov AV. Use of biologic dmards in russian patients with rheumatic diseases: Analysis of the 6 year-experience of the moscow regional research and clinical institute. Ann Rheum Dis. 2016;75:1253. doi: 10.1136/annrheumdis-2016-eular.4105. Exclusion Code: X3. [CrossRef]

Sokolove J, Strand V, Greenberg JD, et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis. 2010/05/08 ed; 2010. p. 1612–7. Exclusion Code: X3. [PubMed: 20448284]

Soliman MM, Hyrich KL, Lunt M, et al. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken). 2012 Aug;64(8):1108–15 doi: 10.1002/acr.21663. PMID: 22422731. Exclusion Code: X3. [PMC free article: PMC3492906] [PubMed: 22422731] [CrossRef]

Soliman MM, Hyrich KL, Lunt M, et al. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register. J Rheumatol. 2012 Feb;39(2):240–6. doi: 10.3899/jrheum.110610. PMID: 22174201. Exclusion Code: X3. [PubMed: 22174201] [CrossRef]

Solomon DH, Avorn J, Katz JN, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum. 2006 12/01/;54(Dec):3790–8. Exclusion Code: X3. [PubMed: 17136752]

Solomon DH, Curtis JR, Saag KG, et al. Cardiovascular risk in rheumatoid arthritis: comparing TNF-alpha blockade with nonbiologic DMARDs. Am J Med. 2013 Aug;126(8):730.e9–.e17. doi: 10.1016/j.amjmed.2013.02.016. PMID: 23885678 Exclusion Code: X3. [PMC free article: PMC4674813] [PubMed: 23885678] [CrossRef]

Solomon DH, Garg R, Lu B, et al. Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial. Arthritis Care Res (Hoboken). 2014 Aug;66(8):1246–51. doi: 10.1002/acr.22285. PMID: 24470436. Exclusion Code: X3. [PMC free article: PMC4467535] [PubMed: 24470436] [CrossRef]

Solomon DH, Harrold LR, Rassen J, et al. Cardiovascular risk reduction associated with tnf blockade: Results from a large multi-site observational study. Arthritis Rheum. 2011;63(10). Exclusion Code: X3.

Solomon DH, Massarotti E, Garg R, et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011 Jun 22;305(24):2525–31. doi: 10.1001/jama.2011.878. PMID: 21693740. Exclusion Code: X3. [PubMed: 21693740] [CrossRef]

Solomon DH, Rassen JA, Kuriya B, et al. Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. Ann Rheum Dis. 2013 Nov;72(11):1813–8. doi: 10.1136/annrheumdis-2012-202136. PMID: 23155221 Exclusion Code: X3. [PubMed: 23155221] [CrossRef]

Solomon DH, Reed GW, Kremer JM, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol. 2015 Jun;67(6):1449–55. doi: 10.1002/art.39098. PMID: 25776112. Exclusion Code: X3. [PMC free article: PMC4446181] [PubMed: 25776112] [CrossRef]

Solomon DH, Shadick NA, Weinblatt ME, et al. Drug safety analyses in a rheumatoid arthritis registry: Application of different approaches regarding timing of exposure and confounder measurement. Arthritis Research and Therapy. 2017;19(1)doi: 10.1186/s13075-017-1330-0. Exclusion Code: X3. [PMC free article: PMC5470201] [PubMed: 28610614] [CrossRef]

Soubrier M, Pereira B, Frayssac T, et al. Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience. Int J Rheum Dis. 2017 doi: 10.1111/1756-185X.13156. Exclusion Code: X3. [PubMed: 28901727] [CrossRef]

Specker C, Kaufmann J, Kellner H, et al. Safe and effective tocilizumab therapy in elderly patients with rheumatoid arthritis. Arthritis and Rheumatology. 2016;68:2005–6 doi: 10.1002/art.39977. Exclusion Code: X3. [CrossRef]

Stefano R, Frati E, Nargi F, et al. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. Clin Rheumatol; 2010. p. 517–24. Exclusion Code: X3. [PubMed: 20082236]

Steunebrink LM, Versteeg GA, Vonkeman HE, et al. Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registry. Arthritis Res Ther. 2016 Mar 08;18:60. doi: 10.1186/s13075-016-0962-9. PMID: 26956382. Exclusion Code: X3. [PMC free article: PMC4784382] [PubMed: 26956382] [CrossRef]

Stolshek BS, Wade SW, De A, et al. Predictors of adherence and costs in first and second years after biologic initiation in patients with rheumatoid arthritis (RA). Arthritis and Rheumatology. 2016;68:2891–3 doi: 10.1002/art.39977. Exclusion Code: X3. [CrossRef]

Strand V, Balbir-Gurman A, Pavelka K, et al. Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years. Rheumatology (Oxford); 2006. p. 1505–13. Exclusion Code: X3. [PubMed: 17062648]

Strand V, Burmester GR, Ogale S, et al. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. Rheumatology (Oxford). 2012 Oct;51(10):1860–9. doi: 10.1093/rheumatology/kes131. PMID: 22753773 Exclusion Code: X3. [PMC free article: PMC3448882] [PubMed: 22753773] [CrossRef]

Strand V, Burmester GR, Zerbini CA, et al. Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial. Arthritis Care Res (Hoboken). 2015 Apr;67(4):475–83. doi: 10.1002/acr.22453. PMID: 25186034. Exclusion Code: X3. [PubMed: 25186034] [CrossRef]

Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med. 1999;159(21):2542–50. Exclusion Code: X3. [PubMed: 10573044]

Strand V, Joseph G, Van Hoogstraten H, et al. Impact of sarilumab on health related quality of life (HRQoL), fatigue, and sleep in rheumatoid arthritis patients at week 24-results of a phase 3, randomized, double-blind, placebo-controlled, multi-center study. Arthritis and Rheumatology. 2014;66:S669–S70. doi: 10.1002/art.38914. Exclusion Code: X3. [CrossRef]

Strand V, Kosinski M, Chen CI, et al. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: Results of a phase III trial. Arthritis Research and Therapy. 2016;18(1)doi: 10.1186/s13075-016-1096-9. Exclusion Code: X3. [PMC free article: PMC5012017] [PubMed: 27600829] [CrossRef]

Strand V, Kremer J, Wallenstein G, et al. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. Arthritis Res Ther. 2015 Nov 04;17:307. doi: 10.1186/s13075-015-0825-9. PMID: 26530039. Exclusion Code: X3. [PMC free article: PMC4632359] [PubMed: 26530039] [CrossRef]

Strand V, Mahajan P, Chen C, et al. Benefit of sarilumab with csdmards on patient productivity in work, household work and family, social, leisure activities in TNF-IR RA patients. Ann Rheum Dis. 2016;75:985. doi: 10.1136/annrheumdis-2016-eular.4295. Exclusion Code: X3. [CrossRef]

Strand V, Smolen JS, van Vollenhoven RF, et al. Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. Ann Rheum Dis. 2011 Jun;70(6):996–1002. doi: 10.1136/ard.2010.143586. PMID: 21415050. Exclusion Code: X3. [PMC free article: PMC3086050] [PubMed: 21415050] [CrossRef]

Strand V, Tugwell P, Bombardier C, et al. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum. 1999 Sep;42(9):1870–8. PMID: 10513801. Exclusion Code: X3. [PubMed: 10513801]

Strand V, van Vollenhoven RF, Lee EB, et al. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. p. 1031. Exclusion Code: X3. [PMC free article: PMC4870388] [PubMed: 26929445]

Strand V, van Vollenhoven RF, Lee EB, et al. Tofacitinib or adalimumab versus placebo: Patientreported outcomes from a phase 3 study of active rheumatoid arthritis. Rheumatology (United Kingdom). 2016;55(6):1031–41. doi: 10.1093/rheumatology/kev442. Exclusion Code: X3. [PMC free article: PMC4870388] [PubMed: 26929445] [CrossRef]

Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther. 2010/01/13 ed; 2010. p. R5. Exclusion Code: X3. [PMC free article: PMC2875631] [PubMed: 20064207]

Strangfeld A, Hyrich K, Askling J, et al. Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers. Rheumatology (Oxford). 2011 Jan;50(1):146–51. doi: 10.1093/rheumatology/keq301. PMID: 20861148 Exclusion Code: X3. [PubMed: 20861148] [CrossRef]

Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA; 2009. p. 737–44. Exclusion Code: X3. [PubMed: 19224750]

Strangfeld A, Richter A, Siegmund B, et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis. 2017;76(3):504–10. doi: 10.1136/annrheumdis-2016-209773. Exclusion Code: X3. [PMC free article: PMC5445993] [PubMed: 27405509] [CrossRef]

Sugimoto N, Nakajima A, Inoue E, et al. Incidence of comprehensive hospitalization due to infection, cardiovascular disease, fractures, and malignancies in patients with rheumatoid arthritis. Rheumatol Int. 2017:1–8 doi: 10.1007/s00296-017-3811-5. Exclusion Code: X3. [PubMed: 28884287] [CrossRef]

Suh YS, Kwok SK, Ju JH, et al. Safe re-administration of tumor necrosis factor-alpha (TNFalpha) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFalpha therapy. J Korean Med Sci. 2014 Jan;29(1):38–42. doi: 10.3346/jkms.2014.29.1.38. PMID: 24431903 Exclusion Code: X3. [PMC free article: PMC3890474] [PubMed: 24431903] [CrossRef]

Suissa S, Baker N, Kawabata H, et al. Comparative risk of malignancy with initiaton of abatacept and other biologics in patients with rheumatoid arthritis: A cohort analysis of a united states claims database. Ann Rheum Dis. 2016;75:719–20. doi: 10.1136/annrheumdis-2016-eular.1275. Exclusion Code: X3. [CrossRef]

Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum; 2006. p. 531–6. Exclusion Code: X3. [PubMed: 16874796]

Suissa S, Ernst P, Hudson M, et al. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. Am J Med. 2004 Jul 15;117(2):87–92. PMID: 15234643. Exclusion Code: X3. [PubMed: 15234643]

Sumida K, Ubara Y, Suwabe T, et al. Adalimumab treatment in patients with rheumatoid arthritis with renal insufficiency. Arthritis Care Res (Hoboken). 2013 Mar;65(3):471–5. doi: 10.1002/acr.21800. PMID: 22807318. Exclusion Code: X3. [PubMed: 22807318] [CrossRef]

Szanto E. Low-dose methotrexate treatment of rheumatoid arthritis; long-term observation of efficacy and safety. Clin Rheumatol. 1989 Sep;8(3):323–20. PMID: 2805607. Exclusion Code: X3. [PubMed: 2805607]

Takahashi N, Kojima T, Kaneko A, et al. Use of a 12-week observational period for predicting low disease activity at 52 weeks in RA patients treated with abatacept: a retrospective observational study based on data from a Japanese multicentre registry study. Rheumatology (Oxford). 2015 May;54(5):854–9. doi: 10.1093/rheumatology/keu418. PMID: 25339638 Exclusion Code: X3. [PubMed: 25339638] [CrossRef]

Takahashi N, Kojima T, Kaneko A, et al. Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity. Clin Rheumatol. 2014 Jan;33(1):39–47. doi: 10.1007/s10067-013-2392-2. PMID: 24057092 Exclusion Code: X3. [PMC free article: PMC3890049] [PubMed: 24057092] [CrossRef]

Takahashi N, Kojima T, Terabe K, et al. Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients. Mod Rheumatol. 2013 Sep;23(5):904–12. doi: 10.1007/s10165-012-0760-4. PMID: 22975734 Exclusion Code: X3. [PubMed: 22975734] [CrossRef]

Takamura A, Hirata S, Nagasawa H, et al. A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology. Mod Rheumatol. 2013 Mar;23(2):297–303. doi: 10.1007/s10165-012-0658-1. PMID: 22572888. Exclusion Code: X3. [PubMed: 22572888] [CrossRef]

Takasugi K, Nishida K, Natsumeda M, et al. IL-6 is an independent predictive factor of drug survival after dose escalation of infliximab in patients with rheumatoid arthritis. Mod Rheumatol. 2017:1–9. doi: 10.1080/14397595.2017.1361802. Exclusion Code: X3. [PubMed: 28828944] [CrossRef]

Takeuchi T, Harigai M, Tanaka Y, et al. Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GOMONO study through 24 weeks. Ann Rheum Dis. 2013 Sep 01;72(9):1488–95. doi: 10.1136/annrheumdis-2012-201796. PMID: 22984173. Exclusion Code: X3. [PMC free article: PMC3756456] [PubMed: 22984173] [CrossRef]

Takeuchi T, Matsubara T, Nitobe T, et al. Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. Mod Rheumatol; 2013. p. 226–35. Exclusion Code: X3. [PubMed: 22684431]

Takeuchi T, Miyasaka N, Zang C, et al. A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis. Mod Rheumatol. 2013 Jul;23(4):623–33. doi: 10.1007/s10165-012-0742-6. PMID: 23011358. Exclusion Code: X3. [PubMed: 23011358] [CrossRef]

Takeuchi T, Tanaka Y, Amano K, et al. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study. Rheumatology (Oxford). 2011 Oct;50(10):1908–15. doi: 10.1093/rheumatology/ker221. PMID: 21752873 Exclusion Code: X3. [PMC free article: PMC3176715] [PubMed: 21752873] [CrossRef]

Takeuchi T, Tanaka Y, Kaneko Y, et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumatol. 2012 Jun;22(3):327–38. doi: 10.1007/s10165-011-0516-6. PMID: 21898074. Exclusion Code: X3. [PMC free article: PMC3375429] [PubMed: 21898074] [CrossRef]

Takeuchi T, Yamamoto K, Yamanaka H, et al. Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis. Mod Rheumatol. 2016;26(4):473–80. doi: 10.3109/14397595.2015.1109182. Exclusion Code: X3. [PMC free article: PMC4898155] [PubMed: 26472043] [CrossRef]

Takeuchi T, Yamamoto K, Yamanaka H, et al. Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies. Mod Rheumatol; 2015. p. 11–20. Exclusion Code: X3. [PubMed: 24842476]

Takeuchi T, Yamanaka H, Tanaka Y, et al. Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2015;25(6):817–24. doi: 10.3109/14397595.2015.1022297. PMID: 25736355 Exclusion Code: X3. [PMC free article: PMC4732515] [PubMed: 25736355] [CrossRef]

Tam LS, Leung CC, Ying SK, et al. Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong--the role of TNF blockers in an area of high tuberculosis burden. Clin Exp Rheumatol. 2010 Sep-Oct;28(5):679–85. PMID: 20822708. Exclusion Code: X3. [PubMed: 20822708]

Tanaka C, Shiozawa K, Hashiramoto A, et al. A study on the selection of DMARDs for the combination therapy with adalimumab. Kobe J Med Sci. 2012 Jun 27;58(2):E41–50. PMID: 22972168. Exclusion Code: X3. [PubMed: 22972168]

Tanaka E, Inoue E, Yamaguchi R, et al. Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan. Mod Rheumatol. 2017;27(2):227–36. doi: 10.1080/14397595.2016.1205799. Exclusion Code: X3. [PubMed: 27472516] [CrossRef]

Tanaka Y, Harigai M, Takeuchi T, et al. Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: Post hoc analysis of the GO-FORTH study. Mod Rheumatol. 2016;26(3):323–30. doi: 10.3109/14397595.2015.1086041. PMID: 26471830 Exclusion Code: X3. [PubMed: 26471830] [CrossRef]

Tanaka Y, Harigai M, Takeuchi T, et al. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis. 2012 Jun;71(6):817–24. doi: 10.1136/ard.2011.200317. PMID: 22121129 Exclusion Code: X3. [PMC free article: PMC3372319] [PubMed: 22121129] [CrossRef]

Tanaka Y, Kubo S, Yamanaka H, et al. Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia((R)) as Biological Intensive Treatment for RA (ORBIT) study. Mod Rheumatol. 2014 Sep;24(5):754–62. doi: 10.3109/14397595.2013.872862. PMID: 25036232 Exclusion Code: X3. [PubMed: 25036232] [CrossRef]

Tanaka Y, Suzuki M, Nakamura H, et al. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken). 2011 Aug;63(8):1150–8. doi: 10.1002/acr.20494. PMID: 21584942. Exclusion Code: X3. [PubMed: 21584942] [CrossRef]

Tanaka Y, Yamamoto K, Takeuchi T, et al. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study. Mod Rheumatol. 2014 Sep;24(5):734–43. doi: 10.3109/14397595.2014.881709. PMID: 24593170 Exclusion Code: X3. [PMC free article: PMC4819587] [PubMed: 24593170] [CrossRef]

Tanaka Y, Yamamoto K, Takeuchi T, et al. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study. Mod Rheumatol. 2014 Sep;24(5):725–33. doi: 10.3109/14397595.2013.865822. PMID: 24372225 Exclusion Code: X3. [PubMed: 24372225] [CrossRef]

Tanaka Y, Yamanaka H, Takeuchi T, et al. Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. Mod Rheumatol. 2017;27(2):237–45. doi: 10.1080/14397595.2016.1206244. Exclusion Code: X3. [PubMed: 27586879] [CrossRef]

Tanaka Y, Yamazaki K, Nakajima R, et al. Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab noninterventional trial for up-verified effects and utility (ANOUVEAU) study. Mod Rheumatol; 2017. p. 1–9. Exclusion Code: X3. [PubMed: 28704126]

Tandon N, Haas S, Waters HC, et al. Persistency with subcutaneous anti-TNF therapy for treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis patients. Annals of the Rheumatic Disease. 2013;71 doi: 10.1136/annrheumdis-2012-eular.1361. Exclusion Code: X3. [CrossRef]

Tang KT, Hung WT, Chen YH, et al. Methotrexate is not associated with increased liver cirrhosis in a population-based cohort of rheumatoid arthritis patients with chronic hepatitis B. Sci Rep. 2016 Mar 01;6:22387. doi: 10.1038/srep22387. PMID: 26928373. Exclusion Code: X3. [PMC free article: PMC4772158] [PubMed: 26928373] [CrossRef]

Tangtavorn N, Yospaiboon Y, Ratanapakorn T, et al. Incidence of and risk factors for chloroquine and hydroxychloroquine retinopathy in Thai rheumatologic patients. Clinical Ophthalmology. 2016;10:2179–85. doi: 10.2147/OPTH.S119872. Exclusion Code: X3. [PMC free article: PMC5098594] [PubMed: 27843287] [CrossRef]

Tantayakom P, Koolvisoot A, Arromdee E, et al. Metabolic syndrome is associated with disease activity in patients with rheumatoid arthritis. Joint Bone Spine. 2016;83(5):563–7 doi: 10.1016/j.jbspin.2015.10.016. Exclusion Code: X3. [PubMed: 27238198] [CrossRef]

Taylor P, Steuer A, Gruber J, et al. Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. Arthritis Rheum. 2006;54(1):47–53. doi: US: http://www​.mrw.interscience​.wiley.com/cochrane​/clcentral/articles​/912/CN-00553912/frame.html Exclusion Code: X3. [PubMed: 16385521]

Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017 Feb 16;376(7):652–62. doi: 10.1056/NEJMoa1608345. PMID: 28199814. Exclusion Code: X3. [PubMed: 28199814] [CrossRef]

Taylor PC, Ritchlin C, Mendelsohn A, et al. Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab. J Rheumatol. 2011 Dec;38(12):2572–80. doi: 10.3899/jrheum.110570. PMID: 22089463. Exclusion Code: X3. [PubMed: 22089463] [CrossRef]

Taylor PC, Steuer A, Gruber J, et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum. 2004;50(4):1107–16. Exclusion Code: X3. [PubMed: 15077292]

Terashima Y, Yurube T, Hirata H, et al. Predictive Risk Factors of Cervical Spine Instabilities in Rheumatoid Arthritis. Spine (Phila Pa 1976). 2017;42(8):556–64. doi: 10.1097/BRS.0000000000001853. Exclusion Code: X3. [PubMed: 27525538] [CrossRef]

Tesser J, Kafka S, DeHoratius RJ, et al. Efficacy and safety of intravenous golimumab plus methotrexate in patients 65 years and younger and those greater than 65 years of age-a post-hoc analysis. Arthritis and Rheumatology. 2016;68:819–20. doi: 10.1002/art.39977. Exclusion Code: X3. [CrossRef]

Theander L, Nyhäll-Wahlin BM, Nilsson JA, et al. Severe extraarticular manifestations in a community based cohort of patients with rheumatoid arthritis: Risk factors and incidence in relation to treatment with tumor necrosis factor inhibitors. J Rheumatol. 2017;44(7):981–7. doi: 10.3899/jrheum.161103. Exclusion Code: X3. [PubMed: 28461642] [CrossRef]

Thorne C, Bensen WG, Choquette D, et al. Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry. Arthritis Care Res (Hoboken). 2014 Aug;66(8):1142–51. doi: 10.1002/acr.22290. PMID: 24470077. Exclusion Code: X3. [PubMed: 24470077] [CrossRef]

Thyagarajan V, Norman H, Alexander KA, et al. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-alpha biologics by rheumatoid arthritis patients. Semin Arthritis Rheum. 2012 Dec;42(3):223–33. doi: 10.1016/j.semarthrit.2012.05.004. PMID: 22748510 Exclusion Code: X3. [PubMed: 22748510] [CrossRef]

Tkacz J, Ellis L, Bolge SC, et al. Utilization and Adherence Patterns of Subcutaneously Administered Anti-Tumor Necrosis Factor Treatment Among Rheumatoid Arthritis Patients. p. 737. Exclusion Code: X3. [PubMed: 24661783]

Tlustochowicz W, Rahman P, Seriolo B, et al. Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study. J Rheumatol. 2016 Mar;43(3):495–503. doi: 10.3899/jrheum.150117. PMID: 26834211. Exclusion Code: X3. [PubMed: 26834211] [CrossRef]

Toh S, Li L, Harrold LR, et al. Comparative safety of infliximab and etanercept on the risk of serious infections: Does the association vary by patient characteristics? Pharmacoepidemiol Drug Saf. 2012;21(5):524–34. doi: 10.1002/pds.3238. Exclusion Code: X3. [PMC free article: PMC3330193] [PubMed: 22411435] [CrossRef]

Torrente-Segarra V, Arana AU, Fernández ASA, et al. RENACER study: Assessment of 12-month efficacy and safety of 168 certolizumab PEGol rheumatoid arthritis-treated patients from a Spanish multicenter national database. Mod Rheumatol. 2016;26(3):336–41. doi: 10.3109/14397595.2015.1101200. Exclusion Code: X3. [PubMed: 26418571] [CrossRef]

Tournadre A, Pereira B, Gossec L, et al. The association of fatigue, comorbidities and anti rheumatic drugs in rheumatoid arthritis: Results from French cohort study of comorbidities. Arthritis and Rheumatology. 2016;68:1927–9. doi: 10.1002/art.39977. Exclusion Code: X3. [CrossRef]

Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009 Jul;60(7):1884–94. PMID: 19565495. Exclusion Code: X3. [PMC free article: PMC2921546] [PubMed: 19565495]

Turkstra E, Ng SK, Scuffham PA. A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. p. 1885. Exclusion Code: X3. [PubMed: 21848493]

Uhlig T, Lie E, Norvang V, et al. Achievement of remission and low disease activity definitions in patients with rheumatoid arthritis in clinical practice: Results from the Nor-Dmard study. J Rheumatol. 2016;43(4):716–23. doi: 10.3899/jrheum.151132. Exclusion Code: X3. [PubMed: 26879358] [CrossRef]

Unverzagt S, Moldenhauer I, Nothacker M, et al. Immunotherapy for metastatic renal cell carcinoma. Cochrane Database of Systematic Reviews: John Wiley & Sons, Ltd; 2017. Exclusion Code: X3.

Urata Y, Uesato R, Tanaka D, et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol. 2011 Feb;21(1):16–23. doi: 10.1007/s10165-010-0337-z. PMID: 20668905. Exclusion Code: X3. [PubMed: 20668905] [CrossRef]

van Dartel SA, Fransen J, Kievit W, et al. Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology (Oxford). 2013 Jun;52(6):1052–7. doi: 10.1093/rheumatology/kes413. PMID: 23365147 Exclusion Code: X3. [PubMed: 23365147] [CrossRef]

van Dartel SA, Fransen J, Kievit W, et al. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis. 2013 Jun;72(6):895–900. doi: 10.1136/annrheumdis-2012-201338. PMID: 22887849 Exclusion Code: X3. [PubMed: 22887849] [CrossRef]

van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004 May;63(5):508–16. PMID: 15082480. Exclusion Code: X3. [PMC free article: PMC1755008] [PubMed: 15082480]

van de Putte LB, Rau R, Breedveld FC, et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis. 2003 Dec;62(12):1168–77. PMID: 14644854. Exclusion Code: X3. [PMC free article: PMC1754401] [PubMed: 14644854]

van der Heijde D, Klareskog L, Boers M, et al. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis. 2005 Nov;64(11):1582–7. PMID: 15860509. Exclusion Code: X3. [PMC free article: PMC1755254] [PubMed: 15860509]

van der Heijde D, Klareskog L, Landewe R, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum; 2007. p. 3928–39. Exclusion Code: X3. [PubMed: 18050208]

van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006 Apr;54(4):1063–74. PMID: 16572441. Exclusion Code: X3. [PubMed: 16572441]

van der Heijde D, Klareskog L, Singh A, et al. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. Ann Rheum Dis. 2006 Mar;65(3):328–34. PMID: 16079172. Exclusion Code: X3. [PMC free article: PMC1798055] [PubMed: 16079172]

van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013 Mar;65(3):559–70. doi: 10.1002/art.37816. PMID: 23348607. Exclusion Code: X3. [PubMed: 23348607] [CrossRef]

van der Maas A, Kievit W, van den Bemt BJ, et al. Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis. 2012 Nov;71(11):1849–54. doi: 10.1136/annrheumdis-2011-200945. PMID: 22504561. Exclusion Code: X3. [PubMed: 22504561] [CrossRef]

van der Veen MJ, van der Heide A, Kruize AA, et al. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis. 1994 Apr;53(4):224–8. PMID: 8203949. Exclusion Code: X3. [PMC free article: PMC1005299] [PubMed: 8203949]

van Dongen H, van Aken J, Lard LR, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007 May;56(5):1424–32. PMID: 17469099. Exclusion Code: X3. [PubMed: 17469099]

van Eijk IC, Nielen MM, van der Horst-Bruinsma I, et al. Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial. Rheumatology (Oxford). 2012 Apr;51(4):686–94. doi: 10.1093/rheumatology/ker355. PMID: 22166255 Exclusion Code: X3. [PMC free article: PMC3306166] [PubMed: 22166255] [CrossRef]

van Halm VP, Nurmohamed MT, Twisk JW, et al. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther; 2006. p. R151. Exclusion Code: X3. [PMC free article: PMC1779436] [PubMed: 16984661]

van Riel PL, Taggart AJ, Sany J, et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: The ADORE study. Ann Rheum Dis. 2006 Feb 7 PMID: 16464988. Exclusion Code: X3. [PMC free article: PMC1798368] [PubMed: 16464988]

Van Riel PLCM, Freundlich B, MacPeek D, et al. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: The ADORE trial. Ann Rheum Dis. 2008;67(8):1104–10. PMID: 2008355994. Exclusion Code: X3. [PubMed: 17666447]

van Vollenhoven RF, Felson D, Strand V, et al. American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial. Arthritis Care Res (Hoboken). 2011 Jan;63(1):128–34. doi: 10.1002/acr.20331. PMID: 20799264. Exclusion Code: X3. [PMC free article: PMC3016460] [PubMed: 20799264] [CrossRef]

van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012 Aug 09;367(6):508–19. doi: 10.1056/NEJMoa1112072. PMID: 22873531 Exclusion Code: X3. [PubMed: 22873531] [CrossRef]

van Vollenhoven RF, Fleischmann RM, Furst DE, et al. Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years. J Rheumatol. 2015 Oct;42(10):1761–6. doi: 10.3899/jrheum.150051. PMID: 26276965. Exclusion Code: X3. [PubMed: 26276965] [CrossRef]

van Vollenhoven RF, Ostergaard M, Leirisalo-Repo M, et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis. 2016 Jan;75(1):52–8. doi: 10.1136/annrheumdis-2014-205726. PMID: 25873634. Exclusion Code: X3. [PMC free article: PMC4717401] [PubMed: 25873634] [CrossRef]

Van Vollenhoven RF, Rubbert-Roth A, Sebba A, et al. Tocilizumab in patients with rheumatoid arthritis and rates of malignancy: Results from long-term extension clinical trials. Rheumatology (United Kingdom). 2014;53:i91–i2. doi: 10.1093/rheumatology/keu101.015. Exclusion Code: X3. [CrossRef]

Varatharajan N, Lim IG, Anandacoomarasamy A, et al. Methotrexate: long-term safety and efficacy in an Australian consultant rheumatology practice. Intern Med J. 2009 Apr;39(4):228–36. PMID: 19402861. Exclusion Code: X3. [PubMed: 19402861]

Varela H, Villamañán E, Plasencia C, et al. Safety of antitumour necrosis factor treatments in chronic rheumatic diseases: Therapy discontinuations related to side effects. J Clin Pharm Ther. 2016;41(3):306–9 doi: 10.1111/jcpt.12393. Exclusion Code: X3. [PubMed: 27191537] [CrossRef]

Varley CD, Deodhar AA, Ehst BD, et al. Persistence of Staphylococcus aureus colonization among individuals with immune-mediated inflammatory diseases treated with TNF-alpha inhibitor therapy. Rheumatology (Oxford). 2014 Feb;53(2):332–7. doi: 10.1093/rheumatology/ket351. PMID: 24173434 Exclusion Code: X3. [PubMed: 24173434] [CrossRef]

Vastesaeger N, Kutzbach AG, Amital H, et al. Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab. Rheumatology (United Kingdom). 2016;55(8):1466–76. doi: 10.1093/rheumatology/kew179. Exclusion Code: X3. [PMC free article: PMC4957672] [PubMed: 27114562] [CrossRef]

Ventura-Rios L, Banuelos-Ramirez D, Hernandez-Quiroz Mdel C, et al. Patient survival and safety with biologic therapy. Results of the Mexican National Registry Biobadamex 1.0. Reumatol Clin. 2012 Jul-Aug;8(4):189–94. doi: 10.1016/j.reuma.2012.02.010. PMID: 22673388 Exclusion Code: X3. [PubMed: 22673388] [CrossRef]

Verbruggen G, Wittoek R, Vander Cruyssen B, et al. Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification. Ann Rheum Dis. 2012 Jun;71(6):891–8. doi: 10.1136/ard.2011.149849. PMID: 22128078 Exclusion Code: X3. [PMC free article: PMC3371224] [PubMed: 22128078] [CrossRef]

Verstappen SM, King Y, Watson KD, et al. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011 May;70(5):823–6. doi: 10.1136/ard.2010.140822. PMID: 21362710 Exclusion Code: X3. [PMC free article: PMC3070273] [PubMed: 21362710] [CrossRef]

Virkki LM, Valleala H, Takakubo Y, et al. Outcomes of switching anti-TNF drugs in rheumatoid arthritis--a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN). Clin Rheumatol. 2011 Nov;30(11):1447–54. doi: 10.1007/s10067-011-1779-1. PMID: 21644062 Exclusion Code: X3. [PubMed: 21644062] [CrossRef]

Vital EM, Dass S, Buch MH, et al. An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial. Ann Rheum Dis. 2015 Jun;74(6):1195–201. doi: 10.1136/annrheumdis-2013-204544. PMID: 24443001 Exclusion Code: X3. [PubMed: 24443001] [CrossRef]

Vollenhoven R, Cifaldi M, Ray S, et al. Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. Arthritis Care Res (Hoboken). 2010;62(2):226–34. doi: 10.1002/acr.20072. PMID: CN-00734281. Exclusion Code: X3. [PubMed: 20191522] [CrossRef]

Wagner C, Chen D, Fan H, et al. Evaluation of serum biomarkers associated with radiographic progression in methotrexate-naive rheumatoid arthritis patients treated with methotrexate or golimumab. J Rheumatol. 2013 May;40(5):590–8. doi: 10.3899/jrheum.120889. PMID: 23457387. Exclusion Code: X3. [PubMed: 23457387] [CrossRef]

Waimann CA, Marengo MF, de Achaval S, et al. Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: consequences of low adherence. Arthritis Rheum. 2013 Jun;65(6):1421–9. doi: 10.1002/art.37917. PMID: 23728826. Exclusion Code: X3. [PMC free article: PMC3691007] [PubMed: 23728826] [CrossRef]

Wakabayashi H, Oka H, Nishioka Y, et al. Do biologics-naive patients with rheumatoid arthritis respond better to tocilizumab than patients for whom anti-TNF agents have failed? A retrospective study. Clin Exp Rheumatol. 2011 Mar-Apr;29(2):314–7. PMID: 21418781. Exclusion Code: X3. [PubMed: 21418781]

Wallenstein GV, Kanik KS, Wilkinson B, et al. Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials. Clin Exp Rheumatol. 2016 May-Jun;34(3):430–42. PMID: 27156561. Exclusion Code: X3. [PubMed: 27156561]

Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004 May 1;38(9):1261–5. PMID: 15127338. Exclusion Code: X3. [PubMed: 15127338]

Ward MM, Guthrie LC, Alba MI. Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials. Ann Rheum Dis. 2015 Sep;74(9):1691–6. doi: 10.1136/annrheumdis-2013-205079. PMID: 24794149 Exclusion Code: X3. [PMC free article: PMC4216638] [PubMed: 24794149] [CrossRef]

Wasko MC, Dasgupta A, Hubert H, et al. Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum. 2013 Feb;65(2):334–42. doi: 10.1002/art.37723. PMID: 23044791. Exclusion Code: X3. [PMC free article: PMC3558553] [PubMed: 23044791] [CrossRef]

Wassenberg S, Rau R, Klopsch T, et al. Efficacy of etanercept on radiographic progression in adult patients with rheumatoid arthritis or psoriatic arthritis: Results from the second interim analysis of a german non-interventional, prospective, multi-center study. Ann Rheum Dis. 2016;75:1259–60. doi: 10.1136/annrheumdis-2016-eular.2053. Exclusion Code: X3. [CrossRef]

Wassenberg S, Rau R, Klopsch T, et al. Efficacy of etanercept on radiographic progression in adult patients with rheumatoid or psoriatic arthritis: Results from the first interim analysis of a German non-interventional, prospective, multi-center study. Ann Rheum Dis. 2015;74:715–6. doi: 10.1136/annrheumdis-2015-eular.4895. Exclusion Code: X3. [CrossRef]

Wasserman MJ, Weber DA, Guthrie JA, et al. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J Rheumatol. 2004 Oct;31(10):1912–7. PMID: 15468353. Exclusion Code: X3. [PubMed: 15468353]

Weaver AL, Lautzenheiser RL, Schiff MH, et al. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry. Curr Med Res Opin. 2006 Jan;22(1):185–98. PMID: 16393444. Exclusion Code: X3. [PubMed: 16393444]

Weber-Schoendorfer C, Chambers C, Wacker E, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: A prospective multicenter cohort study. Arthritis and Rheumatology; 2014. p. 1101–10 Exclusion Code: X3. [PubMed: 24470106]

Weber-Schoendorfer C, Hoeltzenbein M, Wacker E, et al. No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study. Rheumatology (Oxford). 2014 Apr;53(4):757–63. doi: 10.1093/rheumatology/ket390. PMID: 24369411 Exclusion Code: X3. [PubMed: 24369411] [CrossRef]

Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum. 2006 Aug 31;54(9):2807–16 PMID: 16947384. Exclusion Code: X3. [PubMed: 16947384]

Weinblatt M, Keystone E, Furst D, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum; 2012. p. 35–45. Exclusion Code: X3. [PubMed: 12528101]

Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis. 2007 Feb;66(2):228–34. PMID: CN-00576417. Exclusion Code: X3. [PMC free article: PMC1798511] [PubMed: 16935912]

Weinblatt ME, Bingham CO, 3rd, Mendelsohn AM, et al. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis. 2013 Mar;72(3):381–9. doi: 10.1136/annrheumdis-2012-201411. PMID: 22661646. Exclusion Code: X3. [PubMed: 22661646] [CrossRef]

Weinblatt ME, Fleischmann R, Huizinga TW, et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology (Oxford). 2012 Dec;51(12):2204–14. doi: 10.1093/rheumatology/kes150. PMID: 22923753 Exclusion Code: X3. [PubMed: 22923753] [CrossRef]

Weinblatt ME, Fleischmann R, van Vollenhoven RF, et al. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Arthritis Res Ther. 2015 Nov 15;17:325. doi: 10.1186/s13075-015-0841-9 PMID: 26568428. Exclusion Code: X3. [PMC free article: PMC4644627] [PubMed: 26568428] [CrossRef]

Weinblatt ME, Keystone EC, Furst DE, et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis. 2006 Jun;65(6):753–9. PMID: 16308341. Exclusion Code: X3. [PMC free article: PMC1798163] [PubMed: 16308341]

Weinblatt ME, Kremer J, Cush J, et al. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study. Arthritis Care Res (Hoboken). 2013 Mar;65(3):362–71. doi: 10.1002/acr.21847. PMID: 22972745. Exclusion Code: X3. [PubMed: 22972745] [CrossRef]

Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999 Jan 28;340(4):253–9. PMID: 9920948. Exclusion Code: X3. [PubMed: 9920948]

Weinblatt ME, Kremer JM, Cush JJ, et al. Tocilizumab monotherapy and tocilizumab plus disease-modifying antirheumatic drugs in a US rheumatoid arthritis population with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum. 2011;63(10). Exclusion Code: X3.

Weinblatt ME, Trentham DE, Fraser PA, et al. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum. 1988 Feb;31(2):167–75. PMID: 3279962. Exclusion Code: X3. [PubMed: 3279962]

Weinblatt ME, Westhovens R, Mendelsohn AM, et al. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial. Ann Rheum Dis. 2014 Dec;73(12):2152–9. doi: 10.1136/annrheumdis-2013-203742. PMID: 24001888 Exclusion Code: X3. [PMC free article: PMC4251163] [PubMed: 24001888] [CrossRef]

Weisman MH, Paulus HE, Burch FX, et al. A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology (Oxford); 2007. p. 1122–5. Exclusion Code: X3. [PubMed: 17470434]

Wells G, Li T, Maxwell L, et al. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis; 2008. p. 260–5. Exclusion Code: X3. [PubMed: 17846044]

Wells G, Li T, Tugwell P. Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance Scale. Ann Rheum Dis. 2010 Oct;69(10):1768–73. doi: 10.1136/ard.2009.119727. PMID: 20610444 Exclusion Code: X3. [PubMed: 20610444] [CrossRef]

Wendler J, Burmester GR, Sorensen H, et al. Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients. Arthritis Res Ther. 2014 Mar 26;16(2):R80. doi: 10.1186/ar4521. PMID: 24670196. Exclusion Code: X3. [PMC free article: PMC4060207] [PubMed: 24670196] [CrossRef]

Wendling D, Streit G, Toussirot E, et al. Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease. Joint Bone Spine. 2008 Oct;75(5):540–3. PMID: 18674945. Exclusion Code: X3. [PubMed: 18674945]

Westhovens R, Cole JC, Li T, et al. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Rheumatology; 2006. p. 1238–46. Exclusion Code: X3. [PubMed: 16567357]

Westhovens R, Kremer JM, Emery P, et al. Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study. Clin Exp Rheumatol. 2014 Jul-Aug;32(4):553–62. PMID: 25005467. Exclusion Code: X3. [PubMed: 25005467]

Westhovens R, Kremer JM, Moreland LW, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. The Journal of rheumatology. 2009;36(4):736–42. Exclusion Code: X3. [PubMed: 19273451]

Westhovens R, Robles M, Ximenes AC, et al. Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis. Ann Rheum Dis. 2015 Mar;74(3):564–8. doi: 10.1136/annrheumdis-2014-206149. PMID: 25550337 Exclusion Code: X3. [PMC free article: PMC4345907] [PubMed: 25550337] [CrossRef]

Westhovens R, Weinblatt M, Han C, et al. Intravenously administered golimumab significantly improves health related quality of life and work productivity in patients with rheumatoid arthritis: Results of a phase III, placebo controlled trial. Arthritis Rheum. 2012;64:S776–S7. doi: 10.1002/art.37735. Exclusion Code: X3. [CrossRef]

Westhovens R, Yocum D, Han J, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum. 2006 Apr;54(4):1075–86. PMID: 16572442. Exclusion Code: X3. [PubMed: 16572442]

Wijesinghe H, Galappatthy P, De Silva R, et al. Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: Results from a randomized double blind controlled clinical trial. BMC Musculoskelet Disord. 2017;18(1)doi: 10.1186/s12891-017-1673-3. Exclusion Code: X3. [PMC free article: PMC5518147] [PubMed: 28724365] [CrossRef]

Wilke T, Mueller S, Lee SC, et al. Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: A retrospective non-interventional cohort analysis. BMC Musculoskelet Disord. 2017;18(1) doi: 10.1186/s12891-017-1684-0. Exclusion Code: X3. [PMC free article: PMC5540414] [PubMed: 28764705] [CrossRef]

Wilsdon TD, Whittle SL, Thynne TR, et al. Methotrexate for psoriatic arthritis. Cochrane Database of Systematic Reviews: John Wiley & Sons, Ltd; 2017. Exclusion Code: X3.

Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013 Mar 06;309(9):887–95. doi: 10.1001/jama.2013.1099. PMID: 23462785. Exclusion Code: X3. [PMC free article: PMC3773213] [PubMed: 23462785] [CrossRef]

Winthrop KL, Baxter R, Liu L, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis. 2013 Jan;72(1):37–42. doi: 10.1136/annrheumdis-2011-200690. PMID: 22523429 Exclusion Code: X3. [PubMed: 22523429] [CrossRef]

Winthrop KL, Park SH, Gul A, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(6):1133–8. doi: 10.1136/annrheumdis-2015-207319. Exclusion Code: X3. [PMC free article: PMC4893093] [PubMed: 26318385] [CrossRef]

Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006 Feb;54(2):628–34. PMID: 16447241. Exclusion Code: X3. [PubMed: 16447241]

Wolfe F, Caplan L, Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol; 2007. p. 172–8. Exclusion Code: X3. [PubMed: 17657669]

Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004 Jun;50(6):1740–51. PMID: 15188349. Exclusion Code: X3. [PubMed: 15188349]

Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med. 2004 Mar 1;116(5):305–11 PMID: 14984815. Exclusion Code: X3. [PubMed: 14984815]

Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum; 2007. p. 1433–9. Exclusion Code: X3. [PubMed: 17469100]

Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study. Arthritis Rheum. 2007;56(9):2886–95. PMID: 2007480317. Exclusion Code: X3. [PubMed: 17729297]

Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 2004 Feb;50(2):372–9. PMID: 14872478. Exclusion Code: X3. [PubMed: 14872478]

Wu CY, Chen DY, Shen JL, et al. The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study. Arthritis Res Ther. 2014 Sep 30;16(5):449. doi: 10.1186/s13075-014-0449-5. PMID: 25267341. Exclusion Code: X3. [PMC free article: PMC4201718] [PubMed: 25267341] [CrossRef]

Xie F, Yun H, Bernatsky S, et al. Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments. Arthritis and Rheumatology. 2016;68(11):2612–7. doi: 10.1002/art.39761. Exclusion Code: X3. [PMC free article: PMC5538140] [PubMed: 27213279] [CrossRef]

Yalçin T, Bal A, Dülgeroǧlu D, et al. Follow-up results of our patients with rheumatoid arthritis. Turkish Journal of Rheumatology. 2012;27(2):98–108. doi: 10.5606/tjr.2012.015. Exclusion Code: X3. [CrossRef]

Yamamoto K, Takeuchi T, Yamanaka H, et al. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial. Mod Rheumatol. 2014 Jul;24(4):552–60. doi: 10.3109/14397595.2013.843764. PMID: 24981319 Exclusion Code: X3. [PubMed: 24981319] [CrossRef]

Yamamoto K, Takeuchi T, Yamanaka H, et al. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. Mod Rheumatol. 2014 Sep;24(5):715–24. doi: 10.3109/14397595.2013.864224. PMID: 24313916 Exclusion Code: X3. [PubMed: 24313916] [CrossRef]

Yamanaka H, Nagaoka S, Lee SK, et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity— results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Mod Rheumatol. 2016;26(5):651–61. doi: 10.3109/14397595.2015.1123349. Exclusion Code: X3. [PubMed: 26698929] [CrossRef]

Yamanaka H, Tanaka Y, Inoue E, et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol. 2011 Apr;21(2):122–33. doi: 10.1007/s10165-010-0366-7. PMID: 20953815. Exclusion Code: X3. [PMC free article: PMC3071926] [PubMed: 20953815] [CrossRef]

Yamanaka H, Tanaka Y, Takeuchi T, et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther. 2016 Jan 28;18:34. doi: 10.1186/s13075-016-0932-2. PMID: 26818974. Exclusion Code: X3. [PMC free article: PMC4730592] [PubMed: 26818974] [CrossRef]

Yang CT, Kuo CF, Luo SF, et al. Discontinuation of anti-TNF-alpha therapy in a Chinese cohort of patients with rheumatoid arthritis. Clin Rheumatol. 2012 Nov;31(11):1549–57. doi: 10.1007/s10067-012-2047-8. PMID: 22847245. Exclusion Code: X3. [PubMed: 22847245] [CrossRef]

Yazici Y, Curtis JR, Ince A, et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis. 2012 Feb;71(2):198–205. doi: 10.1136/ard.2010.148700. PMID: 21949007. Exclusion Code: X3. [PubMed: 21949007] [CrossRef]

Yonemoto Y, Okamura K, Takeuchi K, et al. Comparison of golimumab 100-mg monotherapy to golimumab 50 mg plus methotrexate in patients with rheumatoid arthritis: Results from a multicenter, cohort study. Mod Rheumatol. 2016;26(1):24–8. doi: 10.3109/14397595.2015.1069472. PMID: 26140464. Exclusion Code: X3. [PubMed: 26140464] [CrossRef]

Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013 Oct;72(10):1613–20. doi: 10.1136/annrheumdis-2012-203090. PMID: 23687260. Exclusion Code: X3. [PMC free article: PMC3786641] [PubMed: 23687260] [CrossRef]

Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: Comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76(2):355–63. doi: 10.1136/annrheumdis-2015-208786. Exclusion Code: X3. [PMC free article: PMC5284338] [PubMed: 27130908] [CrossRef]

Yoo DH, Racewicz A, Brzezicki J, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther. 2016 Apr 02;18:82. doi: 10.1186/s13075-016-0981-6. PMID: 27038608 Exclusion Code: X3. [PMC free article: PMC4818886] [PubMed: 27038608] [CrossRef]

Yoshida Y, Takahashi Y, Yamashita H, et al. Clinical characteristics and incidence of methotrexate-related lymphoproliferative disorders of patients with rheumatoid arthritis. Mod Rheumatol. 2014 Sep;24(5):763–5. doi: 10.3109/14397595.2013.878016. PMID: 24498893 Exclusion Code: X3. [PubMed: 24498893] [CrossRef]

Yount S, Sorensen M, Cella D, et al. Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis. Clin Exp Rheumatol; 2012. p. 838–46. Exclusion Code: X3. [PubMed: 18173917]

Yun H, Xie F, Beyl RN, et al. Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis. Arthritis Care Res. 2017;69(10):1526–34. doi: 10.1002/acr.23141. Exclusion Code: X3. [PMC free article: PMC5420339] [PubMed: 27813327] [CrossRef]

Yun H, Xie F, Delzell E, et al. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken). 2015 May;67(5):731–6. doi: 10.1002/acr.22470. PMID: 25201241. Exclusion Code: X3. [PMC free article: PMC5765980] [PubMed: 25201241] [CrossRef]

Yun H, Xie F, Delzell E, et al. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare. Arthritis Rheumatol. 2016 Jan;68(1):56–66. doi: 10.1002/art.39399. PMID: 26315675. Exclusion Code: X3. [PubMed: 26315675] [CrossRef]

Zafar ZA, Mahmud TH, Rasheed A, et al. Frequency of metabolic syndrome in Pakistani cohort of patients with rheumatoid arthritis. J Pak Med Assoc. 2016;66(6):671–6 Exclusion Code: X3. [PubMed: 27339567]

Zeb S, Wazir N, Waqas M, et al. Comparison of short-term efficacy of leflunomide and methotrexate in active rheumatoid arthritis. Journal of Postgraduate Medical Institute. 2016;30(2):177–80. Exclusion Code: X3.

Zerbini C, Real R, Pedersen R, et al. Remission maintenance with etaqnercept-DMARD combination therapy compared with DMARDS alone in Latin America patients with active rheumatoid arthritis. J Clin Rheumatol. 2016;22(3):130–1. doi: 10.1097/RHU.0000000000000372. Exclusion Code: X3. [CrossRef]

Zhang FC, Hou Y, Huang F, et al. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from China. APLAR J Rheumatol. 2006;9(2):127–30 PMID: 2006338105. Exclusion Code: X3.

Zhang J, Xie F, Delzell E, et al. Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2015 May;67(5):624–32. doi: 10.1002/acr.22510. PMID: 25370912. Exclusion Code: X3. [PMC free article: PMC4412783] [PubMed: 25370912] [CrossRef]

Zhang J, Xie F, Yun H, et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis. 2016 doi: 10.1136/annrheumdis-2015-207870. Exclusion Code: X3. [PubMed: 26792814] [CrossRef]

Zhang X, Chen YC, Fettner S, et al. Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther. 2013 Aug;51(8):620–30. doi: 10.5414/cp201904. PMID: 23782588. Exclusion Code: X3. [PubMed: 23782588] [CrossRef]

Zhang X, Zhang F, Wu D, et al. Safety of infliximab therapy in rheumatoid arthritis patients with previous exposure to hepatitis B virus. Int J Rheum Dis. 2013 Aug;16(4):408–12. doi: 10.1111/1756-185x.12125. PMID: 23992260. Exclusion Code: X3. [PubMed: 23992260] [CrossRef]

Zhou H, Jang H, Fleischmann RM, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007 Mar;47(3):383–96. doi: 10.1177/0091270006298188. PMID: 17322150. Exclusion Code: X3. [PubMed: 17322150] [CrossRef]

Zink A, Listing J, Kary S, et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis. 2005 Sep;64(9):1274–9. PMID: 15708884. Exclusion Code: X3. [PMC free article: PMC1755655] [PubMed: 15708884]

Ajeganova S, Andersson ML, Frostegard J, et al. Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational cohort study. J Rheumatol. 2013 Dec;40(12):1958–66. doi: 10.3899/jrheum.130365. PMID: 23950188. Exclusion Code: X4. [PubMed: 23950188] [CrossRef]

Al-Kaissi E, Al-Muhtaseb N, Al-Muhtaseb N. The influence of adding antibiotic in treatment of rheumatoid arthritis patients on Streptococcus pyogenes carrier rate and on the lipids profile. International Journal of Pharmacy and Pharmaceutical Sciences. 2015;7(2):245–51. Exclusion Code: X4.

Bejarano V, Conaghan PG, Quinn MA, et al. Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis. Rheumatology (Oxford). 2010 Oct;49(10):1971–4. doi: 10.1093/rheumatology/keq194. PMID: 20595536 Exclusion Code: X4. [PubMed: 20595536] [CrossRef]

Bonafede M, Johnson BH, Fox KM, et al. Risk factors for non-initiation of disease modifyinganti-rheumatic drugs (DMARD) by patients with newlydiagnosed rheumatoid arthritis (RA). Value Health. 2011;14(3):A123. Exclusion Code: X4.

Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Mar;46(3):614–24. PMID: 11920396. Exclusion Code: X4. [PubMed: 11920396]

Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis. 2004 Sep;63(9):1062–8. PMID: 15082469. Exclusion Code: X4. [PMC free article: PMC1755108] [PubMed: 15082469]

Cohen SB, Woolley JM, Chan W. Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. J Rheumatol. 2003 Feb;30(2):225–31. PMID: 12563672. Exclusion Code: X4. [PubMed: 12563672]

Combe B, Logeart I, Belkacemi MC, et al. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort. Ann Rheum Dis. 2015 Apr;74(4):724–9. doi: 10.1136/annrheumdis-2013-204178. PMID: 24399234 Exclusion Code: X4. [PubMed: 24399234] [CrossRef]

Drosos A, Voulgari P, Papadopoulos I, et al. Cyclosporine A in the treatment of early rheumatoid arthritis. A prospective, randomized 24-month study. Clin Exp Rheumatol; 2012. p. 695–701. Exclusion Code: X4. [PubMed: 9844762]

Emery P, Hammoudeh M, FitzGerald O, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med. 2014 Nov 06;371(19):1781–92. doi: 10.1056/NEJMoa1316133. PMID: 25372086. Exclusion Code: X4. [PubMed: 25372086] [CrossRef]

Euesden J, Matcham F, Hotopf M, et al. The Relationship between Mental Health, Disease Severity, and Genetic Risk for Depression in Early Rheumatoid Arthritis. Psychosom Med. 2017;79(6):638–45. doi: 10.1097/PSY.0000000000000462. Exclusion Code: X4. [PMC free article: PMC5638421] [PubMed: 28282363] [CrossRef]

Fidahic M, Jelicic KA, Radic M, et al. Celecoxib for rheumatoid arthritis. Cochrane Database of Systematic Reviews: John Wiley & Sons, Ltd; 2017. Exclusion Code: X4.

Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (rmetHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 2003 Apr;48(4):927–34. PMID: 12687534. Exclusion Code: X4. [PubMed: 12687534]

Fleischmann RM, Tesser J, Schiff MH, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis. 2006 Aug;65(8):1006–12. PMID: 16396977. Exclusion Code: X4. [PMC free article: PMC1798263] [PubMed: 16396977]

Hetland ML, Stengaard-Pedersen K, Junker P, et al. Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Ann Rheum Dis. 2010 Oct;69(10):1789–95. doi: 10.1136/ard.2009.125534. PMID: 20444751 Exclusion Code: X4. [PubMed: 20444751] [CrossRef]

Hickling P, Jacoby RK, Kirwan JR. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Br J Rheumatol. 1998 Sep;37(9):930–6. PMID: 9783756. Exclusion Code: X4. [PubMed: 9783756]

Innala L, Moller B, Ljung L, et al. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther. 2011 Aug 15;13(4):R131. doi: 10.1186/ar3442. PMID: 21843325. Exclusion Code: X4. [PMC free article: PMC3239373] [PubMed: 21843325] [CrossRef]

Karanikolas G, Charalambopoulos D, Vaiopoulos G, et al. Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study. Rheumatology (Oxford); 2008. p. 1384–8. Exclusion Code: X4. [PubMed: 18603660]

Katigbak G, Lorenzo JP, Villarubin AO. The socio-demographic and clinical profile of rheumatoid arthritis patients and its correlation with the disease activity score. Int J Rheum Dis. 2013;16:56. Exclusion Code: X4.

Kwok KY, Leung MH. Tight control early rheumatoid arthritis clinic in Hong Kong: a pilot study. Hong Kong Med J. 2012 Apr;18(2):108–14. PMID: 22477733. Exclusion Code: X4. [PubMed: 22477733]

Langer HE, Missler-Karger B. Kineret: efficacy and safety in daily clinical practice: an interim analysis of the Kineret response assessment initiative (kreative) protocol. Int J Clin Pharmacol Res. 2003;23(4):119–28. PMID: 15224501. Exclusion Code: X4. [PubMed: 15224501]

Machein U, Buss B, Spiller I, et al. Effective treatment of early rheumatoid arthritis with a combination of methotrexate, prednisolone and cyclosporin. Rheumatology (Oxford). 2002 Jan;41(1):110–1. PMID: 11792891. Exclusion Code: X4. [PubMed: 11792891]

Mueller RB, Reshiti N, Kaegi T, et al. Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM). Clin Rheumatol. 2017 Jan;36(1):59–66. doi: 10.1007/s10067-016-3468-6. PMID: 27838788. Exclusion Code: X4. [PubMed: 27838788] [CrossRef]

Neumann V, Grindulis K, Hubball S, et al. Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: leeds-Birmingham trial. Br Med J (Clin Res Ed); 2012. p. 1099–102. Exclusion Code: X4. [PMC free article: PMC1549360] [PubMed: 6138116]

Nuki G, Bresnihan B, Bear MB, et al. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Nov;46(11):2838–46. PMID: 12428223. Exclusion Code: X4. [PubMed: 12428223]

Pasma A, Schenk CV, Timman R, et al. Non-adherence to disease-modifying antirheumatic drugs is associated with higher disease activity in early arthritis patients in the first year of the disease. Arthritis Res Ther. 2015 Oct 08;17:281. doi: 10.1186/s13075-015-0801-4. PMID: 26449852 Exclusion Code: X4. [PMC free article: PMC4599322] [PubMed: 26449852] [CrossRef]

Schiff M, Takeuchi T, Fleischmann R, et al. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Research and Therapy. 2017;19(1) doi: 10.1186/s13075-017-1410-1. Exclusion Code: X4. [PMC free article: PMC5604362] [PubMed: 28923098] [CrossRef]

Schiff MH, DiVittorio G, Tesser J, et al. The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. Arthritis Rheum. 2004 Jun;50(6):1752–60. PMID: 15188350. Exclusion Code: X4. [PubMed: 15188350]

Sugihara T, Ishizaki T, Hosoya T, et al. Structural and functional outcomes of a therapeutic strategy targeting low disease activity in patients with elderly-onset rheumatoid arthritis: a prospective cohort study (CRANE). Rheumatology (Oxford). 2015 May;54(5):798–807. doi: 10.1093/rheumatology/keu395. PMID: 25296748 Exclusion Code: X4. [PubMed: 25296748] [CrossRef]

Svensson B, Andersson M, Forslind K, et al. Persistently active disease is common in patients with rheumatoid arthritis, particularly in women: a long-term inception cohort study. Scand J Rheumatol. 2016 Nov;45(6):448–55. doi: 10.3109/03009742.2016.1147595. PMID: 27095008 Exclusion Code: X4. [PubMed: 27095008] [CrossRef]

Tesser J, Fleischmann R, Dore R, et al. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis. J Rheumatol. 2004;31(4):649–54. Exclusion Code: X4. [PubMed: 15088288]

van Jaarsveld CH, Jahangier ZN, Jacobs JW, et al. Toxicity of Anti-Rheumatic Drugs in a Randomized Clinical Trial of Early Rheumatoid Arthritis. Rheumatology (Oxford). 2000;39(12):1374–82. Exclusion Code: X4. [PubMed: 11136881]

Wassenberg S, Rau R, Steinfeld P, et al. Very Low-Dose Prednisolone in Early Rheumatoid Arthritis Retards Radiographic Progression Over Two Years: a Multicenter, Double-Blind, Placebo-Controlled Trial. Arthritis and rheumatism. 2005;52(11):3371–80. Exclusion Code: X4. [PubMed: 16255011]

Xiang N, Li XM, Zhang MJ, et al. Total glucosides of paeony can reduce the hepatotoxicity caused by Methotrexate and Leflunomide combination treatment of active rheumatoid arthritis. Int Immunopharmacol. 2015 Sep;28(1):802–7. doi: 10.1016/j.intimp.2015.08.008. PMID: 26292180. Exclusion Code: X4. [PubMed: 26292180] [CrossRef]

Albrecht K, Callhoff J, Schneider M, et al. High variability in glucocorticoid starting doses in patients with rheumatoid arthritis: observational data from an early arthritis cohort. Rheumatol Int. 2015 Aug;35(8):1377–84. doi: 10.1007/s00296-015-3229-x. PMID: 25663291. Exclusion Code: X5. [PubMed: 25663291] [CrossRef]

Ally MM, Hodkinson B, Meyer PW, et al. Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. BMC Musculoskelet Disord. 2015 May 29;16:130. doi: 10.1186/s12891-015-0587-1. PMID: 26021985 Exclusion Code: X5. [PMC free article: PMC4446850] [PubMed: 26021985] [CrossRef]

Andersen T, Hvid M, Johansen C, et al. Interleukin-23 in early disease development in rheumatoid arthritis. Scand J Rheumatol. 2015;44(6):438–42. doi: 10.3109/03009742.2015.1033007. PMID: 26087654 Exclusion Code: X5. [PubMed: 26087654] [CrossRef]

Andersson ML, Svensson B, Bergman S. Chronic widespread pain in patients with rheumatoid arthritis and the relation between pain and disease activity measures over the first 5 years. J Rheumatol. 2013 Dec;40(12):1977–85. doi: 10.3899/jrheum.130493. PMID: 24187108. Exclusion Code: X5. [PubMed: 24187108] [CrossRef]

Baker JF, Baker DG, Toedter G, et al. Associations between vitamin D, disease activity, and clinical response to therapy in rheumatoid arthritis. Clin Exp Rheumatol. 2012 Sep-Oct;30(5):658–64. PMID: 22776409. Exclusion Code: X5. [PubMed: 22776409]

Baker JF, Conaghan PG, Emery P, et al. Relationship of patient-reported outcomes with MRI measures in rheumatoid arthritis. Ann Rheum Dis. 2017;76(3):486–90. doi: 10.1136/annrheumdis-2016-209463. Exclusion Code: X5. [PubMed: 27432355] [CrossRef]

Bakker MF, Jacobs JW, Welsing PM, et al. Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study. Ann Rheum Dis. 2011 Jun;70(6):1099–103. doi: 10.1136/ard.2010.137943. PMID: 21406458 Exclusion Code: X5. [PubMed: 21406458] [CrossRef]

Bakker MF, Verstappen SM, Welsing PM, et al. The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial. Arthritis Res Ther. 2011 May 08;13(3):R70. doi: 10.1186/ar3331. PMID: 21539729. Exclusion Code: X5. [PMC free article: PMC3218879] [PubMed: 21539729] [CrossRef]

Balduzzi S, Scire CA, Sakellariou G, et al. In early inflammatory polyarthritis more intensive management according to the 2010 ACR/EULAR criteria leads to higher rates of clinical remission: comparison of two cohorts treated according to different treat-to-target protocols. Clin Exp Rheumatol. 2017 May-Jun;35(3):401–5. PMID: 27974097. Exclusion Code: X5. [PubMed: 27974097]

Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis. 2015 Jun;74(6):1037–44 doi: 10.1136/annrheumdis-2013-204769. PMID: 24550168. Exclusion Code: X5. [PMC free article: PMC4431334] [PubMed: 24550168] [CrossRef]

Bykerk VP, Jamal S, Boire G, et al. The Canadian Early Arthritis Cohort (CATCH): patients with new-onset synovitis meeting the 2010 ACR/EULAR classification criteria but not the 1987 ACR classification criteria present with less severe disease activity. J Rheumatol. 2012 Nov;39(11):2071–80. doi: 10.3899/jrheum.120029. PMID: 22896026. Exclusion Code: X5. [PubMed: 22896026] [CrossRef]

Choy E, Scott D, Kingsley G, et al. Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: a randomised double blind trial of sulphasalazine vs diclofenac sodium. Clin Exp Rheumatol; 2012. p. 351–8. Exclusion Code: X5. [PubMed: 12102471]

Cuppen BV, Jacobs JW, Ter Borg EJ, et al. Necessity of TNF-alpha inhibitor discontinuation in rheumatoid arthritis is predicted by smoking and number of previously used biological DMARDs. Clin Exp Rheumatol. 2017 Mar-Apr;35(2):221–8. PMID: 27749223. Exclusion Code: X5. [PubMed: 27749223]

Curtis JR, Xie F, Chen L, et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis. 2011 Aug;70(8):1401–6. doi: 10.1136/ard.2010.146365. PMID: 21586439 Exclusion Code: X5. [PMC free article: PMC3128235] [PubMed: 21586439] [CrossRef]

Cutolo M, Bolosiu H, Perdriset G. Efficacy and safety of leflunomide in DMARD-naive patients with early rheumatoid arthritis: comparison of a loading and a fixed-dose regimen. Rheumatology (Oxford). 2013 Jun;52(6):1132–40. doi: 10.1093/rheumatology/kes321. PMID: 23401601 Exclusion Code: X5. [PubMed: 23401601] [CrossRef]

Dale J, Stirling A, Zhang R, et al. Targeting ultrasound remission in early rheumatoid arthritis: The results of the TaSER study, a randomised clinical trial. Ann Rheum Dis. 2016;75(6):1043–50. doi: 10.1136/annrheumdis-2015-208941. Exclusion Code: X5. [PubMed: 27026689] [CrossRef]

Emery P, van der Heijde D, Ostergaard M, et al. Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis. Ann Rheum Dis. 2011 Dec;70(12):2126–30. doi: 10.1136/ard.2011.154500. PMID: 21926186 Exclusion Code: X5. [PMC free article: PMC3212698] [PubMed: 21926186] [CrossRef]

Fan H, Li Y, Zhang L, et al. Lack of association between MTHFR A1298C polymorphism and outcome of methotrexate treatment in rheumatoid arthritis patients: evidence from a systematic review and meta-analysis. Int J Rheum Dis. 2017;20(5):526–40. doi: 10.1111/1756-185X.13100. Exclusion Code: X5. [PubMed: 28544525] [CrossRef]

Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, et al. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis. 2010 Jan;69(1):65–9. doi: 10.1136/ard.2008.097683. PMID: 19155234. Exclusion Code: X5. [PubMed: 19155234] [CrossRef]

Greisen SR, Moller HJ, Stengaard-Pedersen K, et al. Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDs. Clin Exp Rheumatol. 2015 Jul-Aug;33(4):498–502. PMID: 25962601. Exclusion Code: X5. [PubMed: 25962601]

Hazlewood GS, Thorne JC, Pope JE, et al. The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann Rheum Dis. 2016;75(6):1003–8. doi: 10.1136/annrheumdis-2014-206504. Exclusion Code: X5. [PubMed: 25979945] [CrossRef]

Heimans L, Wevers-deBoer KV, Ronday HK, et al. Can we prevent rapid radiological progression in patients with early rheumatoid arthritis? Clin Rheumatol. 2015 Jan;34(1):163–6. doi: 10.1007/s10067-014-2815-8. PMID: 25431327. Exclusion Code: X5. [PubMed: 25431327] [CrossRef]

Hobl EL, Mader RM, Jilma B, et al. A randomized, double-blind, parallel, single-site pilot trial to compare two different starting doses of methotrexate in methotrexate-naive adult patients with rheumatoid arthritis. Clin Ther. 2012 May;34(5):1195–203. doi: 10.1016/j.clinthera.2012.03.059. PMID: 22516039 Exclusion Code: X5. [PubMed: 22516039] [CrossRef]

Jansen D, Emery P, Smolen J, et al. FRI0219 Association between conversion to ACPA/RF seronegative status and clinical outcomes following treatment with abatacept in combination with methotrexate compared with methotrexate alone in patients with early rheumatoid arthritis and poor prognostic indicators. Ann Rheum Dis. 2017;76(Suppl 2):566-. doi: 10.1136/annrheumdis-2017-eular.1716. Exclusion Code: X5. [CrossRef]

Kastbom A, Forslind K, Ernestam S, et al. Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial. Ann Rheum Dis. 2016 Feb;75(2):356–61. doi: 10.1136/annrheumdis-2014-205698. PMID: 25550338 Exclusion Code: X5. [PMC free article: PMC4752667] [PubMed: 25550338] [CrossRef]

Keystone EC, Haraoui B, Guerette B, et al. Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study. J Rheumatol. 2014 Feb;41(2):235–43. doi: 10.3899/jrheum.121468. PMID: 24293583. Exclusion Code: X5. [PubMed: 24293583] [CrossRef]

Kikuchi J, Kondo T, Shibata A, et al. Efficacy and tolerability of six-week extended dosing interval with tocilizumab therapy in a prospective cohort as remission maintenance in patients with rheumatoid arthritis. Mod Rheumatol. 2017:1–8. doi: 10.1080/14397595.2017.1366092. Exclusion Code: X5. [PubMed: 28849709] [CrossRef]

Konijn N, Tuyl L, Boers M, et al. Do Short and Sustained Periods of American College of Rheumatology/European League Against Rheumatism Remission Predict Functional and Radiographic Outcome in Early Rheumatoid Arthritis Patients With Low Overall Damage Progression? Arthritis Care Res (Hoboken); 2017. p. 989–96. Exclusion Code: X5. [PubMed: 27696732]

Konijn NPC, van Tuyl LHD, Boers M, et al. Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial. Rheumatology (Oxford). 2017 Sep 01;56(9):1586–96. doi: 10.1093/rheumatology/kex223. PMID: 28859326 Exclusion Code: X5. [PubMed: 28859326] [CrossRef]

Kuusalo L, Puolakka K, Kautiainen H, et al. Patient-reported outcomes as predictors of remission in early rheumatoid arthritis patients treated with tight control treat-to-target approach. Rheumatol Int. 2017;37(5):825–30. doi: 10.1007/s00296-017-3692-7. Exclusion Code: X5. [PubMed: 28289873] [CrossRef]

Kuusalo LA, Puolakka KT, Kautiainen H, et al. Intra-articular glucocorticoid injections should not be neglected in the remission targeted treatment of early rheumatoid arthritis: a post hoc analysis from the NEORACo trial. Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1038–44. PMID: 27494516. Exclusion Code: X5. [PubMed: 27494516]

Lau CS, Gibofsky A, Damjanov N, et al. Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review. Rheumatol Int. 2017:1–10. doi: 10.1007/s00296-017-3780-8. Exclusion Code: X5. [PMC free article: PMC5645436] [PubMed: 28852832] [CrossRef]

Lee JJ, Bykerk VP, Dresser GK, et al. Reduction in serum uric acid may be related to methotrexate efficacy in early rheumatoid arthritis: Data from the Canadian Early Arthritis Cohort (CATCH). Clin Med Insights Arthritis Musculoskelet Disord. 2016;9:37–43. doi: 10.4137/CMAMD.S38092. Exclusion Code: X5. [PMC free article: PMC4821431] [PubMed: 27081318] [CrossRef]

Liao TL, Lin CH, Chen HH, et al. Significant associations of neurological complications of herpes zoster with stroke in rheumatoid arthritis patients. Journal of the American Heart Association. 2017;6(7)doi: 10.1161/JAHA.117.006304. Exclusion Code: X5. [PMC free article: PMC5586320] [PubMed: 28724649] [CrossRef]

Lourdudoss C, Wolk A, Nise L, et al. Are dietary Vitamin D, omega-3 fatty acids and folate associated with treatment results in patients with early rheumatoid arthritis? Data from a Swedish population-based prospective study. BMJ Open. 2017;7(6)doi: 10.1136/bmjopen-2017-016154. Exclusion Code: X5. [PMC free article: PMC5541601] [PubMed: 28601838] [CrossRef]

Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum; 2006. p. 2817–29. Exclusion Code: X5. [PubMed: 16947782]

Maska LB, Sayles HR, O’Dell JR, et al. Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012 Dec;64(12):1804–10. doi: 10.1002/acr.21758. PMID: 22730343. Exclusion Code: X5. [PMC free article: PMC3467327] [PubMed: 22730343] [CrossRef]

Michelsen B, Kristianslund EK, Hammer HB, et al. Discordance between tender and swollen joint count as well as patient’s and evaluator’s global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: Data from the prospective multicentre NORDMARD study. Ann Rheum Dis. 2016 doi: 10.1136/annrheumdis-2016-210283. Exclusion Code: X5. [PubMed: 27707730] [CrossRef]

Modi JV, Patel KR, Patel ZM, et al. Dose response relationship of hydroxychloroquine sulphate in the treatment of rheumatoid arthritis: A randomised control study. International Journal of Pharmaceutical Sciences and Research. 2017;8(2):856–8. doi: 10.13040/IJPSR.0975-8232.8(2).856-58 Exclusion Code: X5. [CrossRef]

Mozaffarian N, Smolen JS, Devanarayan V, et al. FRI0086 Biomarkers identify radiographic progressors and clinical responders among patients with early rheumatoid arthritis. Ann Rheum Dis. 2013 Jun 2013 2017-06-14;72 doi: http://dx​.doi.org/10​.1136/annrheumdis-2013-eular.1213. PMID: 1777911717. Exclusion Code: X5.

Mueller RB, Schiff M, Kaegi T, et al. The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis. Clin Rheumatol. 2015 Jan;34(1):51–9. doi: 10.1007/s10067-014-2737-5. PMID: 25024096. Exclusion Code: X5. [PubMed: 25024096] [CrossRef]

Myasoedova E, Crowson CS, Nicola PJ, et al. The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol. 2011 Aug;38(8):1601–6. doi: 10.3899/jrheum.100979. PMID: 21572155. Exclusion Code: X5. [PMC free article: PMC3337549] [PubMed: 21572155] [CrossRef]

Nikiphorou E, Carpenter L, Morris S, et al. Hand and foot surgery rates in rheumatoid arthritis have declined from 1986 to 2011, but large-joint replacement rates remain unchanged: results from two UK inception cohorts. Arthritis Rheumatol. 2014 May;66(5):1081–9. doi: 10.1002/art.38344. PMID: 24782174. Exclusion Code: X5. [PubMed: 24782174] [CrossRef]

Pappas DA, Griffith J, Litman HJ, et al. Time to initiation of biologic agents is associated with glucocorticoid use: Results from the CORRONA registry. Arthritis and Rheumatology. 2016;68:3509–10. doi: 10.1002/art.39977. Exclusion Code: X5. [CrossRef]

Pasma A, Den Boer E, Van’t Spijker A, et al. Non-adherence to disease modifying antirheumatic drugs in the first year after diagnosis: Comparing three adherence measures in early arthritis patients. Ann Rheum Dis. 2015;74:547. doi: 10.1136/annrheumdis-2015-eular.3030. Exclusion Code: X5. [PubMed: 27354686] [CrossRef]

Peterfy CG, Olech E, DiCarlo JC, et al. Monitoring cartilage loss in the hands and wrists in rheumatoid arthritis with magnetic resonance imaging in a multi-center clinical trial: IMPRESS (NCT00425932). Arthritis Res Ther. 2013 Mar 20;15(2):R44. doi: 10.1186/ar4202. PMID: 23514433. Exclusion Code: X5. [PMC free article: PMC4060230] [PubMed: 23514433] [CrossRef]

Ranganath VK, Motamedi K, Haavardsholm EA, et al. Comprehensive appraisal of magnetic resonance imaging findings in sustained rheumatoid arthritis remission: a substudy. Arthritis Care Res (Hoboken). 2015 Jul;67(7):929–39. doi: 10.1002/acr.22541. PMID: 25581612. Exclusion Code: X5. [PMC free article: PMC4482777] [PubMed: 25581612] [CrossRef]

Rannio T, Asikainen J, Kokko A, et al. Early remission is a realistic target in a majority of patients with DMARD-naive rheumatoid arthritis. J Rheumatol. 2016;43(4):699–706. doi: 10.3899/jrheum.141480. Exclusion Code: X5. [PubMed: 26879355] [CrossRef]

Rantalaiho V, Kautiainen H, Jarvenpaa S, et al. Failure in longterm treatment is rare in actively treated patients with rheumatoid arthritis, but may be predicted by high health assessment score at baseline and by residual disease activity at 3 and 6 months: the 5-year followup results of the randomized clinical NEO-RACo trial. J Rheumatol. 2014 Dec;41(12):2379–85. doi: 10.3899/jrheum.140267. PMID: 25274892. Exclusion Code: X5. [PubMed: 25274892] [CrossRef]

Rodríguez-Bautista E, Rosario V, Peña-Blanco R, et al. Impact of obesity activity indices and therapeutic dosage in patients with rheumatoid arthritis in dominican republic. Arthritis and Rheumatology. 2016;68:3310–1. doi: 10.1002/art.39977. Exclusion Code: X5. [CrossRef]

Rodriguez-Rodriguez L, Leon L, Ivorra-Cortes J, et al. Treatment in rheumatoid arthritis and mortality risk in clinical practice: the role of biologic agents. Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1026–32 PMID: 27749239. Exclusion Code: X5. [PubMed: 27749239]

Roux CH, Breuil V, Valerio L, et al. Etanercept compared to intraarticular corticosteroid injection in rheumatoid arthritis: double-blind, randomized pilot study. J Rheumatol. 2011 Jun;38(6):1009–11 doi: 10.3899/jrheum.100828. PMID: 21406499. Exclusion Code: X5. [PubMed: 21406499] [CrossRef]

Safy M, Jacobs J, ND IJ, et al. Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial. Ann Rheum Dis. 2017 Aug;76(8):1432–5. doi: 10.1136/annrheumdis-2016-210647. PMID: 28450312 Exclusion Code: X5. [PubMed: 28450312] [CrossRef]

Sharma TS, Wasko MC, Tang X, et al. Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients. J Am Heart Assoc. 2016 Jan 04;5(1)doi: 10.1161/jaha.115.002867. PMID: 26727968. Exclusion Code: X5. [PMC free article: PMC4859400] [PubMed: 26727968] [CrossRef]

Smolen JS, van der Heijde DM, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab - Results from the ASPIRE trial. Arthritis and Rheumatism (USA). 2006 03/01/;54(Mar):702–10. Exclusion Code: X5. [PubMed: 16508926]

Soubrier M, Lukas C, Sibilia J, et al. Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis. 2011 Apr;70(4):611–5. doi: 10.1136/ard.2010.137695. PMID: 21242235 Exclusion Code: X5. [PMC free article: PMC3048626] [PubMed: 21242235] [CrossRef]

Svensson AL, Christensen R, Persson F, et al. Multifactorial intervention to prevent cardiovascular disease in patients with early rheumatoid arthritis: Protocol for a multicentre randomised controlled trial. BMJ Open. 2016;6(4)doi: 10.1136/bmjopen-2015-009134. Exclusion Code: X5. [PMC free article: PMC4838680] [PubMed: 27098820] [CrossRef]

Tanaka Y, Yamanaka H, Ishiguro N, et al. Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study. Arthritis Research and Therapy. 2017;19(1)doi: 10.1186/s13075-017-1264-6. Exclusion Code: X5. [PMC free article: PMC5348900] [PubMed: 28288682] [CrossRef]

Trampisch U, Krause D, Trampisch H, et al. Comparison of the efficacy and safety of two starting dosages of prednisolone in early active rheumatoid arthritis (CORRA): study protocol for a randomized controlled trial. Trials; 2014. p. 344. Exclusion Code: X5. [PMC free article: PMC4247757] [PubMed: 25181946]

Tweehuysen L, van den Ende CH, Beeren FM, et al. Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis A Systematic Review. p. 301. Exclusion Code: X5. [PMC free article: PMC5299504] [PubMed: 27696778]

van Schaardenburg D, Valkema R, Dijkmans BA, et al. Prednisone Treatment of Elderly-Onset Rheumatoid Arthritis. Disease Activity and Bone Mass in Comparison With Chloroquine Treatment. Arthritis and rheumatism. 1995;38(3):334–42 Exclusion Code: X5. [PubMed: 7880187]

Verschueren P, Esselens G, Westhovens R. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. Rheumatology (Oxford). 2008 Jan;47(1):59–64. PMID: 18039681. Exclusion Code: X5. [PubMed: 18039681]

Verstappen S, Bakker M, Heurkens A, et al. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. Ann Rheum Dis; 2010. p. 1044–8. Exclusion Code: X5. [PubMed: 19581281]

Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007 Nov;66(11):1443–9. PMID: 17519278. Exclusion Code: X5. [PMC free article: PMC2111604] [PubMed: 17519278]

Visvanathan S, Rahman M, Keystone E, et al. Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study. Arthritis Res Ther; 2010. p. R211. Exclusion Code: X5. [PMC free article: PMC3046519] [PubMed: 21083889]

Westhovens R, Han C, Weinblatt ME, et al. Hemoglobin is a better predictor for radiographic progression than DAS28 in patients with moderate to severe rheumatoid arthritis-analysis from intravenously administered golimumab go-further study. Ann Rheum Dis. 2016;75:237–8. doi: 10.1136/annrheumdis-2016-eular.2015. Exclusion Code: X5. [CrossRef]

Wevers-de Boer KV, Heimans L, Visser K, et al. Four-month metacarpal bone mineral density loss predicts radiological joint damage progression after 1 year in patients with early rheumatoid arthritis: exploratory analyses from the IMPROVED study. Ann Rheum Dis. 2015 Feb;74(2):341–6. doi: 10.1136/annrheumdis-2013-203749. PMID: 24285491 Exclusion Code: X5. [PubMed: 24285491] [CrossRef]

White D, Pahau H, Duggan E, et al. Trajectory of intensive treat-to-target disease modifying drug regimen in an observational study of an early rheumatoid arthritis cohort. BMJ Open. 2013;3(7)doi: 10.1136/bmjopen-2013-003083. Exclusion Code: X5. [PMC free article: PMC3731780] [PubMed: 23903812] [CrossRef]

Zhang LL, Wei W, Xiao F, et al. A randomized, double-blind, multicenter, controlled clinical trial of chicken type II collagen in patients with rheumatoid arthritis. Arthritis Rheum. 2008 Jul 15;59(7):905–10. PMID: 18576295. Exclusion Code: X5. [PubMed: 18576295]

Andersson ML, Forslind K, Hafström I. Comparing five year out-come in two cohorts of patients with early rheumatoid arthritis – A BARFOT study. Open Rheumatol J. 2014;9(1):8–15. Exclusion Code: X6. [PMC free article: PMC4319195] [PubMed: 25674182]

Aslibekyan S, Sha J, Redden D, et al. Gene-body mass index interactions are associated with methotrexate toxicity in rheumatoid arthritis. Ann Rheum Dis; 2014. p. 785–6. Exclusion Code: X6. [PMC free article: PMC3970399] [PubMed: 24291656]

Bingham CO, 3rd, Rizzo W, Kivitz A, et al. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis. 2015 May;74(5):818–22. doi: 10.1136/annrheumdis-2013-204427. PMID: 24448345 Exclusion Code: X6. [PMC free article: PMC4392200] [PubMed: 24448345] [CrossRef]

Bissell LA, Hensor EM, Kozera L, et al. Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis-results from the IDEA study. Rheumatology (Oxford). 2016 Dec;55(12):2181–90. doi: 10.1093/rheumatology/kew306. PMID: 27638812 Exclusion Code: X6. [PubMed: 27638812] [CrossRef]

Black RJ, Hill CL, Lester S, et al. The Association between Systemic Glucocorticoid Use and the Risk of Cataract and Glaucoma in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. PLoS One. 2016;11(11):e0166468. doi: 10.1371/journal.pone.0166468. PMID: 27846316 Exclusion Code: X6. [PMC free article: PMC5112962] [PubMed: 27846316] [CrossRef]

Bonafede M, Fox KM, Watson C, et al. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther. 2012 Aug;29(8):664–74. doi: 10.1007/s12325-012-0037-5. PMID: 22886712. Exclusion Code: X6. [PubMed: 22886712] [CrossRef]

Burmester GR, Landewe R, Genovese MC, et al. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017 Feb;76(2):414–7. doi: 10.1136/annrheumdis-2016-209322. PMID: 27338778. Exclusion Code: X6. [PMC free article: PMC5284339] [PubMed: 27338778] [CrossRef]

Cardiel MH, Pons-Estel BA, Sacnun MP, et al. Treatment of early rheumatoid arthritis in a multinational inception cohort of Latin American patients: the GLADAR experience. J Clin Rheumatol. 2012 Oct;18(7):327–35. doi: 10.1097/RHU.0b013e31826d6610. PMID: 23047532 Exclusion Code: X6. [PubMed: 23047532] [CrossRef]

Carlevaris LR. Metothrexate plus leflunomide step-up therapy in early rheumatoid arthritis patients with non response to initial methotrexate in monotherapy. Ann Rheum Dis. 2016;75:1039–40. doi: 10.1136/annrheumdis-2016-eular.3056. Exclusion Code: X6. [CrossRef]

Charles-Schoeman C, Wang X, Lee YY, et al. Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheumatol. 2016 Mar;68(3):577–86. doi: 10.1002/art.39502. PMID: 26606398. Exclusion Code: X6. [PMC free article: PMC4774543] [PubMed: 26606398] [CrossRef]

Charles-Schoeman C, Yin Lee Y, Shahbazian A, et al. Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial. Arthritis and Rheumatology. 2017;69(1):46–57. doi: 10.1002/art.39833. Exclusion Code: X6. [PMC free article: PMC5195879] [PubMed: 27483410] [CrossRef]

Citro A, Scrivo R, Martini H, et al. CD8⁺ T cells specific to apoptosis-associated antigens predict the response to tumor necrosis factor inhibitor therapy in rheumatoid arthritis. PLoS One. 2015;10(6)doi: 10.1371/journal.pone.0128607. Exclusion Code: X6. [PMC free article: PMC4465029] [PubMed: 26061065] [CrossRef]

Conaghan PG, O’Connor P, McGonagle D, et al. Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis Rheum. 2003 Jan;48(1):64–71. doi: 10.1002/art.10747. PMID: 12528105. Exclusion Code: X6. [PubMed: 12528105] [CrossRef]

Emery P, Genovese MC, van Vollenhoven R, et al. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol. 2009 Jul;36(7):1429–41. doi: 10.3899/jrheum.081018. PMID: 19369462. Exclusion Code: X6. [PubMed: 19369462] [CrossRef]

Engvall IL, Svensson B, Tengstrand B, et al. Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study. Arthritis Res Ther. 2008;10(6):R128. doi: 10.1186/ar2542. PMID: 18986531. Exclusion Code: X6. [PMC free article: PMC2656227] [PubMed: 18986531] [CrossRef]

Engvall IL, Tengstrand B, Brismar K, et al. Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months. Arthritis Res Ther. 2010;12(5):R197. doi: 10.1186/ar3169. PMID: 20964833. Exclusion Code: X6. [PMC free article: PMC2991034] [PubMed: 20964833] [CrossRef]

Eriksson JK, Karlsson JA, Bratt J, et al. Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. Ann Rheum Dis. 2015 Jun;74(6):1094–101. doi: 10.1136/annrheumdis-2013-205060. PMID: 24737786. Exclusion Code: X6. [PMC free article: PMC4431324] [PubMed: 24737786] [CrossRef]

Gottheil S, Pope J, Schieir O, et al. Comparing initial treatment strategies with methotrexate on first use of biologic therapy: Results from the Canadian early arthritis cohort. Ann Rheum Dis. 2016;75:124–5. doi: 10.1136/annrheumdis-2016-eular.2103. Exclusion Code: X6. [CrossRef]

Gu T, Shah N, Deshpande G, et al. Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort Study. Drugs - Real World Outcomes. 2016;3(4):369–81. doi: 10.1007/s40801-016-0093-2. Exclusion Code: X6. [PMC free article: PMC5127933] [PubMed: 27757919] [CrossRef]

Guler-Yuksel M, Allaart CF, Watt I, et al. Treatment with TNF-alpha inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis. Osteoarthritis Cartilage. 2010 Oct;18(10):1256–62. doi: 10.1016/j.joca.2010.07.011. PMID: 20691795 Exclusion Code: X6. [PubMed: 20691795] [CrossRef]

Haagsma CJ, Blom HJ, van Riel PL, et al. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis. 1999;58(2):79–84. Exclusion Code: X6. [PMC free article: PMC1752831] [PubMed: 10343521]

Hallinen T, Soini E, Eklund K, et al. Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting (Structured abstract). Rheumatology; 2010. p. 767–77. Exclusion Code: X6. [PMC free article: PMC2838414] [PubMed: 20100793]

Hambardzumyan K, Bolce R, Saevarsdottir S, et al. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Ann Rheum Dis; 2015. p. 1102–9. Exclusion Code: X6. [PMC free article: PMC4431327] [PubMed: 24812287]

Haraoui B, Bykerk VP, Van Vollenhoven R, et al. Long-term safety in rheumatoid arthritis before and after certolizumab pegol dose increase/decrease: Analysis of data pooled from the rapid1 and RAPID2 randomized trials. Ann Rheum Dis. 2014;73 doi: 10.1136/annrheumdis-2014-eular.1763. Exclusion Code: X6. [CrossRef]

Harigai M, Takamura A, Atsumi T, et al. Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a report from the Japan College of Rheumatology Ad Hoc Committee for Safety of Biological DMARDs. Mod Rheumatol. 2013 Mar;23(2):284–96. doi: 10.1007/s10165-012-0657-2. PMID: 22588312. Exclusion Code: X6. [PubMed: 22588312] [CrossRef]

Haugeberg G, Conaghan PG, Quinn M, et al. Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2009 Dec;68(12):1898–901. doi: 10.1136/ard.2008.106484 [doi]. PMID: 19386610. Exclusion Code: X6. [PubMed: 19386610] [CrossRef]

Haugeberg G, Morton S, Emery P, et al. Effect of intra-articular corticosteroid injections and inflammation on periarticular and generalised bone loss in early rheumatoid arthritis. Ann Rheum Dis. 2011 Jan;70(1):184–7. doi: 10.1136/ard.2009.128124. PMID: 20805297 Exclusion Code: X6. [PubMed: 20805297] [CrossRef]

Hoff M, Kvien TK, Kalvesten J, et al. Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study. Ann Rheum Dis; 2009. p. 1171–6. Exclusion Code: X6. [PMC free article: PMC2689520] [PubMed: 18801760]

Hoff M, Kvien TK, Kalvesten J, et al. Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study. BMC Musculoskelet Disord. 2011 Feb 27;12:54. doi: 10.1186/1471-2474-12-54 PMID: 21352592. Exclusion Code: X6. [PMC free article: PMC3053306] [PubMed: 21352592] [CrossRef]

Johnston S, Kelly S, Nadkarni A, et al. Healthcare costs associated with serious infections among biologic-naïve rheumatoid arthritis patients initiating first-line biologic treatment. Intern Med J. 2015;45:29–30. doi: 10.1111/imj.12752. Exclusion Code: X6. [CrossRef]

Juby A, Davis P. An evaluation of the impact of seniors on a rheumatology referral clinic: demographics and pharmacotherapy. Clin Rheumatol. 2011 Nov;30(11):1507–9. doi: 10.1007/s10067-011-1845-8. PMID: 21935585. Exclusion Code: X6. [PubMed: 21935585] [CrossRef]

Jurgens MS, Jacobs JW, Boers M, et al. Alternative Ways to Quantify Sustained Remission: Applying the Continuity Rewarded Score and Patient Vector Graph. Arthritis Care Res (Hoboken). 2015 Oct;67(10):1471–4. doi: 10.1002/acr.22565. PMID: 25708452. Exclusion Code: X6. [PubMed: 25708452] [CrossRef]

Katayama K, Okubo T, Sato T, et al. Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice. Mod Rheumatol. 2015 Jan;25(1):50–5. doi: 10.3109/14397595.2014.924385. PMID: 24983407 Exclusion Code: X6. [PubMed: 24983407] [CrossRef]

Klarenbeek NB, Guler-Yuksel M, van der Heijde DM, et al. Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab. Ann Rheum Dis. 2010 Dec;69(12):2107–13. doi: 10.1136/ard.2010.131201. PMID: 20610442. Exclusion Code: X6. [PubMed: 20610442] [CrossRef]

Konijn NPC, van Tuyl LHD, Boers M, et al. The short-term effects of two high-dose, step-down prednisolone regimens on body composition in early rheumatoid arthritis. Rheumatology (United Kingdom). 2016;55(9):1615–22. doi: 10.1093/rheumatology/kew221. Exclusion Code: X6. [PubMed: 27247434] [CrossRef]

Krintel SB, Dehlendorff C, Hetland ML, et al. Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis. Pharmacogenomics J. 2016 Apr;16(2):141–6 doi: 10.1038/tpj.2015.30. PMID: 25939484. Exclusion Code: X6. [PubMed: 25939484] [CrossRef]

Laivoranta-Nyman S, Möttönen T, Hannonen P, et al. Association of tumour necrosis factor a, b and c microsatellite polymorphisms with clinical disease activity and induction of remission in early rheumatoid arthritis. Clin Exp Rheumatol; 2012. p. 636–42. Exclusion Code: X6. [PubMed: 17207378]

Levitsky A, Wick MC, Mottonen T, et al. Early treatment intensification induces favourable radiographic outcomes according to predicted versus observed radiographic progression in early rheumatoid arthritis: a subanalysis of the randomised FIN-RACo and NEO-RACo trials. Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1065–71. PMID: 27607411. Exclusion Code: X6. [PubMed: 27607411]

Ling SF, Stylianou K, Ho P, et al. Absolute monocyte counts are associated with adverse EULAR response after 6 months of treatment with a biologic agent for rheumatoid arthritis. Ann Rheum Dis. 2016;75:203. doi: 10.1136/annrheumdis-2016-eular.1441. Exclusion Code: X6. [CrossRef]

Machold KP, Stamm TA, Nell VP, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford). 2007 Feb;46(2):342–9. doi: 10.1093/rheumatology/kel237. PMID: 16899498. Exclusion Code: X6. [PubMed: 16899498] [CrossRef]

Mahadeva S, Pok SL, Teng JY, et al. Nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal adverse effects in adults with chronic rheumatological disorders-A multi-centre, retrospective, cohort study. Journal of Gastroenterology and Hepatology (Australia). 2016;31:60. doi: 10.1111/jgh.13540. Exclusion Code: X6. [CrossRef]

Markusse I, Dirven L, Han K, et al. Continued participation in a ten-year tight control treat-to-target study in rheumatoid arthritis: why keep patients doing their best? Arthritis Care Res (Hoboken); 2015. p. 739–45 Exclusion Code: X6. [PubMed: 25581505]

Martí-Carvajal AJ, Solà I, Lathyris D, et al. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database of Systematic Reviews: John Wiley & Sons, Ltd; 2017. Exclusion Code: X6.

McComish J, Mundy J, Sullivan T, et al. Changes in peripheral blood B cell subsets at diagnosis and after treatment with disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: correlation with clinical and laboratory parameters. Int J Rheum Dis. 2015 May;18(4):421–32. doi: 10.1111/1756-185x.12325. PMID: 24589014. Exclusion Code: X6. [PubMed: 24589014] [CrossRef]

Merkesdal S, Kirchhoff T, Wolka D, et al. Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure (Structured abstract). European Journal of Health Economics; 2010. p. 95–104. Exclusion Code: X6. [PubMed: 19967426]

Michaud K, Wolfe F. The association of rheumatoid arthritis and its treatment with sinus disease. J Rheumatol; 2006. p. 2412–5 Exclusion Code: X6. [PubMed: 17143978]

Moholt E, Aga AB, Olsen IC, et al. Aiming for remission in early RA: Impact on pain during the first 2 years of treatment. Ann Rheum Dis. 2016;75:129–30. doi: 10.1136/annrheumdis-2016-eular.4847. Exclusion Code: X6. [CrossRef]

Mukherjee K, Kamal KM. Socio-demographic factors and out-of-pocket expenditure for prescription drugs in rheumatoid arthritis. Value Health. 2016;19(3):A232. Exclusion Code: X6.

Mustila A, Korpela M, Haapala AM, et al. Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies. Clin Exp Rheumatol. 2011 May-Jun;29(3):500–5. PMID: 21640044. Exclusion Code: X6. [PubMed: 21640044]

Navarro-Millan I, Charles-Schoeman C, Yang S, et al. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum. 2013 Jun;65(6):1430–8. doi: 10.1002/art.37916. PMID: 23460074. Exclusion Code: X6. [PMC free article: PMC3672346] [PubMed: 23460074] [CrossRef]

Ng B, Chu A, Khan MM. A retrospective cohort study: 10-Year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers. BMJ Open. 2013;3(4)doi: 10.1136/bmjopen-2012-002468. Exclusion Code: X6. [PMC free article: PMC3641511] [PubMed: 23562815] [CrossRef]

Quintana-Duque MA, Rondon-Herrera F, Mantilla RD, et al. Predictors of remission, erosive disease and radiographic progression in a Colombian cohort of early onset rheumatoid arthritis: a 3-year follow-up study. Clin Rheumatol. 2016 Jun;35(6):1463–73. doi: 10.1007/s10067-016-3246-5. PMID: 27041382. Exclusion Code: X6. [PubMed: 27041382] [CrossRef]

Rantalaiho V, Kautiainen H, Korpela M, et al. Physicians’ adherence to tight control treatment strategy and combination DMARD therapy are additively important for reaching remission and maintaining working ability in early rheumatoid arthritis: a subanalysis of the FIN-RACo trial. Ann Rheum Dis; 2014. p. 788–90. Exclusion Code: X6. [PubMed: 24297374]

Rezaei H, Saevarsdottir S, Forslind K, et al. In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial. Ann Rheum Dis. 2012 Feb;71(2):186–91. doi: 10.1136/annrheumdis-2011-200038. PMID: 21930734. Exclusion Code: X6. [PubMed: 21930734] [CrossRef]

Schulze-Koops H, Strand V, Nduaka C, et al. Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies. Rheumatology (Oxford). 2017 Jan;56(1):46–57. doi: 10.1093/rheumatology/kew329. PMID: 28028154 Exclusion Code: X6. [PubMed: 28028154] [CrossRef]

Schwartzman S, Parenti D, Black S, et al. Real world united states-based clinical experience with prior biologic use among first time golimumab intravenous and infliximab treated rheumatoid arthritis patients. Arthritis and rheumatology. Conference: american college of rheumatology/association of rheumatology health professionals annual scientific meeting, ACR/ARHP 2016. United states. Conference start: 20161111. Conference end: 20161116; 2017. p. 781–3. Exclusion Code: X6.

Seegobin SD, Ma MH, Dahanayake C, et al. ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial. Arthritis Res Ther. 2014 Jan 16;16(1):R13. doi: 10.1186/ar4439. PMID: 24433430. Exclusion Code: X6. [PMC free article: PMC3979097] [PubMed: 24433430] [CrossRef]

Sergeant JC, Hyrich KL, Anderson J, et al. Prediction of non-response to methotrexate therapy in the rheumatoid arthritis medication study (RAMS). Ann Rheum Dis. 2016;75:57–8. doi: 10.1136/annrheumdis-2016-eular.4282. Exclusion Code: X6. [CrossRef]

Sode J, Krintel S, Carlsen A, et al. Circulating micro-rna profiles in responders to adalimumab plus methotrexate versus methotrexate alone: A placebo-controlled clinical trial. Arthritis and Rheumatology; 2015. Exclusion Code: X6.

Soini E, Hallinen T, Puolakka K, et al. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis (Structured abstract). J Med Econ; 2012. p. 340–51. Exclusion Code: X6. [PubMed: 22168785]

Takeuchi T, Miyasaka N, Tatsuki Y, et al. Inhibition of plasma IL-6 in addition to maintenance of an efficacious trough level of infliximab associated with clinical remission in patients with rheumatoid arthritis: analysis of the RISING Study. Ann Rheum Dis; 2012. p. 1583–5. Exclusion Code: X6. [PubMed: 22562980]

Tam LS, Shang Q, Li EK, et al. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis -- a randomized trial. J Rheumatol. 2012 Dec;39(12):2267–75. doi: 10.3899/jrheum.120541. PMID: 22984272. Exclusion Code: X6. [PubMed: 22984272] [CrossRef]

van den Broek M, Klarenbeek NB, Dirven L, et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis. 2011 Aug;70(8):1389–94. doi: 10.1136/ard.2010.147751. PMID: 21515916 Exclusion Code: X6. [PubMed: 21515916] [CrossRef]

van der Goes MC, Jacobs JW, Jurgens MS, et al. Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied? Osteoporos Int. 2013 Apr;24(4):1429–36. doi: 10.1007/s00198-012-2073-z. PMID: 23011680. Exclusion Code: X6. [PMC free article: PMC3604583] [PubMed: 23011680] [CrossRef]

Verhoeven AC, Boers M, te Koppele JM, et al. Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone. Rheumatology (Oxford). 2001 Nov;40(11):1231–7. PMID: 11709606. Exclusion Code: X6. [PubMed: 11709606]

Vermeer M, Kuper HH, Hoekstra M, et al. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Arthritis Rheum. 2011 Oct;63(10):2865–72. doi: 10.1002/art.30494. PMID: 21647867. Exclusion Code: X6. [PubMed: 21647867] [CrossRef]

Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis. 2010 Jul;69(7):1333–7. doi: 10.1136/ard.2009.121160. PMID: 20498212 Exclusion Code: X6. [PubMed: 20498212] [CrossRef]

Wang N, Guo Y, Yang L, et al. Effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: A cohort study. Neural Regeneration Research. 2012;7(11):862–6. doi: 10.3969/j.issn.1673-5374.2012.11.011. Exclusion Code: X6. [PMC free article: PMC4342715] [PubMed: 25737715] [CrossRef]

Wechalekar MD, Quinn S, Lester S, et al. A Treat-to-Target Strategy Preserves Work Capacity in a Rheumatoid Arthritis Inception Cohort Treated with Combination Conventional DMARD Therapy. J Clin Rheumatol. 2017;23(3):131–7. doi: 10.1097/RHU.0000000000000506. Exclusion Code: X6. [PubMed: 28277345] [CrossRef]

Wiland P, Dudler J, Veale D, et al. The effect of reduced or withdrawn etanerceptmethotrexate therapy on patient-reported outcomes in patients with early rheumatoid arthritis. J Rheumatol. 2016;43(7):1268–77. doi: 10.3899/jrheum.151179. Exclusion Code: X6. [PubMed: 27252426] [CrossRef]

Yuen KCJ, Buttgereit F, McCabe D, et al. Profound suppression of endogenous cortisol secretion with PF-04171327 (a dissociated agonist of glucocorticoid receptor) compared to prednisone. Endocr Rev. 2015;36. Exclusion Code: X6.

Aaltonen K, Virkki L, Malmivaara A, et al. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One; 2012. Exclusion Code: X9. [PMC free article: PMC3260264] [PubMed: 22272322]

Acurcio FA, Machado MAA, Moura CS, et al. Medication Persistence of Disease-Modifying Antirheumatic Drugs and Anti– Tumor Necrosis Factor Agents in a Cohort of Patients With Rheumatoid Arthritis in Brazil. Arthritis Care Res. 2016;68(10):1489–96. doi: 10.1002/acr.22840. Exclusion Code: X9. [PubMed: 26814681] [CrossRef]

Ai JW, Zhang S, Ruan QL, et al. The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-alpha Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies. J Rheumatol. 2015 Dec;42(12):2229–37. doi: 10.3899/jrheum.150057. PMID: 26472414. Exclusion Code: X9. [PubMed: 26472414] [CrossRef]

Ajeganova S, van Steenbergen HW, van Nies JA, et al. Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms. Ann Rheum Dis. 2016 May;75(5):867–73. doi: 10.1136/annrheumdis-2014-207080. PMID: 25972519 Exclusion Code: X9. [PubMed: 25972519] [CrossRef]

Alfaro-Lara R, Espinosa-Ortega HF, Arce-Salinas CA. Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis. Reumatol Clin. 2017 doi: 10.1016/j.reuma.2017.07.020. Exclusion Code: X9. [PubMed: 28867467] [CrossRef]

Almeida C, Choy EH, Hewlett S, et al. Biologic interventions for fatigue in rheumatoid arthritis. Cochrane Database of Systematic Reviews: John Wiley & Sons, Ltd; 2016. Exclusion Code: X9. [PMC free article: PMC7175833] [PubMed: 27271314]

Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: Systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord; 2008. Exclusion Code: X9. [PMC free article: PMC2377247] [PubMed: 18419803]

An M, Zou Z, Shen H, et al. The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials (Structured abstract). Eur J Clin Pharmacol; 2010. p. 49–59. Exclusion Code: X9. [PubMed: 19936725]

Anonymous. Comparative effectiveness of cycling of tumor necrosis factor-alpha (TNF-alpha) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-alpha inhibitor using a Bayesian approach. p. 662. Exclusion Code: X9. [PubMed: 24469604]

Anonymous. Systematic Review of Tumor Necrosis Factor Inhibitor Discontinuation Studies in Rheumatoid Arthritis. p. 1850. Exclusion Code: X9. [PMC free article: PMC3917677] [PubMed: 24156821]

Baji P, Pentek M, Czirjak L, et al. Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. Eur J Health Econ. 2014 May;15 Suppl 1:S53–64. doi: 10.1007/s10198-014-0594-4. PMID: 24832836 Exclusion Code: X9. [PMC free article: PMC4046078] [PubMed: 24832836] [CrossRef]

Barnabe C, Martin B, Ghali W. Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis (Structured abstract). Arthritis Care Res; 2011. p. 522–9. Exclusion Code: X9. [PubMed: 20957658]

Barnabe C, Martin BJ, Ghali WA. Systematic Review and Meta-Analysis: Anti-Tumor Necrosis Factor alpha Therapy and Cardiovascular Events in Rheumatoid Arthritis. p. 522. Exclusion Code: X9. [PubMed: 20957658]

Barra L, Ha A, Sun L, et al. Efficacy of biologic agents in improving the Health Assessment Questionnaire (HAQ) score in established and early rheumatoid arthritis: a meta-analysis with indirect comparisons. Clin Exp Rheumatol. 2014 May-Jun;32(3):333–41. PMID: 24480452. Exclusion Code: X9. [PubMed: 24480452]

Beauparlant P, Papp K, Haraoui B. The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum. 1999 Dec;29(3):148–58. PMID: 10622679. Exclusion Code: X9. [PubMed: 10622679]

Bergman G, Hochberg M, Boers M, et al. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs (Structured abstract). Semin Arthritis Rheum; 2010. p. 425–41. Exclusion Code: X9. [PubMed: 20223500]

Bergman GJ, Hochberg MC, Boers M, et al. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum; 2010. p. 425–41. Exclusion Code: X9. [PubMed: 20223500]

Bergrath E, Wallenstein G, Gerbert R, et al. Tofacitinib versus biologic treatments in moderate to severe rheumatoid arthritis patients who have had an inadequate response to nonbiologic DMARDS: Systematic literature review and network meta-analysis. Ann Rheum Dis. 2016;75:726. doi: 10.1136/annrheumdis-2016-eular.4456. Exclusion Code: X9. [PMC free article: PMC5362710] [PubMed: 28377787] [CrossRef]

Bergstra SA, Allaart CF, Stijnen T, et al. Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug–Naive Early Rheumatoid Arthritis Patients. Arthritis Care Res. 2017;69(10):1473–83. doi: 10.1002/acr.23164. Exclusion Code: X9. [PubMed: 27992656] [CrossRef]

Bernatsky S, Habel Y, Rahme E. Observational Studies of Infections in Rheumatoid Arthritis: A Metaanalysis of Tumor Necrosis Factor Antagonists. p. 928. Exclusion Code: X9. [PubMed: 20360181]

Berti A, Felicetti M, Peccatori S, et al. EBV-induced lymphoproliferative disorders in rheumatic patients: A systematic review of the literature. Joint Bone Spine. 2017 doi: 10.1016/j.jbspin.2017.01.006. Exclusion Code: X9. [PubMed: 28196776] [CrossRef]

Bijlsma JW. Disease control with glucocorticoid therapy in rheumatoid arthritis. p. iv9. Exclusion Code: X9. [PubMed: 22685274]

Birnbaum J, Bingham CO, 3rd. Non-length-dependent and length-dependent small-fiber neuropathies associated with tumor necrosis factor (TNF)-inhibitor therapy in patients with rheumatoid arthritis: expanding the spectrum of neurological disease associated with TNF-inhibitors. Semin Arthritis Rheum. 2014 Apr;43(5):638–47. doi: 10.1016/j.semarthrit.2013.10.007. PMID: 24439654 Exclusion Code: X9. [PMC free article: PMC4605274] [PubMed: 24439654] [CrossRef]

Blay P, Mouterde G, Barnetche T, et al. Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: Metaanalysis of randomized controlled trials. J Rheumatol; 2012. p. 712–5. Exclusion Code: X9. [PubMed: 22382344]

Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006 May 17;295(19):2275–85. PMID: 16705109. Exclusion Code: X9. [PubMed: 16705109]

Bongartz T, Warren FC, Mines D, et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis; 2009. p. 1177–83. Exclusion Code: X9. [PubMed: 19019889]

Bredemeier M, Campos GG, de Oliveira FK. Updated systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis. Clin Rheumatol. 2015 Oct;34(10):1801–5. doi: 10.1007/s10067-015-2977-z. PMID: 26070536 Exclusion Code: X9. [PubMed: 26070536] [CrossRef]

Bredemeier M, de Oliveira FK, Rocha CM. Low- Versus High-Dose Rituximab for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. p. 228. Exclusion Code: X9. [PubMed: 23983134]

Bredemeier M, Oliveira F, Rocha C. Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis (Provisional abstract). Arthritis Care Res; 2014. p. 228–35. Exclusion Code: X9. [PubMed: 23983134]

Brodszky V, Gulacsi L, Balogh O, et al. Evaluating the efficacy of biosimilar infliximab with the acr 50 response in patients with rheumatoid arthritis; A meta-analysis in bayesian framework. Value Health. 2013;16(7):A556. doi: 10.1016/j.jval.2013.08.1454. Exclusion Code: X9. [CrossRef]

Buckley F, Finckh A, Huizinga TW, et al. Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis. J Manag Care Spec Pharm. 2015 May;21(5):409–23. doi: 10.18553/jmcp.2015.21.5.409. PMID: 25943002 Exclusion Code: X9. [PMC free article: PMC10397966] [PubMed: 25943002] [CrossRef]

Buckley F, Finckh A, W. Huizinga T, et al. Comparative efficacy of biologics as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with an inadequate response to conventional dmards: A network meta-analysis. Rheumatology (United Kingdom). 2013;52:i93. doi: 10.1093/rheumatology/ket197. Exclusion Code: X9. [PMC free article: PMC10397966] [PubMed: 25943002] [CrossRef]

Campbell L, Chen C, Bhagat S, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials (Structured abstract). Rheumatology; 2011. p. 552–62. Exclusion Code: X9. [PubMed: 21078627]

Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. p. 552. Exclusion Code: X9. [PubMed: 21078627]

Capell H, Madhok R, Porter D, et al. Combination therapy with sulphasalazine and methotrexate is more effective than either drug alone in rheumatoid arthritis (ra) patients with a suboptimal response to sulphasalazine: Results from the double blind placebo controlled mascot study. Ann Rheum Dis. 2007 Feb;66(2):235–41. doi: 10.1136/ard.2006.057133. Exclusion Code: X9. [PMC free article: PMC1798490] [PubMed: 16926184] [CrossRef]

Carpenter T, Hall J, Katz S. Review of the safety of disease-modifying anti-rheumatic drug therapy in patients with chronic kidney disease. Can J Hosp Pharm; 2015. p. 76. Exclusion Code: X9.

Castañeda O, Jaller J, Citera G, et al. Safety of tofacitinib for the treatment of rheumatoid arthritis in patients from Latin America and the rest of the world. Ann Rheum Dis. 2016;75:1041. doi: 10.1136/annrheumdis-2016-eular.1793. Exclusion Code: X9. [CrossRef]

Chang S, Sawyer L, Dejonckheere F, et al. Tocilizumab in methotrexate-naive rheumatoid arthritis-a cost-utility model for Slovakia. Value Health; 2015. p. A648. Exclusion Code: X9.

Chatterjea R, Laughlin M, Kuhn I, et al. Risk of skin cancer following anti-tumour necrosis factor treatment in rheumatoid and psoriatic arthritis: A systematic literature review. Ann Rheum Dis; 2015. p. 715. Exclusion Code: X9.

Chatzidionysiou K, Emamikia S, Nam J, et al. Efficacy and safety of conventional and targeted synthetic disease-modifying antirheumatic drugs as well as glucocorticoids: a systematic literature review informing the 2016 update of the eular recommendations for the management of rheumatoid arthritis. Arthritis and rheumatology. Conference: american college of rheumatology/association of rheumatology health professionals annual scientific meeting, ACR/ARHP 2016. United states. Conference start: 20161111. Conference end: 20161116; 2017. p. 3434–7. Exclusion Code: X9.

Chatzidionysiou K, Lie E, Nasonov E, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis. 2011 Sep;70(9):1575–80. doi: 10.1136/ard.2010.148759. PMID: 21571731 Exclusion Code: X9. [PubMed: 21571731] [CrossRef]

Chauffier K, Salliot C, Berenbaum F, et al. Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. p. 60. Exclusion Code: X9. [PubMed: 21515629]

Clark W, Jobanputra P, Barton P, et al. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. Health Technol Assess. 2004 May;8(18):iii–iv, ix–x, 1–105. PMID: 15130461. Exclusion Code: X9. [PubMed: 15130461]

Connock M, Tubeuf S, Malottki K, et al. Certolizumab pegol (CIMZIA(R)) for the treatment of rheumatoid arthritis. Health Technol Assess. 2010 Oct;14(Suppl. 2):1–10 doi: 10.3310/hta14suppl2/01. PMID: 21047485. Exclusion Code: X9. [PubMed: 21047485] [CrossRef]

Conway R, Low C, Coughlan R, et al. Methotrexate and interstitial lung disease in rheumatoid arthritis-a systematic literature review and meta-analysis. Ir J Med Sci; 2013. p. S94. Exclusion Code: X9.

Conway R, Low C, Coughlan R, et al. Leflunomide use is not associated with an increased risk of lung disease in rheumatoid arthritis: A meta-analysis of randomised controlled trials. Arthritis and Rheumatology; 2014. p. S205. Exclusion Code: X9.

Conway R, Low C, Coughlan R, et al. Methotrexate use and liver disease in rheumatoid arthritis: A meta-analysis of randomised controlled trials. Ann Rheum Dis; 2014. Exclusion Code: X9.

Conway R, Low C, Coughlan R, et al. Methotrexate and lung disease-a meta-analysis of randomized controlled trials. Ir J Med Sci; 2014. p. S516–s7. Exclusion Code: X9.

Conway R, Low C, Coughlan R, et al. Methotrexate and lung disease in rheumatoid arthritis - a meta-analysis of randomized controlled trials (Provisional abstract). Arthritis Rheum; 2014. p. 803–12. Exclusion Code: X9. [PubMed: 24757133]

Conway R, Low C, Coughlan RJ, et al. Leflunomide Use and Risk of Lung Disease in Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis of Randomized Controlled Trials. p. 855. Exclusion Code: X9. [PubMed: 26980577]

Conway R, Low C, Coughlan RJ, et al. Methotrexate and Lung Disease in Rheumatoid Arthritis. p. 803. Exclusion Code: X9. [PubMed: 24757133]

Curtis JR, Chastek B, Becker L, et al. Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population. J Manag Care Spec Pharm. 2015 Apr;21(4):318–29. doi: 10.18553/jmcp.2015.21.4.318. PMID: 25803765 Exclusion Code: X9. [PMC free article: PMC10398240] [PubMed: 25803765] [CrossRef]

Curtis JR, Lee EB, Kaplan IV, et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis. 2016 May;75(5):831–41. doi: 10.1136/annrheumdis-2014-205847. PMID: 25902789 Exclusion Code: X9. [PMC free article: PMC4853586] [PubMed: 25902789] [CrossRef]

De Cock D, Vanderschueren G, Meyfroidt S, et al. Two-year clinical and radiologic follow-up of early RA patients treated with initial step up monotherapy or initial step down therapy with glucocorticoids, followed by a tight control approach: lessons from a cohort study in daily practice. Clin Rheumatol. 2014 Jan;33(1):125–30. doi: 10.1007/s10067-013-2398-9. PMID: 24077951 Exclusion Code: X9. [PubMed: 24077951] [CrossRef]

De Vecchis R, Palmisani L, Pucciarelli A, et al. Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: Novel therapeutic insights coming from a meta-analysis of the literature data. G Ital Cardiol. 2014;15(4):e54. doi: 10.1714/1501.16521. Exclusion Code: X9. [PMC free article: PMC5336700] [PubMed: 26467356] [CrossRef]

Desai R, Hansen R, Rao J, et al. Mixed treatment comparison of the treatment discontinuations of biologic disease-modifying antirheumatic drugs in adults with rheumatoid arthritis. The Annals of pharmacotherapy; 2012. p. 1491–505. Exclusion Code: X9. [PubMed: 23092868]

Desai RJ, Thaler KJ, Mahlknecht P, et al. Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review. p. 1078. Exclusion Code: X9. [PubMed: 26663412]

Devine EB, Alfonso-Cristancho R, Sullivan SD. Effectiveness of Biologic Therapies for Rheumatoid Arthritis: An Indirect Comparisons Approach. p. 39. Exclusion Code: X9. [PubMed: 21182357]

Diamantopoulos A, Finckh A, Huizinga T, et al. Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK. p. 775. Exclusion Code: X9. [PMC free article: PMC4113684] [PubMed: 24854959]

Downey C. Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review. Int J Rheum Dis. 2015 doi: 10.1111/1756-185X.12659. Exclusion Code: X9. [PubMed: 26200188] [CrossRef]

Drouin J, Haraoui B. Predictors of clinical response and radiographic progression in patients with rheumatoid arthritis treated with methotrexate monotherapy. J Rheumatol. 2010 Jul;37(7):1405–10. doi: 10.3899/jrheum.090838. PMID: 20436076. Exclusion Code: X9. [PubMed: 20436076] [CrossRef]

Emery P, Kavanaugh A, Bao Y, et al. Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis? Ann Rheum Dis. 2015 Dec;74(12):2165–74. doi: 10.1136/annrheumdis-2014-205302. PMID: 25139667 Exclusion Code: X9. [PMC free article: PMC4680119] [PubMed: 25139667] [CrossRef]

Eng G, Stoltenberg M, Szkudlarek M, et al. Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: a systematic review of cohort studies with focus on dose (Provisional abstract). Semin Arthritis Rheum; 2013. p. 144–51. Exclusion Code: X9. [PubMed: 23838092]

Fautrel B, Granger B, Combe B, et al. Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort. Arthritis Res Ther. 2012 Nov 19;14(6):R249. doi: 10.1186/ar4092. PMID: 23164197. Exclusion Code: X9. [PMC free article: PMC3674616] [PubMed: 23164197] [CrossRef]

Favalli EG, Pregnolato F, Biggioggero M, et al. The role of biologic agents in damage progression in rheumatoid arthritis: Indirect comparison of data coming from randomized clinical trials. Ther Adv Musculoskelet Dis. 2012;4(4):213–23. doi: 10.1177/1759720X12449082. Exclusion Code: X9. [PMC free article: PMC3403255] [PubMed: 22859920] [CrossRef]

Flaig T, Douros A, Bronder E, et al. Tocilizumab-induced pancreatitis: case report and review of data from the FDA Adverse Event Reporting System. J Clin Pharm Ther. 2016;41(6):718–21. doi: 10.1111/jcpt.12456. Exclusion Code: X9. [PubMed: 27670839] [CrossRef]

Garg N, Perry L, Deodhar A. Intra-articular and soft tissue injections, a systematic review of relative efficacy of various corticosteroids (Structured abstract). Database of Abstracts of Reviews of Effects; 2014. p. epub. Exclusion Code: X9.

Gartlehner G, Glechner A, Kien C, et al. Drug Class Review: Targeted Immune Modulators: Final Update 5 Report. Portland, OR: Oregon Health & Science University; Jun 2016. Exclusion Code: X9. [PubMed: 23166955]

Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol. 2006 Dec;33(12):2398–408. Exclusion Code: X9. [PubMed: 17225293]

Gaujoux-Viala C, Giampietro C, Gaujoux T, et al. Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J Rheumatol. 2012 Feb;39(2):233–9. doi: 10.3899/jrheum.110865. PMID: 22174213. Exclusion Code: X9. [PubMed: 22174213] [CrossRef]

Gaujoux-Viala C, Mitrovic S, Barnetche T, et al. Efficacy of glucocorticoids for early rheumatoid arthritis (RA): A meta-analysis of randomised controlled trials. Ann Rheum Dis; 2014. Exclusion Code: X9.

Gaujoux-Viala C, Nam J, Ramiro S, et al. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis (Provisional abstract). Ann Rheum Dis; 2014. p. 510–5. Exclusion Code: X9. [PMC free article: PMC3932966] [PubMed: 24395555]

Gaujoux-Viala C, Smolen JS, Landewe R, et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010 Jun;69(6):1004–9. [pii]; 10.1136/ard.2009.127225 [doi]. PMID: 20447954. Exclusion Code: X9. [PubMed: 20447954] [CrossRef]

Genovese M, Fleischmann R, Mangan E, et al. Efficacy and safety of sarilumab in subgroups of patients with rheumatoid arthritis from 2 phase 3 studies. Arthritis and rheumatology. Conference: american college of rheumatology/association of rheumatology health professionals annual scientific meeting, ACR/ARHP 2016. United states. Conference start: 20161111. Conference end: 20161116; 2017. p. 2032–5. Exclusion Code: X9.

Genovese MC, Rubbert-Roth A, Smolen JS, et al. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol. 2013 Jun;40(6):768–80. doi: 10.3899/jrheum.120687. PMID: 23457383. Exclusion Code: X9. [PubMed: 23457383] [CrossRef]

Gerasimova K, Avxentyeva M, Goryaynov S, et al. Pharmacoeconomic analysis of abatacept for treatment of adults with rheumat oid arthritis in Russia. Value Health. 2013;16(7):A564. doi: 10.1016/j.jval.2013.08.1499. Exclusion Code: X9. [CrossRef]

Golicki D, Newada M, Lis J, et al. Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials. Pol Arch Med Wewn. 2012;122(1-2):22–32. PMID: 22353705. Exclusion Code: X9. [PubMed: 22353705]

Gonzalez-Vacarezza N, Aleman A, Gonzalez G, et al. Rituximab and tocilizumab for the treatment of rheumatoid arthritis (Provisional abstract). Database of Abstracts of Reviews of Effects; 2014. p. 282–8. Exclusion Code: X9.

Graudal N, Hubeck-Graudal T, Faurschou M, et al. Combination Therapy With and Without Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: A Meta-Analysis of Randomized Trials. p. 1487. Exclusion Code: X9. [PubMed: 25989246]

Graudal N, Jurgens G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons (Structured abstract). Arthritis Rheum; 2010. p. 2852–63. Exclusion Code: X9. [PubMed: 20560138]

Guyot P, Taylor P, Christensen R, et al. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United Kingdom (Structured abstract). J Rheumatol; 2012. p. 1198–206. Exclusion Code: X9. [PubMed: 22505698]

Guyot P, Taylor P, Christensen R, et al. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis (Provisional abstract). Arthritis Research and Therapy; 2011. p. R204. Exclusion Code: X9. [PMC free article: PMC3334657] [PubMed: 22151924]

Guyot P, Taylor PC, Christensen R, et al. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom. J Rheumatol. 2012 Jun;39(6):1198–206. doi: 10.3899/jrheum.111345. PMID: 22505698. Exclusion Code: X9. [PubMed: 22505698] [CrossRef]

Hammoudeh M, Al Awadhi A, Hasan EH, et al. Safety, tolerability, and efficacy of tocilizumab in rheumatoid arthritis: An open-label phase 4 study in patients from the middle east. Int J Rheumatol. 2015;2015 doi: 10.1155/2015/975028. Exclusion Code: X9. [PMC free article: PMC4452319] [PubMed: 26089907] [CrossRef]

Haraoui B, Bykerk VP, Van Vollenhoven R, et al. Analysis of pooled data from two randomized controlled trials and their open-label extensions: Long-term safety in rheumatoid arthritis before and after certolizumab pegol dose increase/decrease. Arthritis and Rheumatology. 2014;66:S199. doi: 10.1002/art.38914. Exclusion Code: X9. [CrossRef]

Harrold LR, Litman HJ, Connolly SE, et al. A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice? Clin Rheumatol. 2017;36(6):1215–20. doi: 10.1007/s10067-017-3588-7. Exclusion Code: X9. [PMC free article: PMC5486472] [PubMed: 28251392] [CrossRef]

Haugeberg G, Boyesen P, Helgetveit K, et al. Clinical and Radiographic Outcomes in Patients Diagnosed with Early Rheumatoid Arthritis in the First Years of the Biologic Treatment Era: A 10-year Prospective Observational Study. J Rheumatol. 2015 Dec;42(12):2279–87. doi: 10.3899/jrheum.150384. PMID: 26568592. Exclusion Code: X9. [PubMed: 26568592] [CrossRef]

Hazlewood G, Barnabe C, Tomlinson G, et al. The comparative efficacy and toxicity of initial disease-modifying anti-rheumatic drug choices for patients with moderate-severe early rheumatoid arthritis: A bayesian network meta-analysis. Arthritis Rheum; 2011. Exclusion Code: X9.

Hazlewood G, Barnabe C, Tomlinson G, et al. The comparative efficacy and toxicity of initial DMARD choices for patients with moderate-severe early rheumatoid arthritis: A bayesian network meta-analysis. J Rheumatol; 2012. p. 1729. Exclusion Code: X9.

Hazlewood GS, Barnabe C, Tomlinson G, et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. p. NIL. Exclusion Code: X9. [PMC free article: PMC4849170] [PubMed: 27102806]

Hazlewood GS, Barnabe C, Tomlinson G, et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. Cochrane Database of Systematic Reviews: John Wiley & Sons, Ltd; 2016. Exclusion Code: X9. [PMC free article: PMC7087436] [PubMed: 27571502]

He Y, Wong A, Chan E, et al. Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis (Provisional abstract). BMC Musculoskelet Disord; 2013. p. 298. Exclusion Code: X9. [PMC free article: PMC3819708] [PubMed: 24139404]

He Y, Wong A, Chan E, et al. Safety of tofacitinib in the treatment of rheumatoid arthritis: A systematic review and meta-analysis. Drug Saf. 2013;36(9):852–3. doi: 10.1007/s40264-013-0087-x. Exclusion Code: X9. [CrossRef]

Hernandez-Cruz B, Garcia-Arias M, Ariza AR, et al. Rituximab in rheumatoid arthritis: a systematic review of efficacy and safety (Provisional abstract). Reumatol Clin; 2011. p. 314–22. Exclusion Code: X9. [PubMed: 21925447]

Hochberg M, Janssen K, Broglio K, et al. Comparison of abatacept and other biologic dmards for the treatment of rheumatoid arthritis patients: A systematic literature review and network meta-analysis. Ann Rheum Dis; 2014. Exclusion Code: X9.

Hochberg MC, Berry S, Broglio K, et al. Mixed treatment comparison of efficacy and tolerability of biologic agents in patients with rheumatoid arthritis. p. 1213. Exclusion Code: X9. [PubMed: 23745516]

Hochberg MC, Tracy JK, Hawkins-Holt M, et al. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis. 2003 2003;62 Suppl 2:ii13–6. Exclusion Code: X9. [PMC free article: PMC1766753] [PubMed: 14532140]

Institution for Clinical and Economic Review (ICER). Targeted Immune Modulators for Rhematoid Arthritis: Effectiveness and Value. April 2017. https://icer-review​.org​/material/ra-final-report/ Exclusion Code: X9.

Isaacs JD, Zuckerman A, Krishnaswami S, et al. Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials. Arthritis Res Ther. 2014 Jul 25;16(4):R158. doi: 10.1186/ar4673. PMID: 25063045. Exclusion Code: X9. [PMC free article: PMC4220634] [PubMed: 25063045] [CrossRef]

Jansen JP, Buckley F, Dejonckheere F, et al. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis. Health Qual Life Outcomes. 2014 Jul 03;12:102. doi: 10.1186/1477-7525-12-102. PMID: 24988902. Exclusion Code: X9. [PMC free article: PMC4101713] [PubMed: 24988902] [CrossRef]

Jiménez MDMR, Molina OG, Carmona JM, et al. Study of effectiveness and safety of adalimumab, etanercept and infliximab in elderly patients with rheumatoid arthritis. European Journal of Hospital Pharmacy. 2017;24:A241. doi: 10.1136/ejhpharm-2017-000640.538. Exclusion Code: X9. [CrossRef]

Jorgensen T, Tarp S, Furst D, et al. Added-value of combining methotrexate with a biological agent compared to biological monotherapy in patients with rheumatoid arthritis: A systematic review and meta-analysis of randomised trials. Ann Rheum Dis; 2015. p. 239–40. Exclusion Code: X9. [PubMed: 30396592]

Jurgens M, Welsing P, Jacobs J. Overview and analysis of treat-to-target trials in rheumatoid arthritis reporting on remission (Structured abstract). Clin Exp Rheumatol; 2012. p. S56–s63. Exclusion Code: X9. [PubMed: 23078808]

Kanters S, Druyts E, Mills EJ, et al. What drives the comparative effectiveness of biologics <it>vs</it> methotrexate in rheumatoid arthritis? Meta-regression and graphical inspection of suspected clinical factors. p. 1264. Exclusion Code: X9. [PubMed: 24599922]

Katchamart W, Trudeau J, Phumethum V, et al. Methotrexate monotherapy versus methotrexate combination therapy with nonbiologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Cochrane Database of Systematic Reviews: John Wiley & Sons, Ltd; 2010. Exclusion Code: X9. [PMC free article: PMC8946299] [PubMed: 20393970]

Kaur K, Kalra S, Kaushal S. Systematic Review of Tofacitinib: A New Drug for the Management of Rheumatoid Arthritis. p. 1074. Exclusion Code: X9. [PubMed: 25047498]

Kaur K, Kalra S, Kaushal S. Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis (Provisional abstract). Database of Abstracts of Reviews of Effects; 2014. p. 1074–86. Exclusion Code: X9. [PubMed: 25047498]

Kawalec P, Mikrut A, Wisniewska N, et al. The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis (Provisional abstract). Database of Abstracts of Reviews of Effects; 2013. p. 1415–24. Exclusion Code: X9. [PMC free article: PMC3778229] [PubMed: 23877486]

Kay J, Fleischmann R, Keystone E, et al. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis. 2015 Mar;74(3):538–46. doi: 10.1136/annrheumdis-2013-204195. PMID: 24344160 Exclusion Code: X9. [PMC free article: PMC4345908] [PubMed: 24344160] [CrossRef]

Kay J, Fleischmann R, Keystone E, et al. Five-year safety data from 5 clinical trials of subcutaneous golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2016;43(12):2120–30. doi: 10.3899/jrheum.160420. Exclusion Code: X9. [PubMed: 27803138] [CrossRef]

Keystone EC. Does Anti-Tumor Necrosis Factor-alpha Therapy Affect Risk of Serious Infection and Cancer in Patients with Rheumatoid Arthritis?: A Review of Longterm Data. p. 1552. Exclusion Code: X9. [PubMed: 21572154]

Khraishi M, Bessette L, Kivitz A, et al. Patient-reported outcomes for etanercept therapy in adult patients with moderate to severe rheumatoid arthritis who failed adalimumab treatment. J Rheumatol. 2017;44(6):947. doi: 10.3899/jrheum.170256. Exclusion Code: X9. [PMC free article: PMC5696291] [PubMed: 28900875] [CrossRef]

Kilcher G, Didden E, Hummel N, et al. Characteristics of patients starting biologic treatments for rheumatoid arthritis in the real world: Systematic review. Value Health. 2015;18(7):A657–A8. Exclusion Code: X9.

Kirwan JR, Bijlsma JW, Boers M, et al. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev; 2007. p. CD006356. Exclusion Code: X9. [PMC free article: PMC6465045] [PubMed: 17253590]

Kivitz A, Haraoui B, Kaine J, et al. A safety analysis of tofacitinib 5 mg twice daily administered as monotherapy or in combination with background conventional synthetic DMARDS in a phase 3 rheumatoid arthritis population. Ann Rheum Dis. 2016;75:247–8. doi: 10.1136/annrheumdis-2016-eular.1846. Exclusion Code: X9. [CrossRef]

Kobelt G. Treating to Target with Etanercept in Rheumatoid Arthritis: Cost-Effectiveness of Dose Reductions When Remission Is Achieved. p. 537. Exclusion Code: X9. [PubMed: 25128046]

Krathen MS, Gottlieb AB, Mease PJ. Pharmacologic Immunomodulation and Cutaneous Malignancy in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis. p. 2205. Exclusion Code: X9. [PubMed: 20810498]

Kristensen L, Jakobsen A, Bartels E, et al. The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials (Structured abstract). Scand J Rheumatol; 2011. p. 1–7. Exclusion Code: X9. [PubMed: 20950126]

Kuijper TM, Lamers-Karnebeek FB, Jacobs JW, et al. Flare rate in patients with rheumatoid arthritis in low disease activity or remission when tapering or stopping synthetic or biologic DMARD: a systematic review. J Rheumatol. 2015 Nov;42(11):2012–22. doi: 10.3899/jrheum.141520. PMID: 26428204. Exclusion Code: X9. [PubMed: 26428204] [CrossRef]

Kuriya B, Arkema E, Bykerk V, et al. Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission (Structured abstract). Ann Rheum Dis; 2010. p. 1298–304. Exclusion Code: X9. [PubMed: 20421343]

Kuriya B, Arkema EV, Bykerk VP, et al. Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission. Ann Rheum Dis. 2010 Jul;69(7):1298–304. doi: 10.1136/ard.2009.118307. PMID: 20421343 Exclusion Code: X9. [PubMed: 20421343] [CrossRef]

Lau AN, Shah A, Deamude M, et al. Effectiveness of etanercept in elderly patients with rheumatoid arthritis: A single center retrospective study. Arthritis Rheum. 2013;65:S627. doi: 10.1002/art.38216. Exclusion Code: X9. [CrossRef]

Launois R, Avouac B, Berenbaum F, et al. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment bayesian metaanalysis (Structured abstract). J Rheumatol; 2011. p. 835–45. Exclusion Code: X9. [PubMed: 21239748]

Launois R, Avouac B, Berenbaum F, et al. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. J Rheumatol. 2011 May;38(5):835–45. doi: 10.3899/jrheum.100665. PMID: 21239748. Exclusion Code: X9. [PubMed: 21239748] [CrossRef]

Lee MY, Park SK, Park SY, et al. Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea. Clin Ther. 2015 Aug;37(8):1662–76.e2. doi: 10.1016/j.clinthera.2015.07.001. PMID: 26243076 Exclusion Code: X9. [PubMed: 26243076] [CrossRef]

Lee Y, Bae S, Song G. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials (Provisional abstract). Rheumatol Int; 2011. p. 1493–9. Exclusion Code: X9. [PubMed: 20473756]

Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis; 2009. p. 1136–45. Exclusion Code: X9. [PubMed: 18753157]

Lethaby A, Lopez-Olivo MA, Maxwell LJ, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews: John Wiley & Sons, Ltd; 2013. Exclusion Code: X9.

Lin T, Shamliyan T, Choi H, et al. The safety of anti-TNF biologic agents in rheumatoid arthritis-a meta-analysis of 35 rcts. Arthritis Rheum. 2012;64:S788–S9. doi: 10.1002/art.37735. Exclusion Code: X9. [CrossRef]

Lindqvist E, Saxne T, Geborek P, et al. Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. Ann Rheum Dis. 2002 Dec;61(12):1055–9. PMID: 12429534. Exclusion Code: X9. [PMC free article: PMC1753974] [PubMed: 12429534]

Lopez-Olivo M, Suarez-Almazor M, Bavineni M. Tofacitinib for rheumatoid arthritis: A systematic review and meta-analysis. Arthritis Rheum; 2013. p. S625. Exclusion Code: X9.

Lopez-Olivo M, Tayar J, Pollono E, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis (Structured abstract). JAMA; 2012. p. 898–908. Exclusion Code: X9. [PubMed: 22948700]

Lopez-Olivo MA, Amezaga UM, McGahan L, et al. Rituximab for rheumatoid arthritis. Cochrane Database of Systematic Reviews: John Wiley & Sons, Ltd; 2015. Exclusion Code: X9.

Lopez-Olivo MA, Bavineni M, Suarez-Almazor ME. Tofacitinib for rheumatoid arthritis. Cochrane Database of Systematic Reviews: John Wiley & Sons, Ltd; 2013. Exclusion Code: X9.

Lopez-Olivo MA, Siddhanamatha HR, Shea B, et al. Methotrexate for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews: John Wiley & Sons, Ltd; 2014. Exclusion Code: X9.

Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy A Meta-analysis. p. 898. Exclusion Code: X9. [PubMed: 22948700]

Lundh A, Lexchin J, Mintzes B, et al. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews: John Wiley & Sons, Ltd; 2017. Exclusion Code: X9.

Luo L, Ye MD, Cao Q. Infliximab and tuberculosis infection in adult patients: A meta-analysis. J Dig Dis. 2014;15:116. . Exclusion Code: X9.

Ma M, Cope A, Scott D. Safety of combination therapies in early rheumatoid arthritis: a systematic comparison between antirheumatic drugs and TNF inhibitors with methotrexate (Structured abstract). Int J Clin Rheumtol; 2010. p. 547–54. Exclusion Code: X9.

Ma M, Kingsley G, Scott D. A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis (Structured abstract). Rheumatology; 2010. p. 91–8. Exclusion Code: X9. [PubMed: 19917618]

Ma MH, Kingsley GH, Scott DL. A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. p. 91. Exclusion Code: X9. [PubMed: 19917618]

Machado M, Maciel A, Lemos L, et al. Adalimumab in rheumatoid arthritis treatment: a systematic review and meta-analysis of randomized clinical trials (Provisional abstract). Revista Brasileira de Reumatologia; 2013. p. 419–30. Exclusion Code: X9. [PubMed: 24316899]

Machado M, Moura C, Behlouli H, et al. Comparative effectiveness of tofacitinib, biologic drugs and traditional disease-modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol. 2017;44(6):937–8. doi: 10.3899/jrheum.170256. Exclusion Code: X9. [CrossRef]

Maetzel A, Wong A, Strand V, et al. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford). 2000 Sep;39(9):975–81. PMID: 10986302. Exclusion Code: X9. [PubMed: 10986302]

Malottki K, Barton P, Tsourapas A, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation (Structured abstract). Health Technology Assessment Database: Health Technology Assessment; 2011. p. 1. Exclusion Code: X9. [PMC free article: PMC4781257] [PubMed: 21439251]

Malottki K, Barton P, Tsourapas A, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation (Provisional abstract). Health Technol Assess; 2011. p. 1–278. Exclusion Code: X9. [PMC free article: PMC4781257] [PubMed: 21439251]

Maneiro R, Salgado E, Carmona L, et al. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: systematic review and meta-analysis (Provisional abstract). Database of Abstracts of Reviews of Effects; 2013. p. 9–17. Exclusion Code: X9. [PubMed: 23290690]

Martinez Lopez JA, Loza E, Carmona L. Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). Clin Exp Rheumatol; 2009. p. 678–84. Exclusion Code: X9. [PubMed: 19772806]

Maxwell L, Singh J. Abatacept for rheumatoid arthritis: a Cochrane systematic review (Structured abstract). J Rheumatol; 2010. p. 234–45. Exclusion Code: X9. [PubMed: 20080922]

Maxwell LJ, Singh JA. Abatacept for Rheumatoid Arthritis: A Cochrane Systematic Review. p. 234. Exclusion Code: X9. [PubMed: 20080922]

Mehta P, Davy K, Williamson R, et al. Meta-analysis of randomised controlled trials of biologics in DMARD-naive and DMARD-inadequate responder subjects with rheumatoid arthritis: Efficacy and safety. Ann Rheum Dis; 2015. p. 239. Exclusion Code: X9.

Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev; 2009. p. CD005121. Exclusion Code: X9. [PubMed: 19160248]

Migliore A, Bizzi E, Petrella L, et al. The Challenge of Treating Early-Stage Rheumatoid Arthritis: The Contribution of Mixed Treatment Comparison to Choosing Appropriate Biologic Agents. p. 105. Exclusion Code: X9. [PubMed: 26905069]